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ABSTRACT
Adoptive cell transfer of T cell receptor (TCR) gene-modified T cells targeting
specific tumor antigens is currently in clinical trials for patients with advanced
malignancies. Despite the clinical responses, there are still hurdles to be overcome in
achieving an effective and safe therapy. One of the limitations in the success of this
type of therapy is the potential for cross-reactivity and unanticipated off-target reactivity
which could lead to autoimmunity. Adverse events encompassing these “off-target, offtumor” cross-reactivities leading to autoimmunity have been seen in patients in different
clinical trials. Here, we demonstrate a novel approach to improve antigen specific
reactivity and to reduce off-target cross-reactivity by modifying the TCR using structureguided mutations. This strategy combines mutations that alter the TCR to enhance
antigen specificity with mutations that alter the TCR/MHC contact residues to reduce
TCR binding with the MHC. Using the DMF5 TCR that targets the melanoma associated
antigen MART-1, we examined HLA-A2 restricted cross-reactivity by measuring the
polyfunctional T cell response by T cells transduced with strategically mutated DMF5
TCRs against a panel of MART-1 homologs. We further investigated how structureguided mutations in the DMF5 TCR affected tumor lysis, processed antigen recognition,
and 3D vs. 2D affinity. We demonstrate that while modified DMF5 TCRs can enhance
on-target specificity, they can also lead to unexpected off-target cross-reactivity. Our
data fully supports the notion that affinity is not always an accurate predictor of T cell
function and cross reactivity. Moreover, we highlight the importance of rigorous prexx

clinical testing to examine the potential for new specificities and reactivities of modified
TCRs. By determining how various TCR mutations can alter functional T cell
phenotypes and on-target responses, we can gain a better understanding of the biology
of the TCR/pMHC (peptide-MHC) interface and thus how to maximize the efficacy and
safety of TCRs to be used in gene-modified T cell in adoptive cell transfer.

xxi

CHAPTER ONE
REVIEW OF LITERATURE
Introduction
T cells play a vital role in adaptive immunity in fighting microbial and viral
infections as well as malignancies. The initiation and the specificity of T cell immunity
lies within the T cell receptor (TCR). Consequently, understanding the different
mechanisms associated with TCR antigen recognition, T cell activation, and T cell
function that are involved in the adaptive immune response is critical for the success of
treatments or therapies that utilize T cells.
Over recent years, immunotherapy has become increasing prevalent and
promising as an instrument to utilize the power of the immune system to fight cancer
and disease. Even though the adaptive immune response is capable of recognizing
infections and malignancies, the response is not always efficient enough for clearance.
Some of the advances in cancer immunotherapy are the result of a variety of different
strategies focused on enhancing the immune response via tumor infiltrating
lymphocytes (TILs), gene-modified T cells, cytokines, chemokines, mono-clonal
antibodies (mAb), and vaccines [1]. Adoptive T cell transfer therapy has been shown to
have clinical success in treating melanoma and other malignancies [1]. This process
commonly involves isolating TILs, ex vivo expansion, and subsequent administration
back into the patient [2]. Albeit, the isolation and further expansion of these TILs can be
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difficult and is not always possible in a wide variety of cancers [3]. One alternative
strategy that has been clinically successful is the use of genetically modified T cells for
adoptive cell transfer. The transduction of T cells or NK (natural killer) cells with
chimeric antigen receptors (CARs) or TCRs has demonstrated the ability to redirect the
specificity of these cells to recognize tumor and/or viral associated antigens of choice
[4]. It is possible to isolate tumor reactive T cell clones from TIL or peripheral blood
lymphocyte (PBL) derived T cells and further identify and clone the TCR genes that
mediate recognition of tumor associated antigens or viral antigens. In this dissertation
we will exclusively study TCR biology by using a retroviral vector encoding TCR genes
to redirect the specificity of T cells to recognize a specific tumor antigen. TCR genemodified T cells for adoptive T cell transfer is a form of a more personalized medicine,
since its procedure is unique for each individual patient. As personalized medicine is
becoming a more attractive treatment strategy and the methodologies used in this
therapy can be applied to a variety of cancers and viral infections, it is imperative to
concentrate on making this therapy as clinically efficient and safe as possible.
One of the challenges in using TCR gene-modified T cells that target selfantigens for therapy, is that the TCRs generally harbor a lower affinity. This is a result of
negative selection in the thymus during development. Negative selection is critical in
order to eliminate potentially autoreactive T cells. Strategies to enhance TCR affinity
commonly include yeast and phage display. Affinity enhancement through random TCR
mutation can allow for potential unpredicted cross-reactivity. Adverse events, even
patient deaths, have been reported where affinity enhanced TCRs were used [5, 6].
Therefore, there is a rising concern in the field in regards to the safety associated with
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using TCRs that target self-antigens, and this concern is even further amplified when
TCR modifications come in to play. In this dissertation, we have developed a novel
strategy to modify the TCR in order to enhance antigen specificity while simultaneously
reducing potential cross-reactivity. The structural explanation and further implications on
T cell function and therapeutic efficacy of TCR gene-modified T cells will be discussed
in this dissertation.
TCR Diversity
This dissertation focuses on TCR gene-modified T cells, therefore, it is important
to understand T cell development, T cell biology, and T cell genetics. The initiation and
the specificity of T cell immunity lies within the TCR. TCR diversity is imperative for
responses against a large number and a diverse group of antigens. Consequently, TCR
diversity allows for an expansive immune response. TCRs are heterodimers expressed
on the T cell surface as either αβ or γδ heterodimers. The extensive repertoire of TCRs
is a result of somatic gene rearrangement of the TCR gene loci to allow for recognition
of roughly 1018 epitopes [7]. The TCR gene segments are comprised of the following
regions: variable (V), diversity (D), joining (J), and constant (C). Only the TCR beta and
delta chains contains the D region [8]. V(D)J recombination occurs in the thymus and is
vital for the generation TCRs with diverse recognition. The process of recombination is
site-specific and occurs between TCR gene segments that are flanked by recombination
signal (RS) sequences. Recombination activating genes-1 and -2 (RAG-1 and RAG-2)
bind to the RS sequences and make single strand nicks in the DNA to initiate
recombination. First, D-J gene rearrangements occur in the TCR beta or delta chain,
followed by V-DJ gene rearrangements [9]. The TCR beta chain will assemble with the
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pre-T alpha chain to form a pre-TCR. The TCR alpha chain is subsequently rearranged.
Specifically, V-J gene rearrangements occur and are mediated by RAG-1 and RAG-2
[10]. During recombination, diversity is also enhanced at junctional regions via the
incorporation of “P” nucleotides and “N” nucleotides and deletion of nucleotides [11-13].
Nonhomologous DNA end-joining (NHEJ) proteins function to then join the rearranged
gene fragments [9, 14]. In summary, this recombination is essential for the generation of
a large and diverse TCR repertoire in order to allow for the recognition of many
pathogens.
T cell Development
T cells arise from hematopoietic stems cell progenitors derived from the bone
marrow that home to the thymus. Commitment to the T cell lineage occurs upon Notch
signaling [15]. This is critical, as mice generated with neonatally induced loss of Notch1
exhibited austere deficiency in thymocyte development [16]. For these studies we focus
only on the αβ TCR and thus, we will further describe T cell development and T cell
function in regards to the αβ TCR. T cells begin as TCR-, CD4-, and CD8- and are
therefore termed double negative (DN). CD4 and CD8 are co-receptors are found on
the surface of T cells and they play an important role in T cell activation. CD4 and CD8
will be described in more detail in a later section. There are four differentiation stages
which are classified by various markers on the T cell surface. In the stages DN2 through
DN4, the developing T cell expresses a pre-TCR [17]. This pre-TCR consists of a fully
rearranged TCR beta chain and a non-rearranged pre-TCR alpha chain in association
with the CD3 signaling complex. The pre-TCR induces T cell survival, expansion, and
differentiation. The pre-TCR also functions to control allelic exclusion of the TCR beta
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locus as well as permitting TCR alpha chain rearrangement [18, 19]. With a fully
rearranged αβ TCR on the T cell surface, the T cell becomes double positive (DP),
expressing both CD4 and CD8 co-receptors, and will move onto the next step in T cell
development [17].
The next step in T cell development consists of positive and negative selection of
the T cells, which occurs in the thymic cortex and medullar, respectively. The TCR
expressed on a T cell recognizes peptide-MHC complexes on stromal or dendritic cells.
If there is no, or weak, recognition by the TCR of MHC and self-antigen, death by
neglect will occur. If the TCR binds too strongly to the MHC and self-antigen, the T cell
is negatively selected and apoptosis occurs [17]. High affinity TCRs can result in
autoreactive T cells and autoimmunity. Thus, negative selection serves to avoid
potential autoimmunity and to establish central tolerance. The TCR must recognize selfantigen in the context of MHC via a weak interaction to be positively selected [17].
However, it is critical that non-thymus related antigens are presented in the thymus to
prevent autoimmunity in other tissues. The transcription factor encoded by the
autoimmune regulator (AIRE) gene has been identified and is critical for the expression
of other tissue-restricted antigens [20-23]. Mutations in the human AIRE gene can result
in multiple different autoimmune diseases [24-26]. Therefore, AIRE is important for
promoting negative selection of T cells with TCR specific for peripheral antigens.
Following positive and negative selection, T cells migrate to the medulla and become
single positive, expressing either the CD4 or CD8 co-receptor, depending upon the
initial TCR signal [27]. Upon selection, these T cells will migrate into the periphery to
elicit an immune response. How TCRs recognize numerous antigens, both self and non-
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self, is discussed in a later section. First, it is important to understand how a TCR
recognizes its ligand to initiate T cell activation.
MHC Restriction
In 1974, Peter Doherty and Rolf Zinkernagel demonstrated the concept of MHC
restriction where T cell activation required two concurrent factors, foreign antigen in the
context of self-MHC [28]. It was later determined through the crystallization of HLA-A2
by Bjorkman and colleagues, that the MHC presented peptides [29, 30]. This has since
been well appreciated as a hallmark in T cell-mediated immunity, as well a unique
receptor-ligand interaction. Accordingly, two models have been proposed regarding the
drivers of the MHC restriction of TCRs.
The germline-encoded model suggests the TCR genes have co-evolved with the
MHC and thus, are selected for inherent motifs important for recognition of the MHC
molecules [31]. This model theorizes that multiple “interaction codons” exist and are
evolutionarily conserved in the TCR V region and MHC molecules to drive their
interaction [32]. The second model, the selection model, suggests that positive selection
during development in the thymus imposes MHC reactivity, not intrinsic reactivity to
MHC [33]. Specifically, this model suggests MHC restriction is driven by CD4 or CD8
co-receptor binding to the MHC for initiation of TCR signaling through localization of Lck
[34, 35]. Structural and functional studies have provided evidence for both of these
models and do not exclude the possibility for either.
There are a few pieces of evidence that support the notion that TCRs have
evolved to intrinsically recognize MHC molecules. First, TCR complementaritydetermining regions (CDRs) are more evolutionarily conserved among species than
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immunoglobulin [36]. CDRs are regions of the TCR, specifically in the variable region,
that bind pMHC. Studies examining TCR/pMHC crystal structures have revealed
evolutionarily conserved residues in the TCR V genes that contact MHC. Results
concluded that TCRs frequently utilize amino acids at positions 28, 29, and 31 of the
CDR1α chain, positions 50, 51, and 52 of the CDR2α chain, positions 28 and 29 of the
CDR1β chain, and position 48 of the CDR2β chain to bind the MHC molecule. For
example, position 31 in the TCR CDR1α chain frequently binds at position 155 in the α2
helix of MHC class I or position 70 in the β helix of MHC class II [37]. Also, around 40%
of human and mouse TCRs have a tyrosine or phenylalanine at position 31 in the TCR
alpha chain [37]. The most conserved residue in published TCR structures is a serine at
position 51 in the CDR2α chain. This residue makes contacts with the conserved
residues at positions 158 and 151 in the MHC class I α helix [38, 39]. One last example
in the TCR alpha chain is position 50 (a tyrosine in 16% of sequenced TCRs) in the
CDR2 region. Residues at this TCR position contact position 158 of MHC class I or
position 73 of the β helix in MHC class II [37]. In the TCR beta chain, a tyrosine or
asparagine at position 29 in the CDR1β often contacts the MHC class I α1 helix [37].
Most notable in the TCR beta chain is a conserved tyrosine at position 48 in the CDR2β
that contacts the MHC class I α1 helix. This residue appears to be critical for anchoring
the TCR to the MHC [37, 40]. There are numerous other specific examples of
conserved residues in TCRs that frequently contact residues in the MHC. Lastly, up to
30% of TCRs display intrinsic reactivity for MHC before completing positive and
negative selection in the thymus [41]. In summary, numerous examples of conserved
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interactions between TCRs and the MHC molecule suggests that TCRs have evolved to
intrinsically recognize MHC molecules.
Another concept that supports the germ-line encoded model is the fact that TCRs
generally bind pMHC in the same angled orientation across the MHC. Specifically, the
TCR alpha chain lies over the α2 helix or β helix in MHC class I or II, respectively, and
the TCR beta chain lies over the α1 or α helix of MHC class I or II, respectively [41].
Furthermore, the pivot point of the TCR centered over the peptide on the MHC is
generally the same. In MHC class I, this is positions 4 through 6 of the peptide versus
position 5 of the peptide in MHC class II [37]. If recognition of MHC was due to positive
selection (hypothesis of the selection model) you might question why the orientation is
not commonly reversed. It has been proposed that conserved residues in the CDR1 and
CDR2 regions of the TCR are responsible for determining the angle and orientation of
the TCR on pMHC, because these conserved interactions occur diagonally and
opposite of each other on the helices [37]. In summary, there are numerous features of
the TCR/pMHC interaction that suggest TCRs have evolved to intrinsically recognize
MHC molecules.
Conversely, there is evidence that also suggests TCRs have not co-evolved to
recognize the MHC molecules. First, TCR genes and MHC genes are found on different
chromosomes, and no mechanism appears to control co-expression of the proteins [37].
Furthermore, studies have demonstrated cases of antigen recognition in a MHC
independent manner [42, 43]. In mice, the deletion of MHC class I, MHC class II, CD4,
and CD8 resulted in the expression of TCRs with the ability to recognize epitopes in an
MHC independent manner [33]. Lastly, examples of reversed docking of the TCR over
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the MHC has been reported [44, 45]. Collectively, studies that analyzed the TCR/pMHC
crystal structure and the pre-selection TCR repertoire have resulted in conclusions that
provided evidence to support both the germline-encoded model and the selection model
for MHC restriction by TCRs. While the concept of MHC restriction is fundamental in
immunology, it is also important to understand how antigen is associated with the MHC
molecule in a process called antigen presentation.
Antigen Presentation
Activation of a T cell requires the engagement of the TCR with peptide in the
context of either MHC class I or MHC class II. MHC class I is expressed on all
nucleated cells, while MHC class II expression is limited to antigen presenting cells
(APCs) such as dendritic cells, macrophages, or B cells. The MHC class I α chain, MHC
class II α chain, and MHC class II β chains are each encoded by three genes in
humans. The classical MHC genes include HLA-A, -B, and -C for MHC class I and HLADR, -DQ, and -DP for MHC class II [46]. MHC is inherited as a haplotype from each
parent. Thus, two siblings have a 50% chance of sharing one haplotype, and a 25%
chance of being genotypically identical [47]. An exception to this is the possibility of
recombination [48]. The two inherited MHC alleles are co-dominantly expressed [49].
MHC genes are extremely polymorphic, with humans having over 800 MHC class I and
over 600 MHC class II alleles [50]. MHC genetic variation is proposed to be important
for fighting pathogens and overall survival and fitness [51-53]. This polymorphism allows
for genetic variation within the MHC region that binds antigen, known as the peptide
binding groove, and thus, affects the potential peptide presentation [54, 55]. In
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summary, the extremely polymorphic and co-dominantly expressed MHC genes, are
critical for the activation of a T cell-mediated immune response.
Peptides presented in the context of the MHC class I molecule and the MHC
class II molecule are derived from two distinct proteolytic mechanisms [46]. For MHC
class I peptide binding, proteins in the cytoplasm undergo degradation by the
proteasome and are transported to the endoplasmic reticulum (ER) by the transporter
associated with antigen processing protein (TAP). Peptides in the ER are loaded onto
the MHC class I molecule in the peptide loading complex and then the complex is
transported through the Golgi to the cell surface [46, 56]. Alternatively, peptides
presented on MHC class II are generally exogenous antigens from outside the cell that
are endocytosed. These exogenous antigens are delivered to late endosomes and are
processed by cathepsins. At this point, the MHC class II protein and the chaperone
HLA-DM protein have passed through the Golgi and into the late endosome [46]. The
class II-associated invariant chain peptide (CLIP) plays an important role in stabilizing
the peptide free complex, but must be removed to allow peptide loading [57, 58].
Peptides are loaded onto the MHC by HLA-DM and subsequently transported to the cell
surface [46]. In summary, antigen presentation occurs via two distinct pathways for
MHC class I and MHC class II.
In these studies we focus on TCRs that recognize peptides in the context of MHC
class I. Therefore, for the remainder of this dissertation, we will focus exclusively on
peptides presented in the context of the MHC class I molecule. MHC class I molecules
are comprised of an alpha chain (three extracellular domains - α1, α2, and α3) that is
non-covalently associated with β2 microglobulin. The alpha chain is commonly referred
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to as the heavy chain and the β2 microglobulin is commonly referred to as the light
chain. The β2 microglobulin lies next to the α3 domain and under the α1 domain [59].
The peptide binding groove is formed by the α1 and α2 domains. These regions are
highly polymorphic to allow for the allele specific peptide presentation [60, 61]. The
membrane-proximal α3 domain is the binding site for the CD8 co-receptor (conserved
among all MHC class I molecules) [62, 63]. MHC class I generally presents peptides of
eight to ten amino acids in length [64]. The interactions between the peptide and the
MHC are dependent upon charge distribution, geometry, and hydrophobicity of the
peptide binding groove [65]. In the heavy chain, six pockets (A-F pockets) in the MHC
peptide binding groove exist to accommodate peptide side chains. Specifically, the Bpocket accommodates the N-terminal anchor of the peptide and the F-pocket
accommodates the C-terminal anchor of the peptide [65-67]. Most anchor residues are
generally considered to be hydrophobic residues, but this can vary depending upon the
MHC class I allele. It is possible that antigen presentation favors more hydrophobic
regions of proteins, as a correlation has been observed between the immunogenicity
and the hydrophobicity of peptides [68]. Previous studies suggested that the exposed
hydrophobic domains in proteins significantly enhanced the rate of proteasomal
degradation and MHC presentation [69]. This correlation between immunogenicity and
hydrophobicity could be of importance when addressing the cross-reactivity of TCRs, a
major topic in this dissertation, and will be discussed in future sections.
pMHC Recognition by the TCR
The TCR/pMHC interaction is like any other protein-protein interaction in that it is
mainly governed by hydrogen bonds and charges, or van der Waals interactions [70].
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The individual van der Waals interactions are often weak, but in combination across the
whole TCR/pMHC interface can equate to considerable binding energies. The specificity
of the TCR/pMHC interaction is dependent upon, and can be enhanced by hydrogen
bonds and salt bridges [71]. On a more macro level, these interactions between the
TCR/pMHC are reliant on the CDRs of the TCR. As mentioned previously, CDRs are
regions of the TCR, specifically in the variable region, that bind pMHC. In summary, the
TCR/pMHC interaction consists of numerous van der Waals interactions and the TCR
CDR loops are critical for recognition of the pMHC.
The diversity of the TCR repertoire is critical for an inclusive T cell-mediated
immune response. The diversity found in the TCR repertoire is due to the six CDR loops
in the αβ TCR. CDR1, CDR2, and CDR3 loops are present in both the TCR alpha chain
and the TCR beta chain. The CDR1 and CDR2 loops are germline-encoded versus the
hypervariable CDR3 loop [8]. It has been estimated that 75-80% of the TCR/pMHC
interaction occurs between the CDR1 and CDR2 regions of the TCR and the MHC
helices [71]. As mentioned previously, TCRs generally bind the pMHC class I complex
in the same angled orientation across the MHC α helices [37]. The Vα domain generally
lies over the amino-end of the peptide and the α2 helix of MHC class I, whereas the Vβ
domain generally lies over the carboxyl-end of the peptide and the α1 helix of MHC
class I. More specifically, the most variable region of the TCR, the CDR3 region, is
positioned in the center of the binding interface in order to make contact with the
peptide. It was previously mentioned that antigen presentation favors hydrophobic
regions of proteins. Furthermore, peptides with a hydrophobic core are favorable for
TCRs to recognize because there is less precise geometry for the CDR loops to match
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or engage [72]. The more conserved regions of the TCR, the CDR1 and CDR2 regions,
are positioned over the tops of the MHC helices. However, it is still entirely possible for
the CDR3 loops to contact the MHC and the CDR1 and CDR2 loops to contact the
peptide [71, 73]. The TCR CDR loops are capable of conformational shifts to
accommodate the pMHC via their intrinsic flexibility. This has been demonstrated by
different TCR conformations in free and bound states, and with the same TCR binding
different ligands [74-79]. In summary, the CDR loops of the TCR orient over the pMHC
in a conserved manner and dictate any potential binding with the pMHC. TCR binding
with the pMHC is the first step for inducing subsequent T cell activation.
T cell Activation
T cell activation occurs when a TCR engages with a peptide in the context of the
MHC molecule. This TCR/pMHC engagement causes a conformational change in the
CD3 signaling complex [80, 81]. The CD3 signaling complex consists of ε, γ, δ, and ζ
subunits. These subunits form a CD3εγ heterodimer, a CD3εδ heterodimer, and a
CD3ζζ homodimer [82]. Upon antigen recognition via the TCR, the Src-family kinase,
Lck, is recruited to the CD3 complex and phosphorylates the immunoreceptor tyrosinebased activation motifs (ITAMS) of the CD3ζ chain [83]. The related Src kinase Fyn also
can phosphorylate the CD3 ITAMs [84-88]. Zap-70 is then recruited to the
phosphorylated ITAMS, is phosphorylated by Lck or itself, and propagates a cascade of
downstream signaling pathways [81, 89, 90]. Through a manifold of signaling pathways,
changes in gene expression occur and result in the production of cytokines and T cell
proliferation, among other factors involved in a pro-inflammatory response. A majority of
these changes in gene expression are initiated by the transcription factors NFAT, NF-
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κB, and AP-1 [83]. Overall, TCR/pMHC engagement induces T cell activation through
the CD3 complex, signaling, and a pro-inflammatory response.
CD4 and CD8 co-receptors can affect TCR/pMHC engagement and T cell
activation. Although not always the case, it is typically appreciated that CD8 + T cells
mediate a cytotoxic T cell response through recognition of peptide in the context of
MHC class I, while CD4+ T cells mediate a helper T cell response through recognition of
peptide in the context of MHC class II [80]. The CD4 and CD8 glycoproteins play an
important role in T cell activation. These co-receptors function by stabilizing the
interaction between the T cell and antigen presenting cell via the MHC on the antigen
presenting cell [85]. This stabilization can also have an impact on the affinity of the
interaction. Additionally, it has been demonstrated that the cytoplasmic tails of CD4 and
CD8 help recruit Lck to the CD3 signaling complex [91, 92]. Therefore, CD4 and CD8
are important co-receptors in T cell activation due to their dual functions.
The CD3 signaling complex is important for both TCR expression and T cell
function. T cell activation and further TCR signaling in response to antigen recognition is
essential to initiate an immune response. However, there are numerous factors within
the TCR/pMHC interface that can impact the downstream T cell response. These
factors and their potential impact on T cell function will be described in the next section.
T cell Function
T cells play a critical role in the adaptive immune response and cell-mediated
immunity. T cells differentiate into a variety of subtypes dependent upon their function.
These subtypes commonly include: effector, cytotoxic, helper, memory, regulatory,
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natural killer, mucosal associated invariant, and gamma delta. Cytotoxic and helper T
cells are the focus of this dissertation and therefore, will be discussed in further detail.
The two major T cell subtypes examined in this dissertation are helper T cells and
cytotoxic, or killer T cells [93]. CD4+ T cells are generally classified as helper T cells
although, but they have been shown to have cytotoxic abilities [94, 95]. Helper T cells
are important for directing an effector response and immune cell differentiation [96].
Secreted cytokine patterns further categorize T helper cells into two major categories,
either Th1 or Th2, but the production of these cytokines are not mutually exclusive [95].
Other categories include Th17, Th22, and Th9. Cytokines important to the studies
completed in this dissertation and their basic function are shown in Table 1. Th1
responses are important for cell-mediated immunity and are generally classified by IFNγ and TNF-α secretion. Th2 responses are important for humoral-mediated immunity
and are generally classified by IL-4, IL-5, and IL-13 secretion [96]. IL-2 has been shown
to be produced in both Th1 and Th2 responses [97]. In summary, T cells are capable of
secreting numerous different cytokines that affect an immune response and the patterns
of cytokine secretion can categorize T cells into various T cell subclasses.
CD8+ T cells are generally classified as cytotoxic or killer T cells. These cells are
important for the clearance of cells infected with intracellular pathogens as well as
cancers [98]. Upon engaging with pMHC on a target cell, CD8+ T cells secrete large
amounts of IFN-γ and TNF-α [99]. Secretory vesicles within the T cell, release perforin
and granzyme which mediate death of the target cell [100]. Cell-mediated targeted cell
death can also occur via the Fas/Fas ligand pathway.
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Cytokine

Function

IFN-γ

Activates T cells, NK cells, and macrophages, increase HLA
expression on tumors, increases chemokine secretion [1, 96]

IFN-α

Involved in viral infections, increases HLA class I expression on
tumors, enhances dendritic cell maturation [1, 101]

TNF-α

Initiates pro-inflammatory innate immune response, induces fever,
cell death, and hemorrhagic necrosis of tumors [1, 102]

IL-2

Stimulates T cell proliferation, activation, and memory
differentiation [97]

IL-4

Induces expansion of Th2 cells, activates B cells, enhances IgG
and IgE production [96, 103]

IL-5

Stimulates antibody production, enhances proliferation of
eosinophils, drives allergic type inflammatory responses [96, 104]

IL-6

Enhances antibody production and cytotoxic T cell differentiation,
inhibit T regulatory differentiation [105-107]

IL-12

Induces expansion of Th1 cells, enhances CD8+ T cell activation,
proliferation, and survival [1, 108]

IL-13

Facilitates B cell activation, promotes mucus production, mediator
of allergic asthma, can inhibit production of pro-inflammatory
cytokines [96, 109]

IL-15

Stimulates T cell and NK cell activation and proliferation, enhances
survival of memory T cells [1, 110]

IL-17

Promotes recruitment and activation of innate cells, enhances B
cell function, induces pro-inflammatory cytokine production [96,
111]
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IL-22

Regulates autoantibody production, promotes tissue regeneration
[96, 112]

GM-CSF

Stimulates stem cells to produce granulocytes, increases dendritic
cell and macrophage activation [1, 113]

Table 1. Cytokines Discussed in this Dissertation and their Basic Function.

Herein, Fas ligand, expressed on activated T cells, binds to Fas expressed on the target
cell and causes cell death through initiated signaling cascades [114]. Following antigen
encounter, T cells can expand and differentiate into effector and memory cells [115].
Additional T cell subclasses are characterized by their level of differentiation. Naïve T
cells differentiate into stem cell memory T cells; central memory T cells; effector
memory T cells; and effector T cells. Memory and proliferation decrease with
differentiation, while effector function increases with differentiation [93]. These T cell
subsets are commonly distinguishable by different surface markers. In CD8+ T cells,
these surface markers include L-selectin (CD62L), CCR-7, CD45RO, and CD45RA
[116, 117]. Specifically, naïve T cells are CD62L+CCR7+CD45RA-CD45RO-, stem cell
memory T cells are CD62L+CCR7+CD45RA+CD45RO+, central memory T cells are
CD62L+CCR7+CD45RA-CD45RO+, effector memory T cells are CD62L-CCR7-CD45RACD45RO+, and effector T cells are CD62L-CCR7-CD45RA+CD45RO- [93]. In CD4+ T
cells, these surface markers include CD25, CD45RA, CD45RO, and CD127.
Specifically, naïve T cells are CD25-CD127+CD45RA+CD45RO-, central memory T cells
are CD25+CD127+CD45RA-CD45RO+, effector memory T cells are CD25CD127+CD45RA-CD45RO+, and effector T cells are CD25+CD127-CD45RA+/-CD45RO+/-
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[93]. Many different factors have been described to be important in inducing memory
differentiation such as strength and duration of TCR/pMHC interaction [118], help from
CD4+ T cells and dendritic cells [119-121], natural killer group 2 member D (NKG2D)
expression [122], and various cytokines and chemokines [123-127]. Memory T cells
have been shown to rapidly re-express cytokines and lytic machinery. This hyperresponsive state allows them to rapidly respond to re-encountered antigen, which differs
from naïve T cells [128-130]. More recently, tissue resident memory T cells have been
identified and are characterized by their non-circulating nature and remain in peripheral
tissue sites [116]. Central memory T cells continuously recirculate throughout the blood
and lymphoid organs, such as the spleen and lymph nodes. Conversely, effector
memory T cells generally traffic to non-lymphoid tissues [131]. These different memory
T cells and further, memory subtypes, have been implicated to be important in
immunotherapy. For instance, CD4+ and CD8+ central memory T cell subsets have
been demonstrated as superior to effector memory T cell subsets in terms of activation,
expansion, and persistence in vivo [132-135]. Strategies for generating these T cell
subsets include purification on surface markers and modulation with cytokines [93, 132,
136, 137]. In conclusion, numerous T cell subsets exist and demonstrate unique
functional phenotypes to elicit a critical role in adaptive immunity.
TCR Affinity
Affinity is a significant factor that shapes an immune response both in regards to
antibodies and TCRs. One way in which TCRs and antibodies differ, is the fact that
antibodies can undergo affinity maturation. Affinity maturation is the process in which
antibodies increase their affinity throughout an immune response [138, 139]. Gene
rearrangement of immunoglobulin V, D, and J segments occurs during B cell

19
development to generate a repertoire of B cells that express diverse antigen receptors.
However, upon recognition of antigen, B cells undergo clonal expansion and affinity
maturation [140]. B cells traffic to the germinal centers of lymphoid follicles and where
they undergo somatic hypermutation in the CDR regions of the immunoglobulin genes
which introduces single nucleotide substitutions to enhance antibody affinity, sometimes
up to 100-fold higher, reaching the nM-pM range [141]. In summary, this process is
imperative for antibody-mediated responses, however, affinity maturation does not exist,
or is not required for T cell responses via their TCR.
TCRs do not undergo affinity maturation, nonetheless, TCR affinity has been
implicated to have importance in a T cell response. Affinity is generally reported by the
dissociation constant, KD, a measurement used to describe the strength of the
interaction between a TCR and a given pMHC complex [142]. Generally speaking,
weakly self-reactive TCRs harbor affinities in the 10-100 μM range and high affinity
TCRs that recognize foreign peptide fall in the 1-10 μM range [142, 143]. It has been
generally appreciated that a higher affinity TCR will elicit a more robust T cell response;
but more recently it is becoming increasing apparent that TCR affinity is not always a
direct correlate or adequate predictor of T cell function [144]. Higher affinity TCRs do
not always elicit the most robust T cell response, as it has been demonstrated that
TCRs with affinities around 1 μM or less result in decreased TCR signaling and T cell
function [142, 145, 146]. Src homology 2 domain-containing phosphatase 1 (SHP-1) is
an important negative regulator in TCR signaling by inactivating Lck. Studies show that
SHP-1 is upregulated in an affinity dependent manner [142]. Overall, TCR affinity has
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been demonstrated to be an important factor in T cell function and antigen recognition
and is a key element of this dissertation.
The interaction between the TCR/pMHC impacts numerous kinetic parameters in
addition to affinity. Another parameter is the dissociation rate (koff) or half-life (t1/2). Serial
triggering is important to allow one pMHC complex to trigger multiple TCRs. It is
estimated that one pMHC can trigger up to 200 TCRs [147]. Therefore, the optimal
dissociation rate will be short enough to allow for other TCRs to bind the same pMHC,
but long enough to allow for complete signaling [148]. This is critical in order to induce T
cell activation despite the presence of very few pMHC complexes [149]. Evidence
suggest that the t1/2 can affect if the TCR behaves as an agonist, partial agonist, or
antagonist [147]. This has been shown to alter patterns of ITAM phosphorylation and
ZAP-70 activation. For example, lower affinity interactions may act as partial agonists
and induce cytokine production but no proliferation [150, 151]. However, maximum
cytokine production requires maintenance of the TCR and APC synapse while the
release of cytotoxic granules is estimated to only require 1 to 3 pMHC complex
interactions [151, 152]. In summary, the affinity of a TCR takes into account, as well as
affects, multiple biophysical variables that successively influence the T cell response.
Methods of Measuring TCR Affinity
There are multiple methods that have been used to quantify TCR binding affinity.
Some of these methods include surface plasmon resonance (SPR) [153], isothermal
titration calorimetry (ITC) [154, 155], fluorescence resonance energy transfer (FRET)
[156-158], fluorescence anisotropy [154, 159], the thermal fluctuation assay [160-162],
tetramer off-rates [163-165], and the micropipette adhesion frequency assay [166].
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Since SPR and the micropipette adhesion frequency assay are used in these studies,
we will focus more in detail on these two methods for measuring TCR affinity.
The “gold standard” for measuring TCR binding affinity is generally via SPR.
Briefly, either soluble TCR or pMHC, is secured to the sensor surface and the binding
partner, either soluble TCR or pMHC, flows over the bound molecule. As binding
occurs, mass accumulates on the sensor surface and increases the signal. When using
SPR with immobilized TCR, the KD is equal to the concentration of free unbound pMHC
when 50% of the immobilized TCR is bound [167]. TCR affinity and kinetic properties
between soluble TCR and pMHC have most frequently been measured via SPR
technology. These measurements provide information about the physical chemistry of
the TCR/pMHC binding interaction. However, because three-dimensional (3D)
measurements via SPR require soluble TCR and pMHC, they fail to account for aspects
unique to membrane-bound proteins. The affinity measurement is limited to and
dependent upon only the ligand-binding site. Therefore, TCR/pMHC binding kinetics
measured via 3D SPR are advantageous for observing molecular TCR/pMHC
properties, however, they have been demonstrated to be subpar for predicting T cell
functional activities [168].
Systems have consequently been developed to study these membrane-bound
interactions in a two-dimensional (2D) manner, and have been demonstrated to be
better predictors of functional T cell outcomes. Unlike in SPR, these are cell to cell
interactions. In one of these systems, the micropipette adhesion frequency assay, a red
blood cell (RBC) serves as the APC and can be coated with pMHC via biotinstreptavidin coupling [169, 170]. Using a micropipette, a T cell and the pMHC coated
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RBC are brought together and pulled apart via micromanipulation. Multiple parameters
can be measured such as affinity, adhesion frequency, force, off-rate, and on-rate [162,
171]. Kinetic parameters of the TCR/pMHC measured in 2D have been shown in both
CD4+ and CD8+ T cells to better correlate to T cell function than when measured in 3D
[170, 172]. Specifically, one study using the 42F3 TCR (alloreactive TCR that
recognizes HD-Ld presenting the peptide p2Ca933-940 of mouse 2-oxoglutarate
dehydrogenase), demonstrated that 2D micropipette affinity measurements with multiple
altered-peptide ligands better correlated to T cell potency than 3D SPR measurements.
However, 3D SPR measurements better correlated with tetramer binding, eluting to the
differences in TCR affinity using purified proteins or membrane-bound interactions
[173]. In conclusion, due to the intrinsic factors of 3D and 2D affinity measurements,
they can differentially correlate with T cell function. Affinity measurements obtained via
SPR (3D) and via the micropipette adhesion frequency assay (2D) are included in this
dissertation. Furthermore, how these measurements correlate to T cell function and
cross-reactivity will be discussed in later chapters.
T cell Cross-Reactivity
Understanding T cell cross-reactivity is essential for my studies. The clonal
selection theory suggested that B cells and T cells have specificity for only one antigen
and it was doubtful they could recognize alternative ligands [174]. It was not until the
1990s that this paradigm was questioned and suggested highly improbable [175, 176].
The need for T cells to be inherently cross-reactive is now a fundamental concept in
adaptive immunity and the idea of TCR binding degeneracy is well appreciated [177]. It
has been estimated that there are less than 108 unique TCRs in the naïve T cell
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population of humans [178]. Albeit, it has been estimated that an effective T cell
repertoire must be capable of recognizing up to 1015 potential foreign antigens [177].
Therefore, the number of potential antigenic peptides exponentially surpasses the
number of potential TCRs. Furthermore, estimations suggest a T cell clone must be
able to recognize at least one million different peptides [176]. There are multiple
reasons as to why a cross-reactive T cell population is advantageous. First, a crossreactive T cell population allows for proficient immunity against an unlimited number of
antigens via a limited number of T cells. Secondly, cross-reactivity reduces the potential
for immune escape by pathogens because escape of recognition by one TCR may be
recognized by another TCR. Thirdly, with cross-reactive T cells, fewer T cells are
needed to scan for foreign antigen, which is both temporally and spatially advantageous
[177]. Overall, it is well appreciated that T cells are cross-reactive and they need to be
in order to maintain a comprehensive immune system and provide protection against
the diverse pathogens we encounter.
The cross-reactivity of a T cell can be influenced by its TCR’s affinity with various
ligands. Although exceptions exist, it is generally appreciated that higher affinity TCRs
are more cross-reactive [179, 180]. It is believed that higher affinity TCRs can better
withstand changes in the peptide structure and still allow for T cell activation.
Conversely, in a lower affinity TCR, these changes in the peptide structure could result
in reduced binding energy and thus, yield an interaction that is below the threshold of T
cell activation [148]. How TCR affinity affects T cell cross-reactivity will be further
discussed throughout this dissertation. In summary, T cells are cross-reactive and the
level of cross-reactivity can be influenced by TCR affinity.
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The Immune System and Cancer
The immune system is essential for controlling many malignant cells. It is
estimated that a cell can experience over 20,000 DNA damaging events a day, but
these are normally repaired [181, 182]. A malignant cell can have more than an
estimated 11,000 mutations [183]. The immune system can detect and kill these
malignant cells. This was first described by Burnet and Thomas in the cancer
immunosurveillance hypothesis [184-186]. When a tumor grows to more than 2-3 mm,
blood supply and stromal remodeling induces proinflammatory cytokines and initiates
the recruitment of innate cells, such as dendritic cells, macrophages, and NK cells, to
the tumor where they produce IFN-γ [187]. The recruited dendritic cells then take up
tumor associated antigens and cross-prime T cells in lymph nodes [188]. Tumor
associated antigens can include viral, mutated, differentiation, cancer germline, or
overexpressed antigens [189]. Conveniently, the “Cancer Antigenic Peptide Database”
provides a regularly updated list and characterization of numerous different tumor
antigens [190]. Tumor antigen specific T cells then traffic to the tumor site and eliminate
the tumor cells [191]. Overall, both innate and adaptive immune cells are important for
the control of malignant cells.
The idea of cancer immunoediting was subsequently described to include the
immune system’s role in both host protection and tumor sculpting. The immunoediting
process has been further described in three phases: elimination, equilibrium, and
escape [192]. After elimination, as described above, the equilibrium phase consists of
continuous elimination of the tumor, while selecting for tumor cell variants that can
evade the immune response. Escape occurs when the tumor cell variants expand
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and/or metastasize due to loss of control by the host immune system [191]. Cancers
have developed numerous mechanisms to escape recognition by the immune system
[191]. Mainly, this is achieved by creating a “cold” immunosuppressive tumor
microenvironment [193]. To name a few of these mechanisms, tumors can
downregulate MHC expression, mutate antigen processing pathways, or lose
expression of, or mutate, the targeted antigen [194]. Tumors can express checkpoint
molecules to suppress T cell function. To generate an immunosuppressive environment,
tumors can recruit regulatory T cells, myeloid-derived suppressor cells, and type II
macrophages [195]. Overall, identification of these numerous immunosuppressive
mechanisms elicited by tumor cells, has been important in expanding the field of tumor
immunology [196].
History of Immunotherapy
Scientists have been searching for decades to find new ways in which the host’s
immune system can be exploited to treat cancer. In the 19th century, it was first
observed that erysipelas infection aided tumor regression [197]. By 1959, it was shown
that Bacillus Calmette-Guerin (BCG), an attenuated live bovine tubercle Bacillus-based
vaccine for tuberculosis, could inhibit tumor growth in mice [198]. This was the first
immunotherapy based treatment utilized for cancer treatment in 1970 [199].
Subsequently, IL-2 was discovered upon its ability to activate and expand T cells [200].
It was further demonstrated that administration of recombinant IL-2 (rIL-2) to tumor
bearing mice elicited regression of pulmonary metastases and subcutaneous tumors
[201]. These exciting results were quickly translated into the clinic. In the first six cancer
patients treated with high dose IL-2, three patients had objective responses [202].
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However, since not all patients responded, the combination of cellular immunotherapy
and IL-2 treatment was investigated. It was demonstrated that peripheral blood
mononuclear cells (PBMCs) cultured with IL-2 could generate lymphocyte-activated
killer (LAK) cells and could then kill tumor cells in vitro [203-205]. In vivo models
combining rIL-2 treatment with adoptive transfer of LAK cells into tumor bearing mice
demonstrated antitumor activity if treated prior to tumor vascularization [206, 207].
Following these results, the first cellular immunotherapy combined high dose IL-2 with
LAK cells [208]. LAK cells are made up of NK cells and NK T cells, however, their antitumor efficacy with high dose IL-2 was as effective as high dose IL-2 alone [209-211].
Since then, IL-2 has been and is currently used in combination with many forms of
immunotherapies in many clinical trials [212].
TIL was an attempt to improve upon the responses obtained with IL-2 or LAK
cells in cancer therapies. TIL have been found in melanoma lesions for over forty years
[213]. It was later demonstrated that culturing TIL ex vivo in high amounts of IL-2 could
restore their proliferation and lytic function [214]. Objective responses were observed in
about 31% of melanoma patients receiving autologous cell transfer of ex vivo TIL
expansions and IL-2 treatment [215]. To improve upon this, these therapies were given
in conjunction with lymphodepletion, where objective responses rose to 55% in
melanoma patients [212, 215-218]. Host lymphodepletion has been demonstrated to be
important to enhance the efficacy of adoptively transferred cells for a few reasons.
Specifically, lymphodepletion can create space for the transferred cells and deplete
regulatory T cells [219, 220]. A 72% response rate was later observed in metastatic
melanoma patients treated with 12 Gy of total-body irradiation prior to TIL and IL-2
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treatment [221]. In summary, the observation of TILs present in the tumor lesions has
eventually supported the notion of utilizing T cells for cancer targeted therapies [222].
Aside from IL-2, LAK, and TIL, numerous other forms immunotherapies have
subsequently been investigated. These include cytokines, chemokines, dendritic cellbased vaccines, antibodies, and gene-modified cells. Other cytokines used in clinical
trials include TNF-α, IFN-γ, IFN-α, IL-15, and GM-CSF [1]. Efficacies of single agent
cytokine therapies ranged between 5% and 43% of patients exhibiting partial responses
and 13% and 42% of patients exhibiting complete response, however, many treatments
exhibited toxicities [1]. One open clinical trial is treating patients with TIL transduced to
express CXCR2, with the expectation that CXCR2 will enhance T cell trafficking to the
tumor [1, 223]. Peptide and peptide pulsed dendritic cell vaccination strategies have not
been successful in melanoma, with only 2.6% of patients having an objective response
[224, 225]. This was most likely due to the observed functional inabilities of melanoma
reactive T cells in patients [226]. Albeit, Sipuleucel-T, a dendritic cell vaccine, has been
FDA approved for treatment of castrate-resistant metastatic prostate cancer [227].
Furthermore, vaccinations targeting patient specific neo-antigens induced expansion of
neo-antigen specific T cells and protected against tumor reoccurrences [228-230]. Neoantigens have become an attractive focus for research, as it has been demonstrated
that tumor mutation burden can be a strong determinant of responses with
immunotherapies [231-235]. Targeting neo-antigens is advantageous due to their
exclusive expression on tumor cells, and thus, could reduce the potential for on-target,
off-tumor cross-reactivity [236, 237]. Overall, ongoing research may provide evidence

28
on the role of vaccination in T cell responses and anti-tumor immunity, especially in the
targeting of neo-antigens.
In the last three decades, advancements have been made in identifying
suppressive receptors that inhibit T cell responses. These receptors are classified as
checkpoints and include programmed cell death protein 1 (PD-1), cytotoxic Tlymphocyte associated protein 4 (CTLA-4), T-cell immunoglobulin and mucin-domain
containing-3 (TIM-3), and lymphocyte activation gene-3 (LAG-3). CTLA-4 was first
identified in 1988 and by 1996 it was demonstrated that blocking CTLA-4 could enhance
anti-tumor responses in mice [238-240]. In subsequent clinical trials, response rates
ranged from 16.2% to 28.5% of patients and responses were often durable, lasting
more than 34 months [241-243]. The checkpoint blockade mAb targeting CTLA-4 was
the first immunotherapy drug to become FDA approved in 2011 for the treatment of
melanoma [240, 244-247]. Overall, CTLA-4 mAb has demonstrated success as a single
agent in immunotherapy.
The second checkpoint, PD-1, was identified and cloned in 1992 and 1994,
respectively [248, 249]. It was later demonstrated that PD-1 ligand (PDL-1) expression
on tumor cells promoted tumor escape via T cell suppression in mice [250, 251].
Furthermore, in mouse models, tumor growth could be suppressed using an anti-PD-L1
mAb [251, 252]. In subsequent clinical trials, up to 40% of patients had objective
responses and responses were durable, lasting more than one year [245, 253, 254].
Consequently, the checkpoint blockade mAb targeting PD-1 or PD-L1 has also been
FDA approved [253, 255]. Overall, checkpoint blockade antibodies demonstrated
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success as single agent therapies and thus, remain a promising area of research for
combination immunotherapies.
A robust T cell response is important for the success of cancer immunotherapies.
Therefore, further improvements in T cell therapies have been developed using TCR or
CAR gene-modified T cells to redirect the specificity of T cells. In the 1980’s, scientists
explored methods of combining the functional response of a T cell with the diversity of
antibody recognition. As a result, CARs were developed to consist of an extracellular
single chain variable fragment linked to an intracellular signaling domain [256]. The first
described CAR contained the Fc receptor (FcR) γ chain signaling domain, and
subsequent CARs contained the zeta chain of the CD3 signaling complex [256, 257].
The CD3ζ chain contains three ITAMs compared to FcRγ’s single ITAM. Succeeding
CARs have been developed over the years with varying signaling and stimulatory
components. Specifically, in addition to the CD3ζ domain, second generation CARs
implemented another costimulatory domain (such as CD28, 4-1BB, or OX40) and third
generation CARs implemented two additional costimulatory domains [257-261]. A
schematic of the different generations of CARs is depicted in Figure 1. CAR genes (and
also TCR genes) are commonly inserted into T cells via viral vectors. Numerous
different viral vectors have been utilized to insert genes into T cells. Some of these
include adenoviral, retroviral, lentiviral (technically retroviral), and poxviral [262].
Retroviruses are commonly used due to their ability to integrate into the host cell’s
genome [263, 264]. Specifically, lentiviral vectors and γ-retroviruses, generally based on
murine leukemia virus (MLV), are frequently used in gene therapy [262].
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Figure 1. Generations of CARs. CARs include an extracellular single chain variable
fragment comprised of variable light (VL) and heavy (VH) chains linked via hinge.
Intracellular domains, linked via hinge, in first generations CARs included either FcRγ or
CD3ζ chain signaling domains. Second generation CARs included an additional
costimulatory domain. Third generation CARs included two costimulatory domains.

In summary, various viral vectors have been utilized to introduce various generations of
CARs into T cells to redirect T cell specificity towards the antigen of choice.
A wide variety of CARs have been developed to target an array of antigens both
in vitro and in vivo. Some of these targets include antigens expressed on glioblastoma,
neuroblastoma, melanoma, hematologic malignancies, prostate cancer, breast cancer,
colorectal cancer, and ovarian cancer [258]. CARs are advantageous due to their ability
to recognize antigen in an MHC independent manner. However, adverse events in
clinical trials have been documented due to “on-target, off-tumor” reactivity, tumor lysis
syndrome, and cytokine storm [258]. CAR T cells have exhibited varying levels of
clinical success, albeit, the greatest success with CAR T cells has been exhibited in
recent years with the treatment of refractory B-cell leukemia [265, 266]. The first clinical
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trial using the CD19-targeting CAR resulted in objective responses in 57% of patients
[265, 266]. These rates have since increased up to almost 80% complete response
rates in patients [267, 268]. Consequently, the use of autologous CAR T cells for the
treatment of large B-cell lymphoma was FDA approved in 2017 [265, 269, 270]. Overall,
the use CAR T cells for treatment of B-cell malignancies has been a significant
breakthrough in the field of immunotherapy and CAR T cells remain a promising area of
research in terms of gene-modified T cells.
TCR gene-modified T cells have also shown success in the clinic and remain a
significant area of research in addition to CAR T cells. TCR gene-modified T cells are
the focus of this dissertation and thus, will be described in more detail. As TIL therapies
exhibited success in many patients, researchers began to identify and isolate tumorreactive TCRs. The first melanoma specific TCRs were cloned in 1994 and 1995 [271,
272]. Subsequently, the use of TCR gene-modified T cells for adoptive cell transfer
moved into clinical trials. A graphical schematic of the process of using TCR genemodified T cells for adoptive T cell transfer therapy is depicted in Figure 2 (this process
is the same for CAR T cells, except CAR genes are inserted into a viral vector instead
of TCR genes). In the first clinical trial, using a TCR targeting a melanoma associated
antigen, 2/15 patients had objective clinical responses and engraftment of the
introduced T cells [273]. In clinical trials thus far, the use of TCR gene-modified T cells
has yielded efficacies in up to 55% of treated patients [1, 274, 275]. Overall, the use of
TCR gene-modified T cells has become increasingly widespread in immunotherapies,
with advancements in utilization as a single agent therapy, as well as in combination
therapies.
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Figure 2. Graphical Representation of Generating TCR Gene-Modified T cells for
Adoptive T cell Transfer Therapy. Tumor reactive T cell clones are isolated and
expanded from the PBMCs or TIL of a patient with cancer. TCR alpha and beta chain
genes that are reactive against tumor associated or viral antigens are identified and
cloned into a viral vector. Packaging and producer cell lines are utilized to make high
titer virus. Patient activated peripheral blood T cells are transduced with viral
supernatant, expanded, and administered back to the patient. The specificity of these
circulating T cells is now redirected toward the specific tumor or viral antigen resulting in
anti-tumor immunity.
Adoptive T cell therapy and the use of TCR gene-modified T cells have
revolutionized the field of immunotherapy through their ability to target specific tumor or
viral antigens of choice [276]. With all the success of this treatment, there are also
potential drawbacks in utilizing TCR gene-modified T cells. First, introduction of another
TCR into the T cell allows for the potential of αβ TCR chain mispairing between the
introduced and endogenous TCR chains. The formation of mixed dimers can lead to
new TCR specificities and result in autoimmunity. This phenomenon has been
demonstrated in murine models [277, 278], but has never been proven to have occurred
in clinical trials. Strategies have been implemented to enhance proper TCR chain
pairing by making modifications to the TCR genes. These strategies include: addition of
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another disulfide bond, replacing human constant regions with murine constant regions,
codon optimization, leucine zipper fusion proteins, and single chain TCRs [94, 279-286].
In vitro evidence suggested modifying the TCR genes to express murine constant
regions or leucine zipper fusion proteins resulted in enhanced proper TCR chain pairing
and T cell function [94]. Overall, one of the challenges associated with the introduction
of a new TCR is TCR chain mispairing. TCR chain mispairing has the potential to cause
autoimmunity, and strategies to enhance proper TCR chain pairing have been
investigated.
Properly paired introduced TCRs can also cause potential cross-reactivity of the
TCR gene-modified T cells. Specifically, TCR gene-modified T cells can recognize the
on-target antigen on normal tissue or an off-target antigen on normal tissue [287]. Ontarget, off-tumor antigen recognition has been described in clinical trials using nonmodified TCRs. Specifically, this occurred where the TCR target was a melanoma
antigen that is also expressed in the ear, eye, and normal melanocytes, and where the
TCR target was a colorectal cancer antigen that is also expressed in epithelial cells
throughout the gastrointestinal tract [288-290]. The clinical implications of this
drawback, moreover when modifying the TCR, will be discussed in the next section. The
focus of this dissertation will include a novel strategy proposed to enhance the efficacy
and safety of TCR gene-modified T cells for adoptive T cell transfer.
Adverse Events Observed in Clinical Trials using Affinity Enhanced TCRs
Despite the success seen in clinical trials, the use of TCR gene-modified T cells
does not elicit an anti-tumor response in every patient. TCRs that target self-antigens
generally harbor a low affinity as a result of negative selection in the thymus. Therefore,
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TCR affinity enhancement has been utilized as a strategy to enhance the anti-tumor
efficacy of TCR gene-modified T cells. Specifically, yeast or phage display is frequently
utilized as a method for affinity enhancement [291-296]. However, random mutation
through yeast or phage display can lead to unanticipated off-target cross-reactivity
[142]. Adverse events have been observed in clinical trials where autologous affinity
enhanced TCR gene-modified T cells were used and have been attributed to crossreactivity. In summary, TCR affinity enhancement can augment the anti-tumor
response, but also has the potential to cause off-target autoimmunity in patients.
There are two clinical trials where affinity enhanced TCRs were utilized in TCR
gene-modified T cells and resulted in unexpected patient deaths. An affinity enhanced
HLA-A2 restricted TCR that targeted MAGE-A3 was used to treat nine cancer patients.
This TCR was previously affinity enhanced by mutating a residue that improved T cell
reactivity in CD8+ T cells and allowed for recognition in CD4+ T cells. This TCR was
chosen from 85 variant TCRs containing single or multiple amino acid substitutions in
the CDR3 region of the TCR alpha chain [297]. 4/9 patients exhibited neurological
toxicity and two of these patients subsequently died. Further investigation indicated that
MAGE-A12 and possibly MAGE-A1, MAGE-A8, and MAGE-A9 were expressed in the
brain. In this case, the reactivity against these other MAGE-A targets was known, but
their expression in the brain was not. It is unclear as to if the WT TCR would have
resulted in the same observed neurological toxicity. These adverse events can be
attributed to an on-target, off-tumor cross-reactivity of the introduced TCR genemodified T cells [5].
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In the second case, an affinity enhanced HLA-A1 restricted TCR that targeted
MAGE-A3 was affinity enhanced via phage display through four substitutions in the
CDR2 region of the TCR alpha chain. Herein, 2/2 treated patients died from cardiac
toxicity four or five days after TCR transduced T cell infusion, respectively. Further
analysis indicated that the TCR gene-modified T cells had trafficked to the heart and
histological results were consistent with immunologically mediated damage. This is an
example of off-target, off-tumor cross-reactivity [6]. It was later determined that the
affinity enhanced TCR recognized the Titin protein expressed on cardiomyocytes,
whereas recognition of Titin was not conferred in T cells expressing the WT TCR. The
MAGE-A3 and Titin peptides differ in sequence in four of nine residues, including the
core, yet the affinity enhanced TCR recognized both peptides in the context of MHC
with almost identical conformation of the CDR loops [298, 299]. This is an example of
how high affinity TCRs can tolerate alterations in the peptide structure [148]. Pre-clinical
screening for potential cross-reactivity of the affinity enhanced TCR was completed
using only a limited number of off-target tissues. However, Titin is only expressed in
beating cardiomyocytes derived from induced pluripotent stem cells and the epitope is
not homologous in the mouse [298, 299]. These results exemplify the potential dangers
of non-specifically affinity enhancing a TCR without extensive pre-clinical screening.
Both of these described clinical trials demonstrated the potential dangers in using
affinity enhanced TCRs, especially non-specific enhancement, even when done so with
an originally low affinity TCR. However, despite the risks involved in using an affinity
enhanced TCR, one affinity enhanced TCR was used in patients that did not result in
adverse events [300-304]. This NY-ESO-1 targeting TCR contained two mutations in
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the CDR3 region of the TCR alpha chain that enhanced T cell reactivity [304]. Overall,
these results indicated that TCR affinity enhancement does not always lead to off-target
cross-reactivity.
Even though affinity enhanced TCRs did not result in adverse events in every
clinical trial, it is evident that we need more advanced and meticulous strategies in order
to enhance the anti-tumor responses of TCR gene-modified T cells while still sustaining
safety for treated patients. The purpose of this dissertation is to address that current
obstacle in the field.
MART-1 and DMF5 TCR
One subclass of tumor associated antigens includes differentiation antigens.
Many differentiation antigens have been identified for their frequent expression in
melanomas. Some of these include tyrosinase [305, 306], premelanosome protein
(PMEL or gp100) [307-309], and tyrosinase related protein 1 and 2 (TRP1 and TRP2)
[310, 311]. Herein, we focus on the melanoma differentiation antigen, melanoma
antigen recognized by T cells 1 (MART-1). MART-1 is lineage-specific protein found in
melanocytes and is important for melanosome maturation [312].
MART-1 was first identified in 1994 by cDNA expression cloning [313]. It was
recognized by a melanoma patient’s HLA-A2 restricted TIL. MART-1 mRNA was found
in 11 out of 14 melanoma lines. Furthermore, expression of MART-1 was confirmed in
retinal tissue, but no other normal tissue lines [313]. Subsequent studies show MART-1
expression in up to 90% of melanomas [314]. MART-1 epitopes have been recognized
in the context numerous different HLAs, expressed on both MHC class I and MHC class
II [315-320]. Expression of this tumor associated antigen has been linked to significantly
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longer overall survival in melanoma patients [321]. In summary, MART-1 has been a
frequently targeted melanoma antigen for therapy due to its recurrent, and sole
expression on melanocytes and melanomas.
MART-1 is a unique antigen because high frequencies of MART-1 reactive T
cells are found in both cancer patients and normal donors [322-324]. Both the MART1(27-35), nonameric, and MART-1(26-35), decameric, peptides are recognized by MART-1
reactive T cells [324, 325]. The MART-1(27-35) epitope (AAGIGILTV) has been regarded
as an immunodominant epitope [326]. MART-1 anchor modified epitopes have been
generated and are discussed in further detail in Chapter Three. It has been
hypothesized that the high frequency of MART-1 reactive T cells in the blood of normal
donors and cancer patients is due to epitope mimicry. This is a result of T cells being
primed by a foreign or pathogen derived antigen and subsequently reacting with a
formerly ignored self-antigen [327]. The MART-1 nonameric epitope is extremely
hydrophobic, with only one neutral threonine at position eight. Transmembrane domains
and leader peptides of proteins are also very hydrophobic. Furthermore, studies show
that cytosolic proteins with central hydrophobic core are the major substrates of
proteasomal degradation. Hence, why it is well appreciated that hydrophobicity is
strongly correlated to immunogenicity [68]. It has been shown that MART-1 derived TIL
cultures and MART-1 specific T cell clones can lyse peptides in the context of HLA-A2
that have some degree of homology with MART-1 [327, 328]. Since MART-1 reactive T
cells are uniquely found in healthy donors, most likely due to epitope mimicry, we
thought it would be an interesting antigen to target while studying the cross-reactive
properties of TCRs.
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Multiple MART-1 reactive TCRs have been used in clinical trials. With the use of
autologous PBMCs engineered to express a MART-1 reactive TCR (unnamed), 2/15
patients demonstrated sustained objective responses [329]. Intra-tumoral injections of
allogeneic T cells expressing the MART-1 reactive TCR, TIL 5 [271, 330], resulted in
1/15 patients demonstrating a partial response [331]. The use of another MART-1
reactive TCR, DMF4, resulted in objective responses in 13% of the patients and none of
the patients exhibited normal melanocyte destruction in the ear or eye [329, 332].
Additionally, the MART-1 reactive TCR, DMF5, was used in a clinical trial where
objective responses were observed [288, 332]. This HLA-A2 restricted DMF5 TCR was
utilized in the studies completed in this dissertation and thus, will be described in further
detail.
The DMF5 TCR was isolated from a MART-1 reactive TIL clone from a
melanoma patient, the same patient from which the DMF4 TCR was cloned. This TCR
is classified as a high affinity/avidity and CD8 independent TCR [332]. The DMF5 TCR
was utilized in a clinical trial using autologous TCR gene-modified T cells for adoptive
cell transfer in 20 melanoma patients. Objective responses were seen in 30% of the
patients. Albeit, 17/20 patients exhibited melanocyte destruction in off-tumor tissues,
specifically the eye, ear, and skin. Some of the patients experienced these adverse
events up to grade 3 toxicities. This is an example of an on-target but off-tumor crossreactivity of the introduced TCR gene-modified T cells. Additionally, some of the
patients exhibited off-tumor melanocyte destruction in the absence of any tumor
rejection. The DMF5 TCR has a higher affinity than the DMF4 TCR. This possibly
explains why the percentages of objective clinical responses were higher with the DMF5
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TCR. Furthermore, this possibly explains the observation of off-tumor melanocyte
destruction with the DMF5 TCR, but not the DMF4 TCR. This clinical trial indicated that
T cells expressing the DMF5 TCR can have a therapeutic anti-tumor response in
melanoma patients [288]. Overall, due to the high level of epitope mimicry observed
with MART-1 “like” epitopes and the clinical relevance of the DMF5 TCR, we believed
the MART-1/DMF5 TCR model was fitting for understanding TCR specificity and crossreactivity.
Novel Structure-Guided Approach
As mentioned previously, one of the strategies for enhancing the anti-tumor
response of TCR gene-modified T cells is by TCR affinity enhancement via yeast or
phage display. It is possible that use of an affinity enhanced TCR can result in
unanticipated cross-reactivity or recognize unpredicted targets, and thus, modified
TCRs for adoptive transfer of TCR gene-modified T cells need to be addressed more
carefully.
The process of introducing mutations into TCRs to alter affinity and T cell
specificity is not a new concept. There are many examples in different TCRs where
introduced mutations affected affinity, binding kinetics, antigen specificity, and crossreactivity. For example, CDR1, CDR2, and CDR3 substitutions in the 2C (alloreactive
TCR that recognizes alpha-ketoglutarate dehydrogenase in the context of H-2Ld and
syngeneic recognition of SIYR peptide in the context of H2-Kb) TCR’s alpha and beta
chains resulted in varying levels of altered-peptide ligand recognition and tetramer
binding. TCR mutations also altered the recognition of the targeted peptide in CD4 + and
CD8+ T cells [333, 334]. More specifically, high affinity mutant TCRs demonstrated
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higher binding to altered-peptide ligands compared to the WT TCR [335]. One TCR
mutation enhanced affinity for the targeted ligand 1,000-fold higher than the WT TCR.
There was a 5- to 10-fold increase in T cell potency against the targeted ligand, but
CD8+ T cells expressing this high affinity 2C TCR were autoreactive [179, 333]. In
another example, high affinity 3.L2 TCR (HI-Ek restricted, recognizes β-chain of mouse
hemoglobin) variants were also more degenerate in their recognition of altered-peptide
ligands, both in potency and in the number of recognized targets, compared to the WT
TCR [336]. In a third example, single CDR3 TCR alpha and beta chain mutations were
introduced into the 1MOG9 TCR (HI-Ab restricted, recognizes myelin oligodendroglial
glycoprotein) based on the importance of TCR CDR3 loops in peptide binding [337340]. Herein, high affinity TCRs did enhance targeted antigen potency and confer coreceptor independence compared to the WT TCR. However, the introduction of
mutations in the 1MOG9 TCR also led to new recognition of self-peptides [341]. Lastly,
yeast libraries have been utilized as a strategy in in vitro directed evolution, specifically,
for intentionally changing the antigen specificity of the A6 TCR (HLA-A2 restricted,
recognizes Tax) [342]. Other studies have claimed to have enhanced targeted antigen
specificity with TCR mutants generated via phage display, but an examination of crossreactivity and T cell recognition of altered-peptide ligands was marginal or absent [343,
344]. Despite the many examples of high affinity TCR variants resulting in new
recognition of altered-peptide ligands, this is not always the case. For example, using a
WT1-specific TCR, two high affinity TCR clones with CDR3 TCR alpha chain mutations
were selected from yeast display libraries. The affinity enhanced TCRs demonstrated
enhanced targeted T cell reactivity in CD4+ and CD8+ T cells compared to the WT TCR.
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Additionally, mice that were injected with T cells expressing the WT or affinity enhanced
TCRs with irradiated peptide pulsed splenocytes, exhibited no signs of autoimmunity,
and expansion of TCR transduced T cells was similar among the different groups.
Pathology after two to three weeks indicated no T cell-mediated tissue damage within
the different treatment groups. These results provided further evidence that not all
affinity enhanced TCRs will cause autoimmunity in vivo [345]. In another example,
single and dual mutations in the CDR3 TCR alpha chain and CDR2 TCR beta chain of
the 1G4 TCR (HLA-A2 restricted, recognizes NY-ESO-1) enhanced affinity and targeted
antigen potency compared to the WT TCR, but cross-reactivity or recognition of alteredpeptide ligands was not addressed in these studies [304]. However, one of these
modified 1G4 TCRs was safe when used in patients [300, 302]. In summary, many
studies suggest TCR mutations in the CDR1, CDR2, and CDR3 regions impact TCR
affinity and T cell specificity. Specifically, TCR mutations can alter binding kinetics,
antigen recognition in CD4+ and CD8+ T cells, and cross-reactivity. The potential offtarget reactivity as of result of TCR mutations, implicates the need for better TCR
mutational methods and approaches.
Herein, in collaboration with the Baker’s laboratory, we have developed and
implemented an approach to improve specific antigen reactivity and reduce off-target
cross-reactivity by modifying the TCR using structure-guided mutations. More
specifically, we used the crystal structures of the TCR/pMHC to implement the
structure-guided design as a novel component versus inducing random mutation in the
TCR. This strategy involves the combinatorial idea of “positive and negative design”.
“Positive and negative design” has been utilized in other fields as a method to alter
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binding specificity [346-348]. Herein, as a way to enhance antigen specificity, the
positive design will introduce mutations in the TCR that enhance binding to the peptide
by introducing favorable interactions. The negative design will introduce mutations in the
TCR that weaken or eliminate binding of TCR residues with the MHC by weakening
existing favorable interactions [349]. Negative mutations could also be translatable to
other TCRs if they are made at conserved MHC contacting residues in the TCR and
thus, would be common to most presented peptides. It is imperative to recognize the
importance of the negative mutations as a way to offset the positive mutations, as
introducing only favorable interactions with the peptide could allow for unwanted effects
on T cell specificity. Instances of this occurring with different TCRs has already been
observed and examples have been described above. Even though negative TCR
mutations would reduce the TCR affinity, the enhanced binding towards the specific
peptide would persist [349]. The combination of these positive and negative TCR
mutations is hypothesized to enhance antigen specificity while simultaneously reducing
potential cross-reactivity. Although these mutations will affect the affinity of the TCR, the
idea is to redistribute the free binding energy and not solely focus on enhancing TCR
affinity. This redistribution of free binding energy would allow for the TCR to have an
increased focus on the peptide and a decreased focus on the MHC [350]. This novel
structure-guided design strategy is used in this dissertation as an approach to fine-tune
TCR specificity and to generate a more focused DMF5 TCR, based on the solved
crystal structure of the TCR/pMHC [351].
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Concluding Remarks
T cells play a significant role in the adaptive immune response. T cell-mediated
immunity is dependent upon TCR recognition of pMHC. In order to maintain an inclusive
immune system, T cells must be cross-reactive. However, negative selection in the
thymus is critical for eliminating highly autoreactive T cells. More recently, T cells have
been harnessed in many forms of immunotherapies for their ability to kill tumor cells.
Namely, the use of TCR gene-modified T cells has shown success in clinical trials. To
improve the efficacy of TCR gene-modified T cells, methods of TCR affinity
enhancement have been utilized. These TCR modifications do not always cause harm
to patients, but affinity enhanced TCR gene-modified T cells have resulted in lethal
adverse events due to off-target cross-reactivity mediated by the introduced T cells.
Consequently, the field needs more advanced and meticulous strategies in order to
enhance the anti-tumor responses of TCR gene-modified T cells while still sustaining
safety for treated patients. In these studies, in collaboration with the Baker lab, we
sought to develop and utilize a novel structure-guided design approach to fine-tune the
antigen specificity of TCRs.
Herein, we utilized the DMF5 TCR/MART-1 model. Specifically, our objective
was to enhance MART-1 specificity while simultaneously reducing cross-reactivity.
Overall, when altering TCRs for therapeutic use, biology and safety should be of the
utmost importance and herein, we emphasize the importance of rigorous preclinical
testing of modified TCRs and the need for advancement in modeling/prediction tools for
protein interactions.

CHAPTER TWO
MATERIALS AND METHODS
Cell Lines, Media, and Reagents
T2 [352, 353] , HEK293GP [354-356], PG13 [357, 358], and Jurkat E6.1 cells
[359] were obtained from the American Type Culture Collection (Manassas, VA). T2
cells are TAP deficient and therefore cannot load their own peptide onto MHC class I.
The MHC becomes stable on the cell surface when loaded with exogenous peptide. T2
cells were used as stimulator cells for T cell functional assays. HEK293GPs are a
human embryonic kidney packaging cell line that were made to express the retroviral
gag and polymerase proteins. HEK293GP cells were used to produce high titer
retrovirus by transient co-transfection using a retroviral vector and a plasmid containing
the vesicular stomatitis virus (VSV) envelope. PG13 cells (based on Gibbon ape
leukemia virus (GaLV)) are a retroviral producer cell line that when transduced with
HEK293GP supernatant, will stably produce high titer retrovirus. Jurkat E6.1 cells are a
CD4-CD8- human T cell lymphoblast used for TCR transduction and functional assays.
The tumor cell lines used in T cell functional assays are listed in Table 2. All tumor lines
were obtained from American Type Culture Collection (Manassas, VA) except MEL 624
and 624-28 [360], UOK131 [361], and SAUJ (Rick Childs, NCBI) [362] were obtained
from the NIH Surgery Branch (Bethesda, MD).
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Name
MEL 624
MEL 624-28
MEL A375
SAUJ
UOK131
SKOV3
CAPAN 1
MDA 231
SW480
HEPG2
SKGT5
U251

Tumor/ Tissue
Melanoma
Melanoma
Melanoma
Renal
Renal
Ovarian
Pancreas
Breast
Colon
Liver
Esophagus
Glioblastoma

MART-1
+
+
-

HLA-A2
+
+
+
+
+
+
+
+
+
+

Table 2. Tumor Cell Lines and Phenotypes. “+” indicates positive and “-“ indicates
negative.

All medium components were obtained from Corning Life Sciences (Corning,
NY), unless otherwise noted. T2 and Jurkat E6.1 cells were maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum (FBS) (Invitrogen Life
Technologies, Carlsbad, CA). HEK293GP cells were maintained in complete medium
consisting of Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS.
PG13 cells were maintained in complete medium consisting of Iscove’s DMEM
supplemented with 10% FBS. All tumor cell lines, except SAUJ cells, were maintained
in complete medium consisting of Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% FBS. SAUJ tumor cells were maintained in complete medium
consisting of RPMI 1640 medium supplemented with 10% FBS.
T cells
All PBMC used in this study came from de-identified apheresis products
purchased from Key Biologics (Memphis, TN). PBMCs were isolated from normal
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healthy donors by Ficoll-Paque (General Electric, Fairfield, CT) density gradient
centrifugation. Briefly, whole blood was diluted 1:2 in phosphate-buffer saline (PBS)
(Mediatech, Inc., Manassas, VA), loaded onto Ficoll density gradients, and spun at
2,000 RPM for 30 minutes at room temperature (RT) without brake. The density of Ficoll
is 1.077 g/mL, which allowed red blood cells to pass through the Ficoll and inhibited the
passage of white blood cells. Buffy coat was collected and washed three times with
PBS. All T cells were maintained in complete T cell medium consisting of RPMI 1640
medium supplemented with 10% FBS, 300 IU/mL recombinant human IL-2 (rhIL-2;
Novartis Pharmaceuticals Cooperation, East Hanover, NJ), and 100 ng/mL recombinant
human IL-15 (rhIL-15; Biologic Resources Branch, NCI, Frederick, MD) at 37°C in a
humidified 5% CO2 incubator.
Peptides
All peptides were obtained from Synthetic Biomolecules (San Diego, CA) and
were HPLC purified at 95%. Peptides were stored at 10 µg/mL in 100% DMSO at -80°C.
Retroviral Vector
Our lab uses a modified SAMEN retroviral construct to introduce TCR genes into T cells
[363]. The structure of this vector is shown in Figure 3. At the 5’ end of the vector is a
human cytomegalovirus (CMV) long terminal repeat (LTR) promoter. This promoter
allows for enhanced constitutive levels of transcription. Following this promoter is a
splice donor and splice acceptor site for RNA splicing. Ψ (psi) is the packing signal. The
TCR alpha gene and TCR beta gene are linked by a P2A self-cleaving peptide. This
allows the alpha and beta chains to be synthesized in a 1:1 ratio.
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Figure 3. Structure of the SAMEN Retroviral Vector Used For TCR Gene Transfer.
A modified SAMEN retroviral vector was used to transfer TCR genes to alternate
effectors. The retroviral vector used in this study contains a CMV promoter, splice donor
(SD) and splice acceptor (SA), psi (ψ) packaging signal, TCR alpha (α) and beta (β)
chains, CD34t, and long terminal repeats (LTR). The TCR α and β genes and the CD34t
molecule are linked via P2A and T2A sequences, respectively. P2A and T2A are selfcleaving peptides cut into three separate proteins. CD34t is used as a marker for
transduction.

Following the TCR beta gene is a T2A self-cleaving peptide followed by CD34t which is
synthesized in a 1:1 ratio with the TCR chains. CD34t is a truncated CD34 molecule
and consequently lacks its intracellular signaling domain [364]. This is a unique marker
of transduction and is beneficial for a number of reasons. There is nothing that limits cell
surface expression of CD34t, therefore its expression levels are analogous to the
amount of TCR protein being made. CD34t can also be used to sort TCR transduced
cells which allows for an easy method of attaining a pure TCR transduced T cell
population. Following the CD34t, is a 3’ LTR sequence for genomic insertion. The
SAMEN vector containing each WT or modified TCR described in the dissertation was
used to generate high titer PG13 producer cell lines.
First Round of DMF5 TCR Mutations
The following seven modified TCRs were made using the WT DMF5 TCR
sequence: αD26Y, βL98W, αD26Y/βL98W, αD26Y/αY50A/βL98W,
αD26Y/αY50V/βL98W, αY50A, and αY50V. This was completed using a GENEART site
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directed mutagenesis kit (Invitrogen). Mutagenesis was completed in the SAMEN vector
with the primers listed below (IDT, Coralville, IA). Base changes are denoted by bold
and underline.
αD26Y forward:
5’-CAACTGCACTTACAGTTACACTGCACTTACAGTCCT-3’
αD26Y reverse:
5’-AGGACTGTAAGTGCAGTGTAACTGTAAGTGCAGTTG-3’
βL98W forward:
5’-TGTACTTCTGTGCCAGCAGTTGGTCCTTCGGAACTGAAGCTTTC-3’
βL98W reverse:
5’-GAAAGCTTCAGTTCCGAAGGACCAACTGCTGGCACAGGAGTACA-3’
αY50A forward:
5’-CCTGAGTTGATAATGTTCATAGCCTCCAATGGTGACAAAGAAGATGG-3’
αY50A reverse:
5’-CCATCTTCTTTGTCACCATTGGAGGCTATGAACATTATCAACTCAGGG -3’
αY50V forward:
5’-CCTGAGTTGATAATGTTCATAGTCTCCAATGGTGACAAAGAAGATGG-3’
αY50V reverse:
5’-CCATCTTCTTTGTCACCATTGGAGACTATGAACATTATCAACTCAGGG -3’
Methylation and PCR amplification was performed using a C1000 Thermal Cycler
(Bio-Rad, Hercules, CA) under the following conditions: 20 minutes at 37°C (one cycle),
2 minutes at 94°C (one cycle), 20 seconds at 94°C, 30 seconds at 57°C, and 5 minutes
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at 68°C (18 cycles), and 5 minutes at 68°C (one cycle). Recombination reaction was
performed at RT for 10 minutes.
Mutated vector DNA was transformed into Escherichia coli DH5α-T1R competent
cells (Invitrogen) onto LB ampicillin plates (25 grams LB agar (Fisher, Hampton, NH) in
1 L de-ionized water supplemented with 100 µg/mL ampicillin (Sigma-Aldrich)) and
colonies were expanded in superbroth (32 grams Tryptone (Fisher), 20 grams yeast
extract (Fisher), 5 grams NaCl (Fisher), 1 liter de-ionized water) with 100 µg/mL
ampicillin (Sigma-Aldrich)). Plasmid DNA from recombinant clones was isolated using a
Miniprep kit (Qiagen). All mutagenesis products were sequenced (Genewiz, South
Plainfield, NJ) to ensure no errors had occurred.
Second Round of DMF5 TCR Mutations
The following four DMF5 mutations were made using the αD26Y/βL98W DMF5
TCR sequence: αD26Y/αN52A/βL98W, αD26Y/βN52A/βL98W, αD26Y/αK68A/βL98W
and αD26Y/βT57A/βL98W. This was completed using a GENEART site directed
mutagenesis kit (Invitrogen). Mutagenesis was completed in the SAMEN vector with the
primers listed below (IDT, Coralville, IA). Base changes are denoted by bold and
underline.
αK68A forward:
5'- CAGCACAGCTCAATGCAGCCAGCCAGTATG -3'
αK68A reverse:
5'- CATACTGGCTGGCTGCATTGAGCTGTGCTG -3'
αN52A forward:
5'-GTTCATATACTCCGCTGGTGACAAAGAAG-3'
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αN52A reverse:
5'-CTTCTTTGTCACCAGCGGAGTATATGAAC-3'
βT57A forward:
5'-TATTCAAATACTGCAGGTACCGCCGGCAAAGGAGAAGTCCC-3'
βT57A reverse:
5'-GGGACTTCTCCTTTGCCGGCGGTACCTGCAGTATTTGAATA-3'
βN52A forward:
5'-CATCCATTATTCAGCTACTGCAGGTACC-3'
βN52A reverse:
5'-GGTACCTGCAGTAGCTGAATAATGGATG-3'
All mutagenesis and DNA isolation was performed with the same methods as described
in the section above. All products were sequenced (Genewiz, South Plainfield, NJ) to
ensure no errors had occurred.
HCV 1406 TCR Mutations
The following two modified TCRs were made using the WT HCV 1406 TCR
sequence: αY59A and αY59V. This was completed using a GENEART site directed
mutagenesis kit (Invitrogen). Mutagenesis was completed in the SAMEN vector with the
primers listed below (IDT, Coralville, IA). Base changes are denoted by bold and
underline.
αY59A forward: 5’-TATTATTTATTCTGGGCCAAGCAGCCTCCCAGC-3’
αY59A reverse: 5’-GCTGGGAGGCTGCTTGGCCCAGAATAAATAATA-3’
αY59V forward: 5’-TATTATTTATTCTGGGTCAAGCAGCCTCCCAGC-3’
αY59V reverse: 5’-GCTGGGAGGCTGCTTGACCCAGAATAAATAATA-3’
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All mutagenesis and DNA isolation was performed with the same methods as described
in the section above. All products were sequenced (Genewiz, South Plainfield, NJ) to
ensure no errors had occurred.
Generating High Titer Producer Cell Lines
Using a HEK293GP packaging cell line, retroviral supernatants were prepared
and used to make a stable retroviral producer PG13 cell line expressing the TCRs in the
SAMEN vector as described [280]. On day 0, 3 million HEK293GPs were plated in 10
cm poly-D-Lysine coated plates (Corning) in 10 mL complete medium and incubated
overnight at 37°C in 5% CO2. HEK293GP cells were transiently co-transfected with 20
µg retroviral SAMEN vector DNA and 5 µg of a plasmid containing the VSV envelope
gene using 50 µL Lipofectamine 2000 (Invitrogen) on day 1. Transfection medium was
replaced 6 hours later with 10 mL fresh complete medium and incubated for 48 hours at
37°C in 5% CO2. On day 2, PG13 cells were seeded at 2 million in a 10 cm tissue
culture plate in 10 mL complete medium and incubated at 37°C in 5% CO 2. On day 3,
fresh HEK293GP viral supernatant was collected and filtered to sterilize using a 0.45
µm filter (Millex, Billerica, MA). PG13 media was replaced with 9 mLs of filtered
HEK293GP viral supernatant and 3 mL complete medium. Plates were incubated for 72
hours at 37°C in 5% CO2. On day 6, PG13 cells were collected and stained using antiCD34-PE mAb (BioLegend) and analyzed for CD34 expression by flow cytometry. Four
days later, cells were stained with an anti-CD34-PE (clone 561) mAb and CD34 positive
cells were sorted for high and uniform expression using a BD FACSAria cell sorter (BD
BioSciences, San Jose, CA) and the final PG13 cells were maintained in complete
medium.
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T cell and Jurkat E6.1 Cell Transduction
T cells derived from normal healthy donors were activated by adding 50 ng/mL
anti-CD3 monoclonal antibody (Miltenyi Biotec, San Diego, CA), 300 IU/mL rhIL-2 (rhIL2; Novartis Pharmaceuticals Cooperation, East Hanover, NJ), and 100 ng/mL rhIL-15
(NCI-Biological Resources Branch, Frederick, MD) to RPMI supplemented with 10%
FBS on day 0. To make high titer retroviral supernatant, PG13 cell lines were seeded
overnight at 8x106 cells/T-175 cm2 cell culture flask at 37°C in 5% CO2 on day 1. On day
2, 25 mLs of complete Iscove’s DMEM supplemented with 0.5 mLs (1 mM) sodium
butyrate (Sigma-Aldrich) and 1 mL (10 mM) HEPES (Sigma-Aldrich) was added to
flasks for 8-10 hours to stimulate virus production. Media was then replaced with fresh
complete medium and incubated overnight at 37°C in 5% CO2. Fresh viral supernatants
were collected on day 3 and filter sterilized to remove any cellular debris using 0.45 µm
filters (Thermo Scientific, Waltham, MA).
Activated T cells were transduced by spinoculation on day 3 as described [330,
363, 365, 366]. Briefly, 24-well-flat-bottom-non-tissue-culture-treated plates were coated
with 0.5mL/well 30 μg/mL Retronectin (Takara, Mountain View, CA) overnight. The next
day, plates were blocked using 2% bovine serum albumin (BSA) in PBS (Thermo
Scientific) for 30 minutes. Next, virus was loaded by adding 2 mL of fresh retroviral
supernatant per well and plates were spun for 2 hours at 2,000xg at 32°C. 1 mL of
2x106 million/mL activated T cells in complete medium were added to the plates with 1
mL of fresh viral supernatant. The plates were spun again for 2 hours at 2,000xg at
32°C and then incubated overnight at 37°C in 5% CO2. After 24 hours, the TCR
transduced T cells were transferred to cell culture flasks and plated at 1x106/mL in
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complete medium. On day 7, transduction efficiency was determined by FACS analysis
using anti-CD34-PE (clone 561) mAb. TCR transduced T cells were purified by positive
selection using CD34 immunomagnetic beads (Miltenyi Biotec, San Diego, CA) and
maintained in complete T cell medium at 37°C in 5% CO2.
Rapid Expansion Protocol
Two days after CD34 enrichment, TCR transduced T cells were further expanded
via a rapid expansion protocol (REP) to generate a large population of CD34 + TCR
transduced T cells for T cell functional assays. 1x106 T cells were cultured in a T-175
cm2 cell culture flask with 200x106 irradiated (50 Gy) allogeneic PBMCs (pooled from
three normal donors) in 150 mL of complete T cell medium consisting of RPMI 1640
medium supplemented with 10% FBS, 300 IU/mL recombinant IL-2 (rhIL-2; Novartis
Pharmaceuticals Cooperation, East Hanover, NJ), and 100 ng/mL recombinant human
IL-15 (rhIL-15; Biologic Resources Branch, NCI, Frederick, MD), and 30 ng/mL anti-CD3
mAb (Miltenyi Biotech). T cells were incubated at 37°C in 5% CO2 for 10 days and
harvested for use in T cell functional assays.
Immunofluorescence Staining
PG13 cells were stained for CD34 surface expression by immunofluorescence
using anti-CD34-PE (clone 581). This was done to confirm retroviral transductions were
successful and to measure transduction efficiency. Briefly, cells were resuspended in 30
μL of 2% PBSA (PBS with bovine serum albumin) and incubated with 1 μL of mAb and
incubated at RT in the dark for 20 minutes. Cells were washed with 2% PBSA and
resuspended in 300 μL of 2% PBSA. T cell surface markers were stained by
immunofluorescence using the following mAbs: anti-CD4-PE/Cy7 (clone RPA-T4), anti-
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CD8-FITC (clone SK1), anti-CD3-APC/Cy7 (clone UCHT1), anti-CD34-AF700 (clone
581), and anti-CD107A-AmCyan (clone H4A3) (BioLegend). Briefly, cells were
resuspended in 30 μL of 2% PBSA and incubated with 1 μL of mAb and incubated at
RT in the dark for 20 minutes. Intracellular cytokines were stained by
immunofluorescence using the following mAbs: anti-IL-2-PerCP/Cy5.5 (clone MQ117H12), anti-IFN-γ-PacBlue (clone 4S.B3), anti-IL-17A-Qdot 585 (clone BL168), antiTNF-α-Qdot 705 (clone MAb11), anti-IL-4-APC (clone 8D4-8), and anti-IL-22-PE (clone
2G12A41). Briefly, cells were resuspended in 30 μL of 2% PBSA and incubated with 1.5
μL of mAb and incubated at RT in the dark for 20 minutes. T2 cells were stained by
immunofluorescence using anti-HLA-A2-APC (clone BB7.2) mAb (BioLegend). Briefly,
cells were resuspended in 30 μL of 2% PBSA and incubated with 1 μL of mAb and
incubated at RT in the dark for 20 minutes. Tumor cells were stained by
immunofluorescence using anti-CD9-FITC (clone HI9a) and anti-HLA-A2-APC mAb
(BioLegend). Briefly, cells were resuspended in 30 μL of 2% PBSA and incubated with 1
μL of mAb and incubated at RT in the dark for 20 minutes. Cells were analyzed using an
LSRFortessa flow cytometer (BD Biosciences, San Jose, CA) and the data was
analyzed using FlowJo software (FlowJo Enterprise, Ashland, OR).
Cytokine Release Assay
Antigen reactivity of the TCR transduced T cells or Jurkat E6.1 cells was
measured in cytokine release assays as described [94, 271, 366]. Briefly, T2 stimulators
were loaded with 10 μg/mL of peptide two hours prior to coculture and incubated at
37°C in 5% CO2. 1x105 washed and re-suspended responder T cells and 1x105 washed
and re-suspended stimulator cells were cocultured in a 1:1 ratio in 96-well U-bottom
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tissue culture plates (Corning) in 200 µL complete medium. Phorbol 12-Myristate 13Acetate (PMA) (Thermo Fisher) was added to cocultures using Jurkat E6.1 cells at 10
ng/mL. Cocultures were incubated at 37°C in 5% CO2 for 18-20 hours. Plates were
centrifuged at 1,500 RPM and supernatants were collected for analysis of cytokine
release.
The amount of cytokine released was measured via sandwich ELISA using
monoclonal antibodies to IFN-γ or IL-2 (BioLegend, San Diego, CA). Briefly, 96-well
plates were coated overnight at 4°C with human IFN-γ capture mAb or IL-2 capture
mAb. The next day, plates were washed with ELISA wash buffer (1X PBS, 0.01%
Tween) then blocked with 200 μL 1X Assay Diluent (phosphate buffered saline solution
containing bovine serum) for 1 hour at RT on a shaker. Plates were washed again with
ELISA wash buffer and 100 μL of samples and standards were added. After 2 hours of
shaking at RT, plates were washed and 100 μL of the enzyme-conjugated IFN-γ or IL-2
detection mAb was added. After 1 hour of shaking at RT, 100 μL of Avidin-HRP was
added and incubated on the shaker for 30 minutes at RT. Plates were then washed and
100 μL of TMB Substrate Solution was added. Plates were incubated at RT in the dark
for 20 minutes or until color developed in standard curve. 100 μL of 2N H2SO4 was used
to stop the reaction. The absorbance of the plates was read at 450 nm using a
spectrophotometer.
Polyfunctional T cell Assay
Polyfunctional antigen reactivity of TCR transduced T cells was measured by
CD107A and intracellular cytokine expression as described [95]. 3x105 TCR transduced
T cells were cocultured with 3x105 peptide loaded T2 cells in 96-well U-bottom tissue
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culture plates in 200 μL of RPMI supplemented with 10% FBS at 37˚C, 5% CO2 for 5
hours. 5.0 ng/mL brefeldin-A, 2.0 nM monensin (BioLegend), and anti-CD107A-AmCyan
mAb were added at the beginning of coculture. After 5 hours, cells were stained for 20
minutes for the following surface markers: anti-CD4-PE/Cy7, anti-CD8-FITC, anti-CD3APC/Cy7, and anti-CD34-AF700 (BioLegend). Cells were fixed, permeabilized, and
stained for the following intracellular markers: anti-IL-2-PerCP/Cy5.5, anti-IFN-γPacBlue, anti-IL-17A-Qdot 585, anti-TNF-α-Qdot 705, anti-IL-4-APC, and anti-IL-22-PE
(BioLgend). Data were acquired using an LSRFortessa flow cytometer. Staining profiles
were gated and analyzed using FlowJo.
Polyfunctional Gating and Analysis
Lymphocyte populations were determined by FSC (forward scatter) vs. SSC
(side scatter). TCR transduced T cell populations were determined by CD34+CD3+
gating. TCR transduced T cells were further gated on CD4-CD8+ and CD4+CD8populations and subsequent single functional markers. An example of gating on cell
surface markers and functional markers is shown in Figures 4-6. Boolean gating was
performed in FlowJo for CD107A, IFN-γ, TNF-α, IL-17A, IL-2, IL-4, and IL-22 to give 27
potential functional phenotypes. After sequential gating in FlowJo, Pestle (NIH,
Bethesda, MD) formatted the multivariate datasets and performed background
subtraction using the irrelevant peptide (T2 + HCV) for each respective DMF5 TCR to
account for background in immunofluorescence staining [367]. SPICE (Simplified
Presentation of Incredibly Complex Evaluations) (NIH, Bethesda, MD) was utilized for
its ability to compare the distributions of all the polyfunctional parameters [367].

57

Figure 4. Gating Strategy for Cell Surface T cell Markers. Samples were first gated
on side scatter (SSC) and forward scatter (FSC) to isolate lymphocyte population. Cells
in the lymphocyte gate were then gated on CD3 and CD34, double positive population
indicates TCR transduced T cells. TCR transduced T cells were subsequently gated on
CD4 and CD8.

Figure 5. Gating Strategy for Functional T cell Markers. CD3+CD34+ and either
CD4+CD8- or CD4-CD8+ (depicted above) cells were subsequently gated on the
following individual functional markers: IFN-γ, CD107A, TNF-α, IL-2, IL-17A, IL-4, and
IL-22. One representative donor and experiment is shown with T cells expressing the
WT DMF5 TCR. (a) Gating strategy against T2 cells loaded with irrelevant, HCV
peptide. (b) Application of gating strategy against T2 cells loaded with the MART-1
9mer peptide.
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Figure 6. Gating Strategy for Functional T cell Markers. Application of previous
gating strategy on CD4-CD8+ T cells transduced to express the αD26Y DMF5 TCR. One
representative donor and experiment is shown. (a) Application of gating strategy against
T2 cells loaded with irrelevant, HCV peptide. (b) Application of gating strategy against
T2 cells loaded with the MART-1 9mer peptide.

Background subtraction can result in values below zero and values between 0.001% 0.09%. One of the advantages of SPICE is that it has a threshold approach. Therefore,
cool plots were generated in SPICE to visualize any positive functional phenotype
present over 0.1%.

LDH (lactate dehydrogenase) Assay
Lysis of tumor targets was measured using a Pierce LDH Cytotoxicity Assay Kit
(Thermo Scientific). 1x105 washed and re-suspended TCR transduced T cells and
1x105 washed and re-suspended target cells were cocultured in a 1:1 ratio in triplicate in
96-well U-bottom tissue culture plates in 100 µL medium. Cells for the following controls
were also plated: effector cell spontaneous LDH release, target cell spontaneous LDH
release, target cell maximum LDH, volume correction, and culture medium background.
Cocultures were incubated at 37°C in 5% CO2 for 18 hours. 45 minutes before
harvesting the supernatant, 10 µL of provided Lysis Buffer was added to wells
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containing the target cell maximum LDH control to determine the maximum lysis and to
wells containing the volume correction control to account for volume increase caused by
the addition of the Lysis Buffer. Plates were spun at 300 x g for 3 minutes and 50 µL of
supernatant was collected and transferred to 96-well flat-bottom tissue culture plates
and mixed with 50 µL of provided Reaction Mixture for 30 minutes at RT, in the dark.
Reaction was stopped with 50 µL of provided Stopping Solution. Absorbance was read
at 490 nm and 680 nm using a spectrophometer. Absorbance value at 680 nm
(background signal from spectrophometer) was subtracted from the absorbance value
at 490 nm to determine LDH activity. The percent cytotoxicity was calculated using the
following formula: % cytotoxicity = ((experimental value – effector cell spontaneous
control – target cell spontaneous control) / (target cell maximum control – target cell
spontaneous control)) x 100.
Combinatorial Peptide Library
Functional assays using a combinatorial peptide library revealed results pertinent
to the conclusions of these studies. These specific experiments were completed by the
Baker Lab at the University of Notre Dame. These results were obtained as follows: A
decameric combinatorial peptide library was obtained from Pepscan (Lelystad,
Netherlands). The library excluded cysteine and fixed p2 and p10 to leucine and valine,

respectively, for a total of 198 (approximately 1.7×1010) peptides. The library was
composed of 152 sub-libraries in which each position of the peptide, except p2 and p10,
was fixed at each amino acid, excluding cysteine. The library scan was conducted as
previously described [368, 369]. Briefly, 1x105 T2 cells were loaded with 100 μM total
peptide concentration of each sub-library for two hours at 37 °C. An equal number of
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PMA simulated (50 ng/mL) Jurkat 76

CD8+

cells transduced with the WT DMF5 TCR,

αD26Y/βL98W DMF5 TCR, or αD26Y/αY50A/βL98W DMF5 TCR were added and
cocultured for 18-20 hours at 37°C, after which supernatant was harvested and assayed
for IL-2 via ELISA. Combinatorial peptide library scans were repeated three times with
freshly generated cells and the results were averaged.
Crystallization and Structural Analysis
TCR/pMHC crystal structures are shown in this dissertation and are a critical
component of the data analysis. These experiments were completed by the Baker Lab
at the University of Notre Dame. The crystal structures were obtained as follows:
Crystals of the αD26Y/βL98W DMF5 TCR/MART-1 decamer/HLA-A2 complexes were
grown from 12% PEG 3350, 0.25 M MgCl2 buffered with 0.1 M HEPES (pH 8.0) at
25°C. Crystallization was performed using sitting drop/vapor diffusion. For
cryoprotection, crystals were transferred into 20% glycerol/80% mother liquor for 30
seconds and immediately frozen in liquid nitrogen. Diffraction data were collected at the
22ID (SER-CAT) beamlines at the Advanced Photon Source, Argonne National
Laboratories, Argonne, IL. Data reduction was performed with HKL2000. The ternary
complexes were solved by molecular replacement using PHENIX and Protein Data
Bank (PDB) entry 3QDG as the reference model [370]. Rigid body refinement, followed
by translation/libration/screw (TLS) refinement and multiple steps of restrained
refinement were performed. TLS groups were automatically chosen by phenix.refine.
Once defined, TLS parameters were included in all subsequent steps of the refinement.
Anisotropic and bulk solvent corrections were taken into account throughout refinement.
After TLS refinement, it was possible to unambiguously trace the position of peptides
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and TCR CDR loops in all structures against σA-weighted 2Fo-Fc maps. Evaluation of
models and fitting to maps were performed using COOT [371]. The template structure
check in WHATIF [372] and MolProbity [373] was used to evaluate the structures during
and after refinement. Atomic positioning was verified with an iterative-build OMIT map
calculated in PHENIX [374]. Structures were visualized using PyMOL. Analysis of
hydrogen bonds was performed with HBPlus [375], using hydrogen-acceptor maximum
distance of 2.7 Å and a donor-acceptor maximum distance of 3.6 Å. Solvent accessible
surface areas were measured in Discovery Studio (Accelrys Inc.) using a probe radius
of 1.4 Å. The structure has been deposited with the Protein Data Bank (PDB ID 4L3E).
Surface Plasmon Resonance
3D affinity measurements are shown in this dissertation and are a critical
component of the data analysis. These experiments were completed by the Baker Lab
at the University of Notre Dame. The 3D affinity measurements were obtained as
follows: A Biacore T200 instrument was used to perform surface plasmon resonance
experiments. Amine coupling was used to immobilize the TCR to CM-5 sensor chips at
1500-2000 response units and pMHC complex was injected as analyte in all
experiments. All samples were thoroughly dialyzed in HBS-EP buffer (10 mM HEPES
(pH 7.4), 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P-20) followed by degassing
for at least 15 minutes before use. pMHC injections covered a concentration range of
0.5-150 μM at a flow rate of 5 μL/minute at 25°C. Multiple steady-state data sets were
globally fit using a 1:1 Langmuir binding model with BIAevaluation 4.1 to extend the
range and accuracy of measurements as previously described [167, 376].
Measurements of TCR binding to the MMW/HLA-A2 complex were performed using a
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kinetic titration assay at 25°C [377], with chip densities near 150 RU for the
αD26Y/βL98W TCR and 500 RU for the αD26Y/αY50A/βL98W TCR. pMHC
concentrations ranged from 32-500 nM for the αD26Y/βL98W TCR and 1-16 μM for the
αD26Y/αY50A/βL98W TCR. Kinetic titrations used a flow rate of 100 μL/minute.
Micropipette Adhesion Frequency Assay
2D affinity measurements are shown in this dissertation and are a critical
component of the data analysis. These experiments were completed by the Evavold
Lab at the University of Utah. The 2D affinity measurements were obtained as follows:
The relative 2D affinity of JurkatE6.1 cells TCR transduced to express the WT and
mutant DMF5 TCRs was measured using the previously characterized 2D micropipette
adhesion frequency assay [162, 378-380]. Briefly, RBCs coated with a range of BiotinLC-NHS (BioVision, Milpitas, CA) were then coated with 0.5 mg/mL streptavidin
(Thermo Scientific) followed by 1 µg of biotinylated MART-1 10mer monomer. The
adhesion frequency between TCR transduced JurkatE6.1 cells and ligand coated RBCs
aspirated on opposing pipettes were observed using an inverted microscope. An
electronically controlled piezoelectric actuator repeated JurkatE6.1 cell contact with the
pMHC coated RBCs 50 times for controlled contact area (Ac) and time (t). Upon
retraction of the T cell, adhesion (binding of TCR-pMHC) was observed by distention of
the RBC membrane, allowing for quantification of adhesion frequency (P a) at
equilibrium. Surface pMHC (ml) and TCR beta (mr) densities were determined by flow
cytometry using MHC class I anti-human HLA-A2 –PE (clone BB7.2) mAb (BioLegend)
and anti-human α/β TCR-PE (clone IP26) mAb (BioLegend), both at saturating
concentrations, and BD QuantiBRITE PE Beads for standardization (BD Biosciences,
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San Jose, CA). The calculation of molecules per area were done by dividing the number
of TCR and pMHC per cell by the respective surface areas. The relative 2D affinities
were calculated using the following equation: AcKa = -ln [1-Pa(1)]/mrml. Normalized
adhesion frequency was calculated using the equation (-ln(1-Pa(s))/mpMHC). Geometric
mean of affinities and normalized adhesion bonds are reported ± SEM.
In vivo NSG A2 Tumor Growth Models
The in vivo studies completed in this dissertation utilized an established human
xenograft mouse model. Using immunocompromised mice, xenografts are
advantageous to examine therapeutic efficacy against human tumors [381-383].
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) HLA-A2 immunodeficient mice were obtained
from Jackson Laboratories (Bar Harbor, ME). All mice were housed in our AALACapproved animal facility at the Loyola University Health Science Campus. The hind
flanks of mice were shaved at least one day prior to tumor challenge. Under inhalatory
anesthesia, 6-8 week old NSG A2 mice were inoculated subcutaneously with 5×106
MEL 624 tumor cells in 100 μL PBS. Tumor growth was assessed 2-3 times a week by
caliper measurements. Tumor areas were determined by the following formula: area =
(3.14 x length x width)/4. All TCR transduced T cells used for therapeutic injection were
CD34 enriched using immunomagnetic beads (Miltenyi Biotec). All TCR transduced T
cell populations completed a REP (previously described) for 10-12 days to obtain a
large number of TCR transduced T cells for therapy. High and uniform CD34 expression
was confirmed amongst treatment groups prior to injection. The number of injected TCR
transduced T cells is stated in subsequent sections in each respective experimental
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model. Mice were sacrificed when tumors reached 150

mm2

in size or 10% of body

weight by CO2 inhalation followed by cervical dislocation.
Human PBMC Engraftment Prior to Tumor Challenge
NSG mice have been previously engrafted with human hematopoietic stems cells
to recapitulate a human immune system in the mouse [384, 385]. We developed a
model of engraftment using human PBMC to determine if engraftment supported
introduced human TCR transduced T cells. First, human PBMCs were thawed and
cultured in RPMI supplemented with 10% FBS, 300 IU/mL rhIL-2, and 100 ng/mL rhIL15 and were incubated at 37°C in 5% CO2 for 24 hours. After 24 hours, 6-8 week old
NSG HLA-A2 mice were injected with 10x106 human PBMCs in 100 uL PBS either via
retro-orbital or intraperitoneal route of injection. The persistence of engrafted cells in the
blood was monitored weekly. Briefly, a 3mm Goldenrod lancet (Fisher Scientific) was
used to obtain one drop of blood from the facial vein. Red blood cells were lysed by
incubation with 200 μL of ACK Lysis Buffer (Lonza, Basel, Switzerland) for 5 minutes at
RT. Cells were washed twice with 1 mL of 2% PBSA and were immunofluorescently
labeled using human anti-CD3-APC/Cy7 antibody (BioLegend). 7 days after PBMC
engraftment, NSG A2 mice were inoculated subcutaneously with 5×106 MEL 624 tumor
cells in 100 μL PBS. Tumor growth was assessed 2-3 times a week by caliper
measurements. 17 days post tumor challenge, or when tumors reached about 4 x 4
mm, 10x106 human TCR transduced T cells in 100 μL PBS were injected retro-orbitally.
The persistence of TCR transduced T cells was monitored weekly in the blood of mice
as described above. Cells were immunofluorescently labeled using human anti-CD3APC/Cy7 and human anti-CD34-PE antibodies (BioLegend). Mice were closely
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observed for cachexia as a potential indicator of autoimmunity. Mice were sacrificed
when tumors reached 150 mm2 in size or 10% of body weight by CO2 inhalation
followed by cervical dislocation.
Cytokine Support of Introduced Human TCR Transduced T cells
Cytokines were administered to NSG A2 mice to determine their effect on
introduced human TCR transduced T cell persistence. 6-8 week old NSG A2 mice were
inoculated subcutaneously with 5×106 MEL 624 tumor cells in 100 μL PBS. Tumor
growth was assessed 2-3 times a week by caliper measurements.17 days later, or when
tumors reached about 4 x 4 mm, 10x106 TCR transduced human T cells in 100 μL PBS
were injected retro-orbitally. Beginning on day 17, groups of mice were given 2.5 μg
rhIL-15 in 100 μL PBS every 3 days or 60,000 IU rhIL-2 in 100 μL PBS twice a day for
four days, then once a day every 3 days via intraperitoneal injection [386, 387]. Tumors
from one to two mice per group were processed on day 16 using a tumor dissociation kit
(Miltenyi Biotec) to examine the persistence of TCR transduced T cells. Spleens from
one to two mice per group were processed on day 16 to examine the persistence of
TCR transduced T cells. Briefly, spleens were manually disrupted using the plunger of a
3 mL syringe over a 70 μm cell strainer (Corning). Red blood cells were lysed by
incubation with 200 μL of ACK Lysis Buffer (Lonza, Basel, Switzerland) for 5 minutes at
RT. Tumor and spleen derived cells were washed twice with 1 mL of 2% PBSA and
were immunofluorescently labeled using human anti-CD3-APC/Cy7 and human antiCD34-PE antibodies (BioLegend). Mice were sacrificed when tumors reached 150 mm2
in size or 10% of body weight by CO2 inhalation followed by cervical dislocation.
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Checkpoint Blockade with Human TCR Transduced T cells
Checkpoint blockade was administered to NSG A2 mice to determine the effect
on introduced human TCR transduced T cell persistence. 6-8 week old NSG A2 mice
were inoculated subcutaneously with 5×106 MEL 624 tumor cells in 100 μL PBS. Tumor
growth was assessed 2-3 times a week by caliper measurements. 17 days later, or
when tumors reached about 4 x 4 mm, 10x106 TCR transduced human T cells in 100 μL
PBS were injected retro-orbitally. Beginning on day 17, groups of mice were given 0.25
mg of anti-PD-1 mAb (Bio X Cell, West Lebanon, NH) in 100 μL Buffer (Bio X Cell, West
Lebanon, NH) every 3 days (10 mg/kg mouse) via intraperitoneal injection. Mice were
sacrificed when tumors reached 150 mm2 in size or 10% of body weight by CO2
inhalation followed by cervical dislocation.
In vivo CTL Assay
An in vivo CTL assay was performed to determine if TCR transduced T cells
could elicit target specific killing in vivo. 6-8 week old NSG A2 mice were injected with
100 μL PBS or 10x106 WT DMF5 TCR transduced T cells in 100 μL PBS on day 0. On
day 1, HLA-A2+ PBMCs were pulsed with the MART-1 9mer peptide for 2 hours, as
previously described. HLA-A2+ PBMCs were incubated with 0.5 μM of
carboxyfluorescein succinimidyl ester (CFSE) (Thermo Fisher) for 8 minutes at 37˚C.
MART-1 9mer pulsed HLA-A2+ PBMCs were incubated with 5 μM of CFSE (Thermo
Fisher) for 8 minutes at 37˚C. CFSE labeled cells were washed 3 times in 25 mLs of
warmed RPMI supplemented with 10% FBS. CFSE high and CFSE low cells were
mixed in a 1:1 ratio. 12x106 CFSE labeled cells in 100 μL PBS were injected into mice
via retro-orbital route. Non-transferred CFSE labeled cells were kept in vitro at 37˚C as
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the non-transferred control. On day 3, spleens were isolated and processed as
described above. Cells were labeled with anti-HLA-A2-APC mAb (BioLegend) and
analyzed via flow cytometry. Ratio = CFSE low:CFSE high. The % MART-1 specific
lysis was determine by the following formula: % specific lysis = ((1-(non-transferred
control ratio))/experimental ratio) x 100.
Statistical Analysis
Comparisons of WT DMF5 TCR vs. mutant DMF5 TCRs were evaluated by twoway ANOVA using Sidak’s multiple comparisons test. **** P <0.0001; *** P < 0.001; ** P
< 0.01; * P < 0.05. Results are represented as mean ± standard error of the mean
(SEM) unless otherwise indicated. Experiments were repeated 2-3 times in 2-4
independent donors.

CHAPTER THREE
RESULTS
Structure-Guided Approach and DMF5 Mutations
Despite the success observed in clinical trials where TCR gene-modified T cells
were used, there still remains areas in which improvement is needed. These areas
include both the efficacy and the safety of the treatment in patients. One of the
drawbacks of using TCRs that target self-antigens in TCR gene-modified T cells is that
they generally harbor a low affinity, due to negative selection during T cell development.
Negative selection is critical in order to eliminate potentially autoreactive T cells [41,
388]. Therefore, their anti-tumor efficacy can be suboptimal for treatment. One strategy
to enhance anti-tumor efficacy is to enhance the affinity of the TCR. Yeast or phage
display strategies have been implemented for affinity enhancement [295, 296, 343, 344,
389]. Albeit, affinity enhanced TCRs can result in unanticipated cross-reactivity in T
cells and have resulted in deaths in clinical trials [5, 6]. Not all affinity enhanced TCRs
have elicited adverse events [302]. However, when modifying a TCR, more meticulous
strategies are needed in order to fine-tune the specificities of a TCR.
Here, in collaboration with the Baker’s laboratory, we have developed a novel
structure-guided design approach to fine-tune TCR antigen specificity while
simultaneously reducing cross-reactivity. This strategy is based on the principles of
positive and negative design. Positive design was proposed to introduce favorable
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interactions between the TCR and the peptide. Conversely, negative design was
proposed to weaken existing favorable interactions between the TCR and the MHC.
Herein, we used the DMF5 TCR and the MART-1 peptide in the context of HLA-A2 for a
model to test this structure-guided approach. A graphical depiction of this positive and
negative design strategy is shown in Figure 7. Both the MART-1 nonameric (positions
27-35) and decameric (positions 26-35) epitopes are recognized by MART-1 reactive T
cells [314, 324-326, 390]. It was further demonstrated that the decameric epitope bound
more tightly to the HLA-A2 molecule than the nonameric epitope [391]. Mutation of the
decameric anchor residue, alanine, to a leucine, further enhanced immunogenicity and
binding to the HLA-A2 molecule, more so than anchor modification with the nonameric
epitope [391, 392]. The DMF5 TCR recognized both the MART-1 nonameric epitope
(AAGIGILTV) and the anchor-modified decameric epitope (ELAGIGILTV) in the context
of HLA-A2. In these studies, MART-1 9mer will refer to the AAGIGILTV peptide, and
MART-1 10mer will refer to the anchor modified, ELAGIGILTV peptide. The crystal
structures of the DMF5 TCR/pMHC indicated that despite differences in the MART-1
9mer and 10mer peptide conformations in HLA-A2, the DMF5 TCR engaged both of the
peptides with identical binding modes. The superimposed structures of the DMF5 TCR
bound to the MART-1 9mer and 10mer peptides/HLA-A2 are shown in Figure 8 [325].
Specifically, the conformations of the CDR loops are the same between the two
peptides in both the side and top view. For these reasons, the crystal structure of the
DMF5 TCR engaged with HLA-A2 and the MART-1 10mer was utilized for structurebased design due to the MART-1 10mer’s enhanced binding and stability in the HLA-A2
molecule [351].
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Figure 7. Graphical Schematic of Positive and Negative Design Approach in the
DMF5 TCR. In collaboration with the Baker lab, we have developed a positive and
negative structure-guided design approach to enhance antigen specificity and reduce
cross-reactivity. This was first implemented in a model using the DMF5 TCR and
MART-1 peptide. The MART-1 peptide in the context of the HLA-A2 MHC class I
molecule is shown in purple and green, respectively. The DMF5 TCR is shown in blue
and CD3 is shown in red. The left complex depicts the WT DMF5 TCR expressed on a
T cell, engaging with the MART-1/HLA-A2 complex on a melanoma cell. The right TCR
depicts the combinatorial strategy of positive and negative (+/-) design in the DMF5
TCR. The TCR is expressed on a T cell and engages with the MART-1/HLA-A2
complex on a melanoma cell. However, positive mutations, depicted by the red/orange
bursts, were introduced in the DMF5 TCR and are proposed to enhance MART-1
peptide specificity. Conversely, negative mutations, depicted by the white space
between the TCR and HLA-A2, were introduced in the DMF5 TCR and are proposed to
weaken TCR binding with the HLA-A2 MHC class I.
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Figure 8. Crystal Structure of the DMF5 TCR and MART-1 Nonamer and Decamer
Peptide/HLA-A2 Complexes. The DMF5 TCR binding with the nonamer peptide/HLAA2 complex is depicted in yellow (AAGIGILTV). The DMF5 TCR binding with the
decameric/HLA-A2 complex is depicted in purple (ELAGIGILTV). (a) Side view of the
DMF5 TCR complex with the nonamer and decamer peptide/HLA-A2 complexes. (b)
Top view of superimposition from panel a. Identical overlap of CDR loops of the DMF5
TCR over the two peptide/HLA-A2 complexes is shown. These structures were provided
by the Baker lab [370].

The structure-guided design strategy, developed in collaboration with the Baker
lab, was first implemented in the DMF5 TCR. Two positive mutations and two negative
mutations were designed based on the crystal structure of the DMF5 TCR/MART-1
10mer/HLA-A2 tri-molecular complex. DMF5 TCR residues were identified for positive
mutations by simulating different point mutations in the TCR within 5.5 Ä of the pMHC
and were chosen based on their predicted ability to enhance the affinity of the DMF5
TCR [351, 393, 394]. The 5.5 Ä distance threshold was set in order to avoid TCR
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mutations enhancing binding with the MHC. The first positive mutation substituted an
aspartic acid with a tyrosine at position 26 (αD26Y) in the CDR1 region of the TCR
alpha chain. This mutation was designed to enhance charge complementarity with the
N-terminal region of the MART-1 peptide. The X-ray structure of the WT DMF5 TCR
compared to the αD26Y DMF5 TCR is shown in Figure 9 [351].
More specifically, in the complex with the WT TCR, αD26 and the glutamic acid
in position 1 of the MART-1 10mer peptide are in close proximity. Consequently, the
negative charges between the aspartic acid and the glutamic acid result in an
unfavorable repulsion of charge (Figure 10) [349]. Furthermore, the αD26 side chain
also induces charge repulsion with the side chain of the glutamic acid at position 58 in
the HLA-A2 α1 helix [349]. Tyrosines are large residues and thus can participate in a
number of van der Waals forces and electrostatic interactions. The rigid, bulky, and
amphipathic nature of tyrosine provides structural utility [395]. This explains why
mutations that have been shown to enhance affinity frequently replaced small polar or
charged amino acids with large hydrophobic or amphipathic amino acids [72]. The
αD26Y TCR mutation eliminates the charge repulsion with the peptide and
consequently enhances charge complementarity with the peptide and increases the
TCR affinity to pMHC (MART-1/HLA-A2). The peptide is only a small exposed area
compared to the MHC and the peptide and MHC are tightly packed together. This
makes it quite difficult, even when utilizing a meticulous targeted design strategy, to
identify residues and mutations in the TCR that will only affect TCR binding with peptide
and not the MHC as well.
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Figure 9. X-ray Structure of WT and αD26Y DMF5 TCRs in Complex with pMHC.
The DMF5 TCR alpha chain is yellow, the HLA-A2 is green, and MART-1 peptide is
magenta. (a) The WT residue, αD26, shown in purple. (b) The mutated, αY26, shown in
purple. Hydrogen bonds involved in the side chain and bound water molecule are
depicted by dashed lines. These structures were provided by the Baker lab [351].

Figure 10. Structural Impact of the αD26Y DMF5 TCR Mutation on Charge
Repulsions with the pMHC. The HLA-A2 complex is shown in blue, the MART-1
10mer peptide is shown in yellow, and the DMF5 TCR is shown in pale brown. (a) In the
WT DMF5 TCR, the αD26 exhibits unfavorable charge repulsion with the glutamic acid
at position 1 of the MART-1 10mer peptide and with the glutamic acid at position 58 in
the HLA-A2 complex. (b) In the αD26Y DMF5 TCR, the charge repulsion with the
peptide and MHC is eliminated. These structures were provided by the Baker lab [349].
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A schematic of how the αD26Y TCR mutation alters unfavorable charge repulsion to
favorable charge repulsion with the pMHC is shown in Figure 10 [349]. In conclusion,
the αD26Y TCR mutation is a positively designed mutation proposed to enhance
binding with the MART-1 peptide by enhancing charge complementarity with the Nterminal region of the MART-1 peptide.
The αD26Y TCR mutation was proposed to enhance charge complementarity
with the N-terminal region of the MART-1 peptide. However, other epitopes that conform
to similar structures in their N-terminal region could consequently be recognized with
this mutation. Therefore, a different positive mutation, βL98W, was designed in the
CDR3 region of the DMF5 TCR beta chain, to be more MART-1 specific [351]. Because
the CDR3 loops of TCRs are most often positioned over the center of the peptide to
make contact with the peptide, the βL98W TCR mutation was designed to target a
specific residue in the MART-1 peptide [71]. This TCR mutation was proposed to
improve shape complementarity with the leucine at position 7 or 8 in the 9mer or 10mer
MART-1 peptide, respectively. The X-ray structure of the WT DMF5 TCR compared to
the βL98W DMF5 TCR is shown in Figure 11 [351]. The βL98W TCR mutation was
chosen based upon its ability to enhance predicted TCR affinity against the MART1/HLA-A2 complexes [351]. As mentioned previously about tyrosine, tryptophan is also
a bulky and amphipathic amino acid and thus, provides structural and chemical value,
and enhanced the DMF5 TCR affinity against the MART-1/HLA-A2 complex [72, 395].
Furthermore, in a previously generated peptide panel comprised of 9mer epitopes
selected upon their sequence homology with the MART-1 peptide, the leucine in
position 7 was absent in about 60% of the sequence homologous epitopes [327].
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Figure 11. X-ray Structure of WT and βL98W DMF5 TCRs in Complex with pMHC.
The DMF5 TCR beta chain is pale pink, the HLA-A2 is green, and MART-1 peptide is
magenta. (a) The WT residue, βL98, shown in purple. (b) The mutated, βW98, shown in
purple. Structures were provided by the Baker lab [351].

This suggested the βL98W TCR mutation might have less of an impact on the majority
of MART-1 mimics in terms of enhancing binding and recognition. Overall, the βL98W
DMF5 TCR mutation is the second positively designed TCR mutation, and is proposed
to improve shape complementarity specifically with the leucine at position 7 or 8 in the
9mer or 10mer MART-1 peptide, respectively.
The field generally considers high affinity TCRs optimal for T cell function and
therapeutic efficacy [180, 396]. Therefore, we wanted to determine the effect of binding
and antigen specificity with a high affinity DMF5 TCR variant by combining the two
previously described TCR mutations. More specifically, we wanted to determine how the
combination of the two positive DMF5 TCR mutations (αD26Y and βL98W) in the
αD26Y/βL98W double mutant DMF5 TCR, altered the recognition of MART-1 compared
to either single mutant DMF5 TCRs. This combination was proposed to result in a
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DMF5 TCR variant with substantial enhancement towards the MART-1/HLA-A2
complex due to the additive binding enhancements. The X-ray crystal structure of the
WT DMF5 TCR overlaid with the αD26Y/βL98W DMF5 TCR is shown in Figure 12
[351]. Compared to the structure bearing the WT DMF5 TCR, there were no alterations
of the interface TCR CDR loops or the peptide with the αD26Y/βL98W TCR, indicating
this structure-based design strategy, utilized to identify specific residues for mutation,
did not disrupt the TCR/pMHC interface or the neighboring side chains. Furthermore,
compared to the WT TCR, the tyrosine and tryptophan mutant side chains more
expansively make direct contact with the MART-1 peptide in the αD26Y/βL98W TCR
[351]. In summary, the αD26Y/βL98W DMF5 TCR is proposed to enhance MART-1
peptide binding more than either single mutant DMF5 TCRs and this is depicted in the
crystal structures.
This structure-guided approach is based upon the idea of positive and negative
design. Even though the αD26Y/βL98W DMF5 TCR did not alter the CDR loops
compared to the WT TCR in the TCR/pMHC complex, it is possible that these mutations
could enhance off-target binding with MART-1 “like” epitopes. Therefore, introduction of
negative mutation would offset this potentially enhanced off-target cross-reactivity. This
is of critical importance because sole implementation of positive mutations, or sole
introduction of only favorable interactions with the peptide could allow for unwanted
effects on specificity. Thus, negative mutations were implemented to offset or
compliment the DMF5 TCR mutations made to enhance peptide binding. Negative
mutations were generated by identifying a TCR residue that if mutated, would weaken
TCR binding with the MHC.
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Figure 12. X-ray Structure of the WT TCR Overlaid with the αD26Y/βL98W DMF5
TCR in Complex with pMHC. The DMF5 TCR alpha chain is yellow, the DMF5 TCR
beta chain is pale pink, the HLA-A2 is green, and MART-1 10mer peptide is magenta.
The α26 TCR residue is shown in purple (above N-terminal end of MART-1 peptide).
Both the aspartic acid and tyrosine residues are depicted. The β98 TCR residue is
shown in purple (closer to C-terminal end of MART-1 peptide). Both the leucine and
tryptophan residues are depicted. Structure was provided by the Baker lab [351].
The αY50 residue in the CDR2 region of the DMF5 TCR alpha chain was
identified and chosen for designing negative mutations for multiple reasons. First, αY50
makes contact with an evolutionarily conserved and exposed region of HLA-A2.
Specifically, αY50 makes contact with the glutamic acid at position 154, the glutamine at
position 155, and the alanine at position 158 in the α2 helix of HLA-A2 [350]. Studies
indicated that up to 16% of sequenced TCRs have a tyrosine at this residue, however,
other amino acids at this residue still demonstrate conserved interaction with the same
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area of HLA-A2 [37]. For example, in all known structures of Vα12-2 TCRs bound to
pMHC, the tyrosine at position 50 interacts with the same residues in the HLA-A2 α2
helix [397]. It has been demonstrated that this TCR residue is important for interaction
with MHC class I in many other TCRs as well [398]. Furthermore, evidence suggest that
tyrosines are one of the more frequently used amino acids in prominent, conserved
interactions. The large amphipathic nature of tyrosine allows it to maintain van der
Waals forces more due to its size, rather than geometry. Overall, this tyrosine at
position 50 in the DMF5 TCR alpha chain could be important for TCR binding with MHC
because it can accommodate variation in structural changes within the TCR upon
binding different peptides in the context of MHC [337].
We and the Baker laboratory believed the αY50 DMF5 TCR residue was a
suitable residue for designing negative mutations, for the reasons described above. Two
different TCR mutations were made at this residue: αY50A and αY50V. The tyrosine to
alanine mutation was proposed to lose all contact with the HLA-A2 at positions 154,
155, and 158, whereas the tyrosine to valine mutation was proposed to weaken binding
with HLA-A2 at positions 154, 155, and 158, but not lose all contact. The X-ray structure
of the αY50A and αY50V DMF5 TCR mutations compared to the WT DMF5 TCR is
shown in Figure 13. Overall, the crystal structures indicated no structural perturbations
in the TCR with both of these mutations, aside from the directed removal or weakening
of bonds with the α2 helix of HLA-A2.
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Figure 13. X-ray Structure of αY50A and αY50V DMF5 TCR Mutations in Complex
with pMHC. The DMF5 TCR alpha chain is yellow, the HLA-A2 is green, the WT αY50
residue is purple, and MART-1 peptide is magenta. (a) The αA50 is shown in orange.
(b) The αV50 is shown in red. Structures were provided by the Baker lab.

The idea for utilizing this design strategy was not necessarily just to enhance
DMF5 TCR affinity with the MART-1/HLA-A2 complex, but rather the idea was to
redistribute the binding free energy to be more focused on the MART-1 peptide and less
focused on the MHC. The combination approach (positive and negative design) is
imperative in order to fine tune the antigen specificity of the DMF5 TCR. Explicitly,
DMF5 TCR mutations that enhance binding to the MART-1 peptide (αD26Y and
βL98W) will be offset, or counterbalanced, by the TCR mutations that weaken binding
with the MHC (αY50A or αY50V). In summary, the proposed net effect of this strategy in
the DMF5 TCR will result in TCRs with an enhanced affinity towards the MART-1
peptide, but weakened affinity towards other, off-target, peptides presented in the
context of HLA-A2.
The following five DMF5 mutant TCRs were generated: αD26Y, βL98W,
αD26Y/βL98W, αD26Y/αY50A/βL98W, and αD26Y/αY50V/βL98W. The 3D affinities of
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each TCR with the MART-1 9mer and 10mer peptides in the context of HLA-A2 were
measured via SPR (Table 3). In general, TCR affinity against pMHC has been
measured to range within 1-300 μM [399]. T cells that recognize self-antigens generally
harbor TCRs with affinities ranging within 10-100 μM, while T cells that recognize
foreign antigen harbor TCRs with affinities up to 1 μM [143, 400]. While implementing
the structure-guided design strategy, it was of interest to generate TCRs that lie within
the low micromolar range since this is similar to TCRs that recognize foreign peptides
and result in full T cell activation. The 3D affinity of the WT DMF5 TCR measured
against the MART-1 9mer/HLA-A2 complex and 10mer/HLA-A2 complex was 37 μM
and 11 μM, respectively. These measurements fall within the range of TCRs that target
self-antigens. The αD26Y TCR mutation enhanced the affinity of the TCR within this
range against the MART-1 9mer and 10mer with the affinity measured to be 7 μM and
1.3 μM, respectively. The βL98W TCR mutation also enhanced the affinity compared to
the WT TCR, with the affinity of the MART-1 9mer and 10mer measured to be 12 μM
and 5.3 μM, respectively. When combined, the αD26Y/βL98W double mutant TCR
further enhanced the affinity compared to the WT TCR, with MART-1 9mer and 10mer
affinity measurements being 1.8 μM and 0.043 μM, respectively. This is notable
because it is very rare to find natural TCRs with affinities in the nanomolar range, as the
upper limit or threshold for optimal T cell function has been observed to fall within 1-5
μM [142, 351]. The αD26Y/αY50A/βL98W TCR reduced affinity compared to the WT
TCR, with MART-1 9mer and 10mer affinities measured to be 228 μM and 36.4 μM,
respectively.
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Table 3. WT and Mutant DMF5 TCR-pMHC 3D Binding Affinities Measured via
SPR. The average KD values of three independent experiments + standard error of the
mean are shown. 3D TCR affinity measurements were performed in the Baker lab.

However, the affinity against the MART-1 10mer still falls within range of normal TCRs
that recognize self-antigen, similar to the affinity of the WT TCR measured with the
MART-1 9mer. Lastly, the αD26Y/αY50V/βL98W TCR also had reduced affinity
compared to the WT TCR, with MART-1 9mer and 10mer affinities measured to be 140
μM and 16.1 μM, respectively. Like the αD26Y/αY50A/βL98W TCR, the affinity of the
αD26Y/αY50V/βL98W TCR with the MART-1 10mer falls within the upper range of
normal TCRs that recognize self-antigen. These results implicate that as predicted, the
DMF5 TCR mutations proposed to enhance binding to the MART-1 peptide, αD26Y and
βL98W, enhanced TCR 3D affinity, and the combination of these two mutations,
αD26Y/βL98W, drastically enhanced TCR 3D affinity compared to the WT DMF5 TCR.
Furthermore, combining the αD26Y/βL98W TCR mutations with a mutation that
weakens TCR binding with the MHC, αD26Y/αY50A/βL98W and αD26Y/αY50V/βL98W,
reduced TCR 3D affinity lower than the WT DMF5 TCR. Lastly, these 3D TCR affinity
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measurements exemplify the effect of optimal peptide N-terminal anchor residues on
TCR affinity. These 3D affinity measurements will be important in later sections in terms
of their correlation to T cell function and cross-reactivity.
WT vs. Mutant DMF5 TCR Recognition of Individual Alterations in the MART-1
Peptide
We first wanted to determine how the structure-guided mutant DMF5 TCRs
affected recognition of the MART-1 9mer peptide when single structural alterations were
introduced, compared to the WT DMF5 TCR. The alanine scan assay is well
established as a method to determine residues in a peptide that are important for TCR
recognition [393, 401, 402]. We generated a panel of alanine substituted peptides
based on the sequence of the MART-1 9mer peptide (AAGIGILTV). If an alanine was
already present at a residue, an isoleucine was substituted instead. Herein, we could
determine how mutations in the DMF5 TCR altered recognition of alanine substituted
MART-1 peptides.
We transduced Jurkat E6.1 cells to express the WT or each mutant DMF5 TCR.
Jurkat E6.1 cells were used here to eliminate the donor variability generally associated
with polyclonal PBL-derived T cells. Transduction efficiencies four days after
transduction are shown in Figure 14. The data indicates that initial Jurkat E6.1
populations were transduced between 13% and 18% (based on our marker of
transduction, CD34). Jurkat E6.1 cells express minimal levels of endogenous CD34, as
shown at 5.06%. TCR transduced Jurkat E6.1 cells were subsequently enriched for high
and uniform CD34 expression using anti-CD34 immunomagnetic beads. CD34 surface
expression after CD34 enrichment is shown in Figure 15. The data indicate that after
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CD34 enrichment, Jurkat E6.1 populations exhibited between 86% and 97% CD34
surface expression. We did not stain for TCR surface expression via TCR alpha or TCR
beta chain mAbs because this quantification would include expression of mispaired
TCRs. Furthermore, we did not stain for TCR surface expression via tetramers or
dextramers because is it possible that the introduced TCR mutations could affect this
quantification. However, previous studies indicated that CD34 surface expression
correlated with TCR surface expression in a linear fashion [94]. Figure 15 depicts an
example of the uniform CD34+ cell populations that were obtained and used for
functional assays after transduction and CD34 enrichment. In this dissertation, this
method of CD34 enrichment, followed by confirmation of uniform and high CD34
expressing populations, was completed each time a transduction generated newly TCR
transduced cells (in both Jurkat E6.1 cells and T cells). These CD34 purified TCR
transduced Jurkat E6.1 cells were used as effector cells and cocultured with T2 cells
loaded with either the WT MART-1 9mer peptide or an alanine substituted peptide. The
amount of IL-2 produced against each alanine substituted peptide was normalized to
the amount of IL-2 produced against the MART-1 9mer peptide for each DMF5 TCR,
respectively. This was done in order to elucidate the residues important for recognition
relative to recognition of the MART-1 9mer peptide, and to easily observe alterations in
the patters of recognition between each of the DMF5 TCRs (Figure 16).
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Figure 14. CD34 Surface Expression on Jurkat E6.1 Cells Pre-CD34 Enrichment.
Four days after retroviral transduction, untransduced and TCR transduced Jurkat E6.1
cells were labeled with an anti-CD34 mAb to measure the transduction efficiency of
each population.
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Figure 15. CD34 Surface Expression on Jurkat E6.1 Cells Post-CD34 Enrichment.
Six days after retroviral transduction, and two days after CD34 immunomagnetic bead
enrichment, TCR transduced Jurkat E6.1 cells were labeled with an anti-CD34 mAb to
measure the CD34 enrichment efficiency of each population. As a result, the data
indicate high and uniform CD34 expression among the different populations.
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Figure 16. Impact of DMF5 TCR Mutations on Recognition of Alanine Substituted
MART-1 9mer Peptides. Jurkat E6.1 cells expressing either the WT TCR or each
mutant DMF5 TCR were stimulated with T2 cells loaded with the WT MART-1 9mer
peptide (AAGIGILTV) or alanine substituted peptides for 18 hours. IL-2 release was
measured by ELISA in triplicate wells. Fold change in reactivity was normalized within
each TCR to reactivity against the WT MART-1 9mer peptide, respectively. Average
MART-1 9mer reactivity was 913 pg/mL. Data are the average of three independent
experiments and error bars represent the standard error of the mean from three
independent experiments.

We first observed the pattern of recognition elicited by the WT DMF5 TCR before
determining how the structure-guided DMF5 TCR mutants affected recognition of
alanine substituted MART-1 9mer peptides. Alanine substitutions at positions 3 through
6 and position 8 of the MART-1 peptide eliminated reactivity in Jurkat E6.1 cells
expressing the WT DMF5 TCR, indicating these residues are critical for WT DMF5
recognition of the MART-1 9mer peptide. Additionally, substitutions at positions 2 and 7
reduced reactivity to 14% and 26% of reactivity compared to the MART-1 9mer peptide,
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respectively, but did not completely eliminate reactivity, indicating these two peptide
residues are important but not critical for recognition of the MART-1 9mer peptide. In
summary, positions 3 through 6, and 8 of the MART- 1 9mer peptide are critical for
recognition by Jurkat E6.1 cells expressing the WT DMF5 TCR.
After determining how Jurkat E6.1 cells expressing the WT DMF5 TCR
recognized alanine substituted MART-1 9mer peptides, we determined how mutations
in the DMF5 TCR altered this pattern of recognition. The pattern of recognition observed
with the WT DMF5 TCR did not hold true in Jurkat E6.1 cells expressing the αD26Y
TCR. In cells expressing the αD26Y TCR, substitutions at positions 4 and 6 reduced
reactivity to that of about 13% and 8% of reactivity against the MART-1 9mer peptide,
respectively. This pattern is different compared to the WT TCR, as now substitutions at
positions 2, 3, 5, 7, and 8 are tolerated. Despite this tyrosine mutation at position 26 of
the TCR alpha chain targeting the N-terminal region of the MART-1 peptide, the αD26Y
TCR allowed for enhanced reactivity relative to the MART-1 9mer peptide at positions 7
and 8. These results indicated the tyrosine TCR mutation enhances binding with the Nterminal region of the peptide, or the pMHC complex, substantially enough, to where the
TCR is tolerant of alterations at the C-terminal end of the MART-1 9mer peptide.
Overall, the αD26Y TCR modification designed to enhance binding to the N-terminal
region of the MART-1 peptide also impacted recognition of MART-1 9mer peptides
containing alanine substitutions at the C-terminal end.
In the next DMF5 TCR mutant, Jurkat E6.1 cells expressing the βL98W TCR
displayed a pattern fairly similar to that of the WT TCR. One exception is the βL98W
TCR mutation now allows for recognition of alanine substitution at position 7, equal to
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that of the MART-1 9mer peptide. This indicated the tryptophan mutation at position 98
of the DMF5 TCR beta chain is not specific for the leucine at position 7 of the MART-1
9mer peptide, as it tolerated an alanine substitution. Furthermore, the βL98W TCR was
more tolerant of alanine substitution at position 8 of the MART-1 9mer peptide
compared to the WT TCR. This indicated that the tryptophan TCR mutation could be
enhancing binding with the peptide beyond position 7. In summary, the βL98W TCR is
not as tolerant with alanine substitutions as the αD26Y TCR, but also is possibly not as
specific for position 7 in the MART-1 peptide as initially proposed.
After determining how the single positive DMF5 TCR mutants altered the
recognition pattern of alanine substituted MART-1 9mer peptides, we determined how
the combination of these DMF5 TCR mutations altered peptide recognition. The
combination of the αD26Y and βL98W TCR mutations in the αD26Y/βL98W TCR
allowed for the most promiscuous pattern of recognition of alanine substituted MART-1
9mer peptides compared to all of the TCRs. The observed pattern resembled a pattern
of recognition most similar to the αD26Y TCR. Only alanine substitution at positions 4
and 6 resulted in reduced reactivity relative to reactivity against the MART-1 9mer
peptide. This suggested the combination of the αD26Y and βL98W TCR mutations
enhanced binding to the pMHC, as the TCR now allows for recognition of an alanine at
position 4 in the MART-1 9mer. With the αD26Y/βL98W TCR, this recognition of alanine
substitution at position 4 was 57% of the MART-1 9mer peptide, compared to about
13% and 0% by the αD26Y and βL98W TCRs, respectively, indicating more than an
additive effect of the two TCR mutations (57% > 13% + 0%). Overall, these results
suggested the enhanced affinity and structural changes of the αD26Y/βL98W TCR
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mutations allow it to be more permissive in recognition of alanine substituted MART-1
9mer peptides compared to the αD26Y, βL98W, and WT DMF5 TCRs.
Our results thus far indicated that single or double positive TCR mutations in the
DMF5 TCR altered the recognition pattern of alanine substituted MART-1 9mer peptides
compared to the WT DMF5 TCR. We next determined how these patterns were affected
by the inclusion of a negative mutation, one that eliminated binding with three residues
in the MHC, to the αD26Y/βL98W TCR. When a TCR mutation that eliminated binding
to three residues in the MHC was added to the two positive TCR mutations, Jurkat E6.1
cells expressing the αD26Y/αY50A/βL98W TCR exhibited a pattern similar to the WT
DMF5 TCR. One minor difference is a slight enhancement in relative recognition when
position 7 is alanine substituted, 52% compared to 26% respectively, relative to
reactivity against the MART-1 9mer peptide. This was most likely due to the presence of
the βL98W TCR mutation which was designed to enhance binding with the leucine at
position 7. Additionally, alanine substitution at position 1 was very well tolerated, which
could be attributed to the strength of the αD26Y and βL98W TCR mutations despite
presence of the αY50A TCR mutation. In summary, these results suggested the low 3D
affinity (228 μM against the MART-1 9mer) and structural changes of the
αD26Y/αY50A/βL98W TCR mutations do not significantly affect the pattern of
recognition of alanine substituted MART-1 9mer peptides compared to the WT TCR.
Lastly, we observed how recognition patterns were affected by the inclusion of a
different negative mutation, one that weakened binding with three residues in the MHC
(but did not eliminate binding like αY50A), to the αD26Y/βL98W TCR. Jurkat E6.1 cells
expressing the αD26Y/αY50V/βL98W TCR exhibited a pattern of recognition very
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similar to the βL98W TCR. This indicated that the addition of α50V and even more so,
α50A, to the αD26Y/βL98W TCR, counterbalanced the permissive reactivity.
Specifically, recognition of alanine substituted position 7 was comparable to reactivity
against the MART-1 9mer peptide, as was the case with the βL98W TCR. Albeit,
reduced relative reactivity was observed at alanine substituted position 7 with the
αD26Y/αY50A/βL98W TCR, indicating the αY50A mutation better offset enhanced
promiscuity at this residue than the αY50V mutation. However, aside from position 7,
the patterns of recognition observed with the αD26Y/αY50A/βL98W TCR and the
αD26Y/αY50V/βL98W TCR closely resemble the pattern observed with the WT TCR,
indicating the addition of the mutations that weaken binding with the MHC, can
counterbalance the promiscuity observed with the αD26Y and αD26Y/βL98W TCRs.
Overall these results suggested that each MART-1 targeting TCR mutation did not
increase MART-1 specificity, but combination with a TCR mutation that weakens
binding with the MHC can enhance target specificity.
Impact of Mutant DMF5 TCRs on On-target Tumor Killing
The intention for designing these TCRs was to study TCR/pMHC interactions and
furthermore, eventually to use them therapeutically to treat melanoma. Therefore,
before moving forward with functional T cell assays, we wanted to confirm T cells
expressing the modified DMF5 TCRs could elicit killing of HLA-A2+ melanoma cells. A
summary of the DMF5 TCRs and their measured affinities with the MART-1 9mer
peptide/HLA-A2 is shown in Table 4. If affinity correlates to targeted killing, based on
the measured 3D affinities, we would expect that cells expressing the αD26Y/βL98W
TCR would elicit the highest level of targeted tumor killing, while cells expressing the
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αD26Y/αY50A/βL98W TCR would elicit the lowest level of targeted tumor killing. An
LDH cytotoxicity assay was performed using human T cells transduced to express
either the WT DMF5 TCR or each mutant DMF5 TCR and an HLA-A2-/MART-1+
melanoma tumor, MEL 624-28, and an HLA-A2+/MART-1+ melanoma tumor, MEL 624
(Figure 17). The percentage of TCR transduced T cells used in these experiments
ranged between 84% and 89% among the different DMF5 TCR expressing T cell
populations. Among the TCR transduced T cell populations, the proportion of CD4 + T
cells ranged between 27% and 35% and the proportion of CD8 + T cells ranged between
65% and 73%. These minor differences in the percentages of TCR transduced T cells
and CD4+ to CD8+ T cell ratios had no correlation with differences observed in targeted
cytotoxicity. All killing by the WT and mutant DMF5 TCR transduced T cells was HLAA2 restricted, as there was no killing observed with HLA-A2- MEL 624-28 (Figure 17). T
cells expressing each of the mutated TCRs exhibited equal or better killing of MEL 624
than T cells expressing the WT TCR. Specifically, T cells expressing the WT DMF5
TCR exhibited 37% cytotoxicity of MEL 624 tumor cells. T cells expressing the αD26Y
TCR or the αD26Y/βL98W TCR exhibited statistically significantly more MEL 624 killing
(65% and 61%, respectively) compared to T cells expressing the WT TCR. Lastly, T
cells expressing the βL98W TCR, αD26Y/αY50A/βL98W TCR, or αD26Y/αY50V/βL98W
TCR, exhibited MEL 624 tumor killing at similar or increased levels (48%, 39%, and
52%, respectively) compared to T cells expressing the WT TCR.
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Table 4. Summary of Structure-Guided DMF5 TCR Mutations. The KD values
indicated were measured in the MART-1 nonameric peptide. DMF5 TCR mutations in
green indicate positive, peptide targeting mutations. DMF5 TCR mutations in red
indicate negative, MHC weakening mutations. 3D TCR affinity measurements were
completed in the Baker lab.
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Figure 17. Impact of DMF5 TCR Mutations on Melanoma Killing. Human
untransduced or TCR transduced T cells (with either the WT TCR or a mutant DMF5
TCR) were cocultured with tumor cells for 18 hours in a 1:1 effector:target ratio. MEL
624-28 tumor cells were used as an HLA-A2-/MART-1+ melanoma control. MEL 624
tumor cells were used as an HLA-A2+/MART-1+ melanoma line. Data represent the
mean of two independent experiments and error bars represent the standard error of
the mean from two independent experiments. One representative donor is shown. ***P
< 0.001; **P < 0.01; *P < 0.05 when compared to the percent MEL 624 killing by the WT
TCR by two-way ANOVA using Sidak’s multiple comparisons test.

Based on 3D affinity, it was unexpected that T cells expressing the
αD26Y/αY50A/βL98W or αD26Y/αY50V/βL98W TCR exhibited equal or better MEL 624
killing compared to T cells expressing the WT TCR. However, it has been demonstrated
that the targeted release of lytic granules only requires engagement of three
TCR/pMHC interactions [152, 403]. This suggests TCR affinity could have less of an
influence on lytic activity in T cells. This could further be supported by the observation
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that despite the higher TCR affinity (roughly 3-fold higher) of the βL98W TCR, it did not
elicit significantly more MEL 624 killing than the WT TCR. Overall, these results
demonstrated T cells expressing each of the modified DMF5 TCRs could elicit HLA-A2
restricted melanoma killing and 3D TCR affinity does not directly correlate with target
cell lysis.
Impact of Mutant DMF5 TCRs on Cross-Reactivity
We next sought to determine how the structure-guided DMF5 TCR mutations
altered cross-reactivity in T cells, beyond alanine substituted peptides, compared to the
WT DMF5 TCR. We utilized a panel of previously described peptides that were selected
because they are homologous with the MART-1 9mer peptide [327, 328]. These
peptides and their sequence homology with the MART-1 9mer are shown in Table 5.
Recurring residues include glycine, alanine, valine, and leucine, as they are featured
extensively in the MART-1 9mer epitope. Many of the selected peptides conform to the
central [G, A, V]xGx motif at positions 3 through 6 of the MART-1 9mer epitope. The
panel is comprised of both self- and non-self-peptides that are naturally occurring and
physiologically relevant. Previous studies demonstrated MART-1 reactive T cells could
lyse target cells loaded with some, but not all, of the peptides in this selected panel
[327]. Therefore, we decided to perform preliminary screenings for cross-reactivity to
determine which MART-1 homologs elicited a significant response from T cells
expressing the WT TCR or each of the modified DMF5 TCRs (Figure 18). Specifically,
TCR transduced T cells expressing either the WT TCR or each mutant DMF5 TCR were
cocultured with T2 cells loaded with the MART-1 9mer peptide or each MART-1
homolog.
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Table 5. MART-1 Homolog Peptide Panel. Homology with the MART-1 9mer is
indicated in black [327]. ● indicates self-peptide. The following abbreviations are used
throughout the text: Human receptor expression enhancing protein 5 (HREEP 5) and Gprotein coupled receptor 3 (GPCR 3).
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Figure 18. Example of Initial Screen for Cross-Reactivity. An example of initial
cross-reactivity screening shown with TCR transduced T cells expressing the αD26Y
DMF5 TCR. For screening, human T cells expressing either WT or mutant DMF5 TCR
stimulated with T2 cells loaded with the HCV NS3 peptide (KLVALGINAV), MART-1
9mer peptide (AAGIGILTV), or MART-1 homologs. IFN-γ release was measured by
ELISA in triplicate wells. Antigen reactivity is defined as a T cell culture that secretes
twice background, or twice the amount of IFN-γ production as with unpulsed T2 cells,
and over 200 pg/mL. One representative experiment from one representative donor is
shown.
The amount of IFN-γ produced against each peptide loaded target was measured. The
representative example shown in Figure 18 depicts antigen reactivity by T cells
expressing the high affinity αD26Y DMF5 TCR. Here, antigen reactivity is defined as a T
cell culture that secretes twice background, or twice the amount of IFN-γ production as
with unpulsed T2 cells, and over 200 pg/mL. It is evident that αD26Y TCR expressing T
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cells recognized target cells loaded with multiple MART-1 homologs. Specifically, in this
donor and experiment, αD26Y TCR expressing T cells recognized target cells loaded
with HSV-1 glycoprotein III, human CD9, M. tuberculosis protein I, ADP-ribose
diphosphatase, and GPCR 3. Furthermore, there are many MART-1 homolog loaded
targets that were not recognized. This is concurrent with previous findings in that
despite sequence homology with the MART-1 9mer peptide, not all MART-1 homolog
loaded target cells elicited a response from MART-1 reactive T cells [327]. This
experiment was repeated six times with T cells expressing the WT TCR or each of the
mutant DMF5 TCRs (two independent experiments in three different healthy donors).
For all future functional experiments, we decided to concentrate on the MART-1
homologs that elicited a T cell response from any of the DMF5 TCRs in any donor or
experiment. Specifically, a T cell response was defined as any MART-1 homolog that
elicited IFN-γ production greater than with T2 cells alone (Table 6). It was interesting to
observe that our results obtained with the alanine scan assay did not completely
coincide with the MART-1 homologs that were recognized. For example, results from
the alanine scan assay (Figure 16) indicated the importance of positions 3 through 6
and 8 in the MART-1 9mer peptide for recognition by WT TCR expressing cells, but
many MART-1 homologs with mutations at one or more of these peptide residues were
recognized (all of the MART-1 homologs in Table 6). Conversely, MART-1 homologs
that maintained sequence homology at one or more of these peptide residues were not
recognized. For example, the S. cerevisiae protein I peptide (in Table 5) differs from the
MART-1 9mer at four residues, but the altered residues are still very hydrophobic, and
sequence homology remains at the central peptide positions, 4 through 6.
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Table 6. MART-1 Homolog Peptide Panel Used In Functional Assays. Homology
with the MART-1 9mer is indicated in black [327]. ● indicates self-peptide.
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However, T cells expressing the WT TCR or modified DMF5 TCRs did not recognize T2
cells loaded with this peptide in any experiment. It would be plausible to hypothesize
that cross-reactive epitopes have a better N-terminal anchor since alanine, the Nterminal anchor in the MART-1 9mer peptide, is generally considered a weak anchor
residue. It has been demonstrated that peptides conform differently in the MHC
depending upon their anchor residues [404, 405]. However this was not the case with
the S. cerevisiae protein I peptide, as it has a leucine N-terminal anchor and was not
recognized. Furthermore, cross-reactivity was observed against MART-1 homologs with
an N-terminal alanine anchor residue (M. tuberculosis protein II, β-endoxylanase, lmrA,
HSV-2 glycoprotein F, HSV-1 glycoprotein III) and conversely, no cross-reactivity was
observed against some MART-1 homologs with N-terminal leucine anchors (E. coli
peptide, P. putida, Measles Virus, S. gordonii). Overall, altered-peptide ligands that
have sequence homology with the MART-1 9mer peptide could be recognized despite
mutations at residues previously implicated as imperative for MART-1 9mer peptide
recognition in the alanine scan. These results indicated that the alanine scan assay can
be a suitable method for making a general prediction about the importance of an
individual residue in the MART-1 9mer peptide for recognition. However, it does not
take into account the effects or contributions of alterations in the peptide with different
amino acids (other than alanine) and/or the combination of multiple alterations in the
peptide. Overall, cross-reactivity against a given peptide is probably more dependent
upon the net effect or, the overall structure and antigenic surface of the peptide in the
HLA-A2 complex, versus individual mutations at a given epitope.
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We next determined how human T cells expressing each mutant DMF5 TCR
altered MART-1 specificity and recognition of the MART-1 homologs compared to T
cells expressing the WT DMF5 TCR in terms of polyfunctional T cell responses. WT
TCR and mutant DMF5 TCR transduced T cells were stimulated with T2 cells loaded
with the MART-1 peptide or the MART-1 homologs (Table 6). The typical functional
readout in the field for T cell function is IFN-γ production. However, it is known that T
cells are capable of more complex functional phenotypes and have been shown to be
polyfunctional [95, 406-411]. Furthermore, analysis of intracellular IFN-γ production from
PBL-derived T cells from stage IV melanoma patients who received therapeutic
vaccination, revealed no correlation to survival [412]. Additionally, multiple T cell
subtypes have been described as important in tumor and disease clearance [413-416].
Therefore, since polyfunctionality could be important for on-target and off-target
recognition, we examined surface expression of CD107A as a surrogate marker for lysis
[417, 418], and intracellular expression of IFN-γ, TNF-α, IL-17A, IL-2, IL-4, and IL-22
following antigen stimulation on a per cell basis. This cytokine panel includes Th1, Th2,
and Th17 cytokines.
We first focused on antigen recognition in CD4+ T cells because true crossreactivity, as a result of changes in the TCR/pMHC interface, are highlighted in the
CD4+ T cells due to the absence of assistance in signaling and stabilization from the
CD8 co-receptor [92]. Furthermore, the DMF5 TCR mutations designed using the
structure-guided approach did not take into account CD8. The gating strategies used for
all experiments are shown in Figures 4-6.
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We first observed antigen specificity and cross-reactivity of

CD4+

T cells

expressing the WT DMF5 TCR. Here, the percentage of antigen reactive T cells
expressed any one or more functional marker (CD107A or cytokines). The percentages
of antigen reactive T cells were determined after respective background subtraction, as
described in Chapter Two. The average of six experiments found 19% of CD4 + T cells
expressing the WT DMF5 TCR were reactive against MART-1 9mer loaded targets
(Figure 19). The MART-1 10mer has a higher binding affinity for HLA-A2 [392],
however, compared to the MART-1 9mer, the percentages of reactive T cells were
similar (22% vs. 19%). This indicated that MART-1 peptide binding stability did not
significantly affect the percentage of antigen reactive CD4+ T cells. Recognition of
MART-1 homologs by CD4+ T cells expressing the WT TCR was low, between 0.15%
and 1.8%, indicating CD4+ WT DMF5 TCR expressing T cells are barely reactive
against the MART-1 homologs. In conclusion, CD4+ T cells expressing the WT DMF5
TCR are MART-1 reactive, but appear to be minimally cross-reactive.
We extended our analysis to the structure-guided mutant DMF5 TCRs after
determining the percentages of MART-1 and MART-1 homolog reactive WT DMF5 TCR
expressing CD4+ T cells. Since the αD26Y TCR mutation enhanced binding with the
MART-1 peptide, we would expect an increase in the percentages of MART-1 reactive T
cells. Although not statistically significant, as predicted, CD4+ T cells expressing the
αD26Y TCR displayed an increase in the percentage of MART-1 9mer reactive T cells
(27%) compared to WT TCR expressing T cells (19%). This result indicated the αD26Y
TCR mutation enhanced binding with MART-1.
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Figure 19. Impact of DMF5 TCR Mutations in TCR Transduced CD4+ T Cells
against MART-1 and MART-1 Homologs. Human TCR transduced T cells were
stimulated with peptide loaded T2 cells for 5 hours and then stained for cell surface
CD3, CD4, CD8, CD34, CD107A, and intracellular IFN-γ, TNF-α, IL-17A, IL-2, IL-4, and
IL-22. Subsequent percent antigen reactive T cells were calculated by subtracting the
percentage of non-reactive TCR transduced CD4+ T cells from 100. As described in
Chapter Two, antigen reactivity was determined after background subtraction
(specifically, subtraction of background immunofluorescence with HCV loaded T2 cells).
Non-reactive TCR transduced CD4+ T cells did not express CD107A or cytokines. The
reactivity of CD3+CD34+CD4+ TCR transduced T cells is shown. Error bars represent
the standard error of the mean from three donors, two independent repeats (6
experiments). Self-peptides are indicated by a black triangle. **** P <0.0001; ***P <
0.001; **P < 0.01; *P < 0.05 when the percentage of antigen reactive T cells against
each peptide with a given TCR was compared to the percentage of antigen reactive T
cells to the respective peptide with the WT TCR by two-way ANOVA using Sidak’s
multiple comparisons tests.
However, compared to T cells expressing the WT TCR, T cells expressing the αD26Y
TCR demonstrated an increase in the percentages of MART-1 homolog reactive T cells
(0.15% - 1.8% vs. 2.4% - 26%), reaching statistical significance with HSV-1 glycoprotein
III and M. tuberculosis protein I (0.7% and 0.9% vs. 29% and 22%). Overall, the tyrosine
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TCR mutation at position 26 in the TCR alpha chain did not increase MART-1
specificity.
We next observed how the introduction of a different MART-1 peptide targeting
TCR mutation, βL98W, affected MART-1 and MART-1 homolog recognition in CD4+ T
cells. Although not significant, as predicted, CD4+ T cells expressing the βL98W TCR
displayed an increase in the percentage of MART-1 9mer reactive T cells (23%)
compared to WT TCR expressing T cells (19%). Furthermore, recognition of MART-1
homologs by T cells expressing the βL98W TCR was low, between 0.4% and 5.9%.
This range was slightly greater than the percentage of MART-1 homolog reactive T cells
expressing the WT TCR, but no statistically significant differences were observed. This
indicated the tryptophan TCR mutation at position 98 of the DMF5 TCR beta chain did
not significantly affect recognition of MART-1 or MART-1 homologs compared to the WT
TCR. We next observed the effect of the combination of the αD26Y TCR and βL98W
TCR mutations on antigen specificity and cross-reactivity. T cells expressing the
αD26Y/βL98W TCR demonstrated a reduction in the percentage of MART-1 9mer
reactive T cells compared to the WT TCR (11.6% vs. 19%). Since the 3D affinity of this
TCR was measured to be 1.8 μM against the MART-1 9mer, this result was not
surprising, as it has been demonstrated when a TCR’s affinity approaches 1 μM, a
decline in TCR signaling and in T cell function is observed [142, 145, 419]. Compared to
T cells expressing the WT TCR, an increase in the percentages of MART-1 homolog
reactive T cells was observed with the αD26Y/βL98W TCR, reaching statistical
significance with HSV-1 glycoprotein III and M. tuberculosis protein I loaded targets
(0.7% and 0.9% vs. 10% and 10%). Overall, these results suggested the combination of
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the tyrosine TCR mutation at position 26 in DMF5 TCR alpha chain and the tryptophan
TCR mutation at position 98 in the TCR beta chain did not increase MART-1 specificity
and attenuated MART-1 specific T cell reactivity.
We next evaluated the effect of the introduction of a MHC weakening TCR
mutation on antigen specificity and cross-reactivity. There was a statistically significant
reduction in the percentage of MART-1 9mer reactive T cells expressing the
αD26Y/αY50A/βL98W TCR compared to the WT TCR, 8% vs. 19%, but this was not
surprising based on its reduced 3D TCR affinity. The percentages of MART-1 homolog
reactive T cells was comparable between T cells expressing the αD26Y/αY50A/βL98W
TCR and the WT TCR (0.6% - 2.1% vs. 0.15% - 1.8%). This indicated the addition of
the αY50A TCR mutation to the αD26Y/βL98W TCR restored the percentage of MART1 homolog reactive T cells to WT TCR levels. Compared to the introduction of the
αY50A TCR mutation, the introduction of the αY50V TCR mutation had less of an effect
on MART-1 and MART-1 homolog recognition. Specifically, T cells expressing the
αD26Y/αY50V/βL98W TCR exhibited a similar percentage of MART-1 9mer reactive T
cells compared to T cells expressing the WT TCR (21% vs. 19%). Furthermore, aside
from minor increases, (0.46% - 4.8% vs. 0.15% - 1.8%), the percentages of MART-1
homolog reactive CD4+ T cells was comparable between T cells expressing the
αD26Y/αY50V/βL98W TCR and the WT TCR. These results were unexpected
considering the measured 3D TCR affinity of the αD26Y/αY50V/βL98W TCR was lower
compared to the WT TCR. In summary, compared to the WT TCR, the percentages of
cross-reactive CD4+ T cells was enhanced with the αD26Y TCR and the αD26Y/βL98W
TCR, and the percentages of MART-1 9mer reactive CD4+ T cells was reduced with the
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αD26Y/βL98W TCR and the αD26Y/αY50A/βL98W TCR. Overall, none of the DMF5
TCR mutations enhanced MART-1 specificity in TCR transduced CD4+ T cells.
TCR affinity has been correlated to antigen specificity and cross-reactivity and
has been implicated to be of importance in T cell function. Thus, it was important to
determine how the MART-1 and MART-1 homolog recognition by the modified DMF5
TCRs correlated to their 3D affinity. It is generally well appreciated that higher affinity
TCRs are more cross-reactive [179, 420]. Based solely on this concept, we would have
expected to observe an increase in the percentages of MART-1, and possibly MART-1
homolog, reactive CD4+ T cells in T cells transduced to express the TCRs whose 3D
affinity was higher than the WT TCR (αD26Y TCR, βL98W TCR, and αD26Y/βL98W
TCR). There was no significant increase (but trending towards) in the percentages of
MART-1 reactive CD4+ T cells expressing the αD26Y TCR or βL98W TCR, compared to
T cells expressing the WT TCR. However, T cells expressing the αD26Y TCR or
αD26Y/βL98W TCR did exhibit a significant increase in the percentage of antigen
reactive CD4+ T cells against two MART-1 homologs (HSV-1 glycoprotein III and M.
tuberculosis protein I), coinciding with their increased 3D TCR affinity. There were no
significant differences observed with T cells expressing the βL98W TCR compared to
the WT TCR despite the 3-fold 3D TCR affinity enhancement of the βL98W TCR.
However, minor increases were observed. Based solely on 3D affinity, we would have
expected a decrease in the percentage of MART-1 and MART-1 homolog reactive CD4+
T cells in T cells transduced to express TCRs whose 3D affinity was lower than the WT
TCR (αD26Y/αY50A/βL98W and αD26Y/αY50V/βL98W). A significant decrease in the
percentage of MART-1 reactive CD4+ T cells was observed in T cells expressing the
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αD26Y/αY50A/βL98W TCR compared to the WT TCR, coinciding with the decrease in
3D TCR affinity. However, the percentage of MART-1 and MART-1 homolog reactive
CD4+ T cells in T cells expressing the αD26Y/αY50V/βL98W TCR was similar to that of
T cells expressing the WT TCR, aside from slight, non-significant increases against a
few MART-1 homologs (ADP-ribose diphosphatase, HREEP 5, human elongation factor
1α, and HSV-2 glycoprotein F). In summary, these results suggested the
αD26Y/αY50V/βL98W TCR’s reduced 3D affinity does not directly correlate to the
observed T cell specificity. However, 3D affinity generally correlated to the percentages
of TCR transduced MART-1 reactive and cross-reactive CD4+ T cells among the WT
TCR and modified DMF5 TCRs.
The analysis of the WT DMF5 TCR and mutant DMF5 TCR transduced CD4+ T
cells allowed us to examine how the structure of the TCR/pMHC influenced T cell
function and cross-reactivity. However, it has been implicated that the CD8 co-receptor
can affect antigen specificity and cross-reactivity through stabilization of the TCR/pMHC
and through T cell signaling [398, 421, 422]. Therefore, we next determined how
recognition of MART-1 and the MART-1 homologs was altered in WT TCR and mutant
DMF5 TCR transduced CD8+ T cells. We first observed antigen specificity and crossreactivity of CD8+ T cells expressing the WT DMF5 TCR. The average of six
experiments found 44% of CD8+ T cells expressing the WT DMF5 TCR were reactive
against MART-1 9mer loaded targets (Figure 20). Contrary to CD4+ T cells, CD8+ T
cells expressing the WT TCR recognized nine MART-1 homolog loaded targets, ranging
from 1.4% to 18% of WT DMF5 TCR transduced T cells. Some of these recognized
MART-1 homologs were self-peptides (HREEP 5, human elongation factor 1α, and

human CD9). In summary WT DMF5 TCR expressing

CD8+
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T cells were more reactive

against MART-1 and MART-1 homolog loaded targets than the CD4+ T cells. These
results implicated the role of CD8 in cross-reactivity.
After determining how CD8+ T cells expressing the WT DMF5 TCR recognized
MART-1 and MART-1 homologs, we determined how mutations in the DMF5 TCR
altered reactivity in TCR transduced CD8+ T cells. Since the αD26Y TCR and βL98W
TCR mutations enhanced binding with the MART-1 peptide, we would expect an
increase in the percentages of MART-1 reactive T cells. However, neither of the TCR
transduced T cell populations expressing TCRs harboring mutations that enhanced
binding to MART-1 (αD26Y TCR and βL98W TCR) demonstrated increased
percentages of MART-1 9mer reactive T cells compared to T cells expressing the WT
TCR (42% and 42% vs. 43%). These results indicate CD8 can minimize the targeted
effects of these mutations. More specifically, the contribution of the CD8 co-receptor in
T cell function appears to overshadow the minor impact of the positive TCR mutations.
This observation indicated the structure-guided strategy can have different effects in
CD4+ and CD8+ T cells. As seen in the TCR transduced CD4+ T cells, the percentage of
MART-1 homolog reactive T cells was increased in T cells expressing the αD26Y TCR
compared to the WT TCR, with statistical significance reached with HSV-1 glycoprotein
III (44%), M. tuberculosis protein I (34%), and GPCR 3 (23%). With the second MART-1
targeting TCR mutation, βL98W, the pattern of antigen reactivity against the MART-1
homologs was similar between T cells expressing the βL98W TCR and the WT TCR.
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Figure 20. Impact of DMF5 TCR Mutations in TCR Transduced CD8+ T Cells
against MART-1 and MART-1 Homologs. Human TCR transduced T cells were
stimulated with peptide loaded T2 cells for 5 hours and then stained for cell surface
CD3, CD4, CD8, CD34, CD107A, and intracellular IFN-γ, TNF-α, IL-17A, IL-2, IL-4, and
IL-22. Subsequent percent antigen reactive T cells were calculated by subtracting the
percentage of non-reactive TCR transduced CD8+ T cells from 100. As described in
Chapter Two, antigen reactivity was determined after background subtraction
(specifically, subtraction of background immunofluorescence with HCV loaded T2 cells).
Non-reactive TCR transduced CD8+ T cells did not express CD107A or cytokines. The
reactivity of CD3+CD34+CD8+ TCR transduced T cells is shown. Error bars represent
the standard error of the mean from three donors, two independent repeats (6
experiments). Self-peptides are indicated by a black triangle. **** P <0.0001; ***P <
0.001; **P < 0.01; *P < 0.05 when the percentage of antigen reactive T cells against
each peptide with a given TCR was compared to the percentage of antigen reactive T
cells to the respective peptide with the WT TCR by two-way ANOVA using Sidak’s
multiple comparisons tests.
However, although not statistically significant, an increase in the percentage of human
CD9 reactive T cells was observed in T cells expressing the βL98W TCR, compared to
the WT TCR (9.4% vs. 3%). With the βL98W TCR mutation, we would expect enhanced
reactivity against the four MART-1 homologs that contain a leucine at position 7 (GPCR
3, β-endoxylanase, ADP-ribose diphosphatase, and HSV-1 glycoprotein III). This was
not observed, indicating the tryptophan is unable to differentiate a leucine from other
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hydrophobic residues at position 7 of the 9mer peptides. We next observed the effect of
the combination of the αD26Y TCR and βL98W TCR mutations on antigen specificity
and cross-reactivity in TCR transduced CD8+ T cells. T cells expressing the
αD26Y/βL98W TCR exhibited a significant decrease in MART-1 reactive T cells
compared to the WT TCR (16% vs. 44%). This again, coincides with this TCR’s
supraphysiological high affinity. Compared to T cells expressing the WT TCR,
expression with the αD26Y/βL98W TCR enhanced the percentages of MART-1
homolog reactive T cells in seven homologs, but none reached statistical significance.
However, it is difficult to discern the extent of how the supraphysiological TCR affinity
affects the percentage of MART-1 and MART-1 homolog reactive T cells. Lastly, we
observed the effect of the introduction of a MHC weakening TCR mutation on antigen
specificity and cross-reactivity in TCR transduced CD8+ T cells. T cells expressing the
αD26Y/αY50A/βL98W TCR demonstrated an overall trend in the reduction of the
percentages of MART-1 homolog reactive CD8+ T cells compared to T cells expressing
the WT TCR (0.25% - 4% vs. 1.4% - 18%), with statistical significance reached with
HSV-1 glycoprotein III (2.3%) and M. tuberculosis protein I (2.3%). Albeit, these T cells
also exhibited a statistically significant reduction in the percentage of MART-1 9mer
reactive T cells compared to the WT TCR (29% vs. 44%). This indicated the addition of
the αY50A mutation to the αD26Y/βL98W TCR was enough to reduce percentages of
cross-reactive T cells, even below WT levels, but at the expense of T cell potency
against MART-1 loaded targets. As observed with the CD4+ T cells, the introduction of
the αY50V TCR mutation yielded different results than the introduction of the αY50A
TCR mutation. Although not statistically significant, there was a trend towards a
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reduction in the percentage of MART-1 9mer reactive T cells in T cells expressing the
αD26Y/αY50V/βL98W TCR compared to T cells expressing the WT TCR. Furthermore,
the pattern of reactivity against MART-1 homologs exhibited by T cells expressing the
αD26Y/αY50V/βL98W TCR was similar to that of T cells expressing the WT TCR. In
summary, these results indicated that the percentage of MART-1 homolog reactive T
cells was enhanced in CD8+ T cells expressing the αD26Y TCR or αD26Y/βL98W TCR,
indicating, cross-reactivity is augmented by CD8. Lastly, our structure-guided design
strategy worked, as CD8+ T cells expressing the αD26Y/αY50A/βL98W TCR exhibited
reduced cross-reactivity compared to T cells expressing the WT TCR. However, this
was at the expense of reduced MART-1 specific T cell reactivity.
We previously described how the 3D TCR affinity correlated to the antigen
specificity and cross-reactivity of CD4+ T cells transduced to express the WT TCR or
each mutant DMF5 TCR. The 3D TCR affinity measurements did not take into account
the CD8 co-receptor, however, it was of interest to determine if the presence of the CD8
co-receptor affected any of the previous correlations. The observed percentages of
MART-1 and MART-1 homolog reactive TCR transduced T cells generally correlated to
3D affinity in the CD8+ T cells, with a few exceptions. Specifically, there was an overall
increase in the percentage of MART-1 homolog reactive T cells expressing the αD26Y
TCR compared to the WT TCR, coinciding with the increased in TCR affinity. However,
despite the 3-fold TCR affinity enhancement in the βL98W TCR, the percentages of
MART-1 and MART-1 homolog reactive T cells were generally similar to T cells
expressing the WT TCR. The statistically significant reduction in the percentage of
MART-1 reactive T cells in T cells expressing the αD26Y/βL98W TCR was most likely
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again, attributed to its high affinity. Although not significant, trends in increased
percentages of MART-1 homolog reactive αD26Y/βL98W TCR expressing T cells were
observed compared to T cells expressing the WT TCR, coinciding with 3D TCR affinity.
As predicted based on its lower 3D TCR affinity, T cells expressing the
αD26Y/αY50A/βL98W TCR exhibited a significant reduction in the percentage of MART1 reactive T cells compared to T cells expressing the WT TCR, and an overall reduction
in MART-1 homolog reactive T cells, reaching statistical significance in two (HSV-1
glycoprotein I and M. tuberculosis protein I). Lastly, although not statistically significant,
T cells expressing the αD26Y/αY50V/βL98W TCR displayed a trend toward a reduction
in the percentage of MART-1 reactive T cells compared to T cells expressing the WT
TCR, coinciding with 3D TCR affinity. However, the percentages of MART-1 homolog
αD26Y/αY50V/βL98W TCR expressing reactive T cells were similar to T cells
expressing the WT TCR. Overall, there were examples where 3D TCR affinity
correlated to MART-1 reactivity and cross-reactivity in TCR transduced CD8+ T cells,
but this was not the case with every DMF5 TCR. Specifically, TCR transduced CD8+ T
cells harboring DMF5 TCRs with the highest or lowest 3D affinities compared to the WT
TCR (αD26Y, αD26Y/βL98W, and αD26Y/αY50A/βL98W) generally correlated with
MART-1 homolog reactivity and/or MART-1 reactivity.
Thus far we have observed how mutations in the DMF5 TCR affected recognition
of the MART-1 homologs by comparing the average percentages of antigen reactive T
cells amongst six experiments. These results demonstrated trends in how mutations in
the DMF5 TCR affected recognition of individual MART-1 homologs. However, it was
difficult to observe the effect of mutations in the DMF5 TCR on the overall, or total, level
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of cross-reactivity compared the WT TCR. Therefore, we wanted to quantitatively
examine how mutations in the DMF5 TCR affected the overall level of cross-reactivity
compared to the WT TCR. For this analysis we focused only on CD8+ T cells for a few
reasons. First, compared to CD4+ T cells expressing the WT TCR, only statistically
significant differences in MART-1 homolog reactivity were observed in CD4+ T cells
expressing the αD26Y TCR or αD26Y/βL98W TCR (Figure 19). Secondly, only two out
of the eleven MART-1 homologs elicited more than 1% WT TCR expressing reactive
CD4+ T cells (Figure 19). Furthermore, these two MART-1 homologs elicited lower than
2% WT TCR expressing reactive CD4+ T cells (Figure 19). The purpose of this analysis
was to determine how each modified DMF5 TCR altered total cross-reactivity compared
to the WT TCR. Since CD8+ T cells were much more cross-reactive, we focused solely
on CD8+ T cells for this analysis of cross-reactivity.
We compared the percentages of MART-1 homolog reactive CD8+ T cells
between each of the modified DMF5 TCRs and the WT DMF5 TCR on a per experiment
basis (Figure 21). Each data point (X, Y value) represents the percentages of reactive
CD8+ T cells in response to a MART-1 homolog by both the WT DMF5 TCR (X-axis)
and a modified DMF5 TCR (Y-axis) in the same experiment. Numbers in the upper left
square of each graph (51, 31, 32, 20, and 28) indicate the total number of occurrences
there was an increased frequency of reactive T cells against a MART-1 homolog by a
modified DMF5 TCR, relative to the WT TCR in the six experiments. Conversely, the
numbers in the bottom right square of each graph (5, 20, 22, 34, and 23) indicate the
total number of occurrences there was an increased frequency of MART-1 homolog
reactivity by the WT TCR, relative to a modified DMF5 TCR in the six experiments.
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There are a total of 66 data points from the six experiments, however, values of 0, 0
were not counted. Therefore, the numbers in the top left and the bottom right corners of
each graph serve as an index of the frequency of cross-reactivity. In the first graph, the
percentages of MART-1 homolog reactive WT TCR expressing T cells were plotted
against the percentages of MART-1 homolog reactive WT TCR expressing T cells.
Thus, a linear regression is observed with a slope of 1 and a Y-intercept of 0. Overall,
there are three pieces of information to analyze from these data. The first piece of
information is the number of occurrences in which a modified TCR elicited a higher
percentage of MART-1 homolog specific T cells compared to the WT TCR. This is a
quantitative, yes/no measurement that does not take into account differences in
magnitudes. The second piece of information is the slope of the linear regression line.
This measurement takes into account the differences in magnitudes amongst a modified
TCR and the WT TCR and overall indicates how the modified DMF5 TCR affected
recognition of the MART-1 homologs in relation to the WT DMF5 TCR. Thirdly, the Yintercept represents the average percentage of cross-reactive T cells expressing a
modified TCR, when the percentage of cross-reactive WT TCR expressing T cells is 0.
Specifically, the higher the Y-intercept, the more cross-reactive the modified TCR is. In
the second graph, the percentages of MART-1 homolog reactive CD8+ T cells
expressing the WT TCR is plotted against the percentages of MART-1 homolog reactive
CD8+ T cells expressing the αD26Y TCR. CD8+ T cells expressing the αD26Y TCR
dramatically enhanced overall cross-reactivity compared to T cells expressing the WT
TCR, specifically, in 51/56 responses against the MART-1 homologs.
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Figure 21. Impact of DMF5 TCR Mutations in TCR Transduced CD8+ T Cells
against MART-1 Homologs. The individual percentages of MART-1 homolog reactive
CD8+ T cells (from Figure 20) were plotted for each TCR with the percentage of reactive
T cells expressing each modified TCR on the Y-axis and the percentage of reactive T
cells expressing the WT TCR on the X-axis. Data from all 6 experiments (two
independent repeats in three donors) are plotted to total 66 data points, each point
being plotted from the same experiment. Numbers in the upper left square indicate the
total number of occurrences there was an increased frequency of reactive T cells
against a MART-1 homolog by a modified TCR relative to the WT TCR and conversely,
the numbers in the bottom right square indicate the total number of occurrences there
was an increased frequency of reactive T cells against a MART-1 homolog by the WT
TCR relative to a modified TCR. Values of 0, 0 were not counted. Linear regression line
and the equation are shown on each graph.
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For simplicity, the frequency in which each modified DMF5 TCR resulted in an increase
in the percentages of MART-1 homolog reactive CD8+ T cells relative to the WT TCR is
shown in Table 7. Percentages over 50% indicated the modified DMF5 TCR, overall,
exhibited an increase in the percentages of MART-1 homolog reactive CD8+ T cells
compared to the WT TCR. Specifically, T cells expressing the αD26Y TCR
demonstrated an increased percentage of MART-1 homolog reactive T cells in 91%
(51/56) of responses compared to the WT TCR. Here, the denominator is 56, not 66,
because values of 0, 0 were not counted. This conclusion was further supported by
observing a slope above 1 (1.3633) in the calculated linear regression. The Y-intercept
of 9.1601 indicates that on average, 9.2% of αD26Y TCR expressing T cells were crossreactive when 0% of WT TCR expressing T cells were cross-reactive. Overall, these
data quantitatively demonstrated the αD26Y TCR mutation elicited an increase in the
level of cross-reactivity compared to the WT TCR. In the third graph, T cells expressing
the βL98W TCR demonstrated an increased percentage of MART-1 homolog reactive
CD8+ T cells in 60.8% (31/51) of responses compared to the WT TCR (Table 7).
Interestingly, the slope of the linear regression line was less than 1 (0.6358), indicating
there was an increase in the percentages of MART-1 homolog reactive WT TCR
expressing T cells. This illustrates the difference in conclusions that can be made about
cross-reactivity based upon the frequency calculation or the slope calculation.
Specifically, the frequency is based upon a yes/no calculation, whereas the slope
accounts for changes in magnitudes between the modified DMF5 TCRs and the WT
DMF5 TCR in all 6 experiments.
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Table 7. Frequencies of Occurrences of Mutated DMF5 TCRs with Enhanced
MART-1 Homolog Recognition Compared To the WT TCR.

Therefore, cross-reactivity is enhanced, or it is not enhanced, with CD8+ T cells
expressing the βL98W TCR compared to the WT TCR, depending upon how the data is
analyzed. The Y-intercept of 1.3796 indicates that on average, 1.4% of βL98W TCR
expressing T cells were cross-reactive when 0% of WT TCR expressing T cells were
cross-reactive. Overall, these data indicated in terms of the number of occurrences and
the Y-intercept, the βL98W TCR mutation enhanced cross-reactivity compared to the
WT TCR. However, in terms of the magnitudes of overall cross-reactivity, the βL98W
TCR mutation decreased cross-reactivity compared to the WT TCR. In the fourth graph,
CD8+ T cells expressing the αD26Y/βL98W TCR demonstrated an increased
percentage of MART-1 homolog reactive T cells in 59.2% (32/54) of responses
compared to the WT TCR (Table 7). Conversely, the slope of the linear regression line
was less than 1 (0.534), indicating there was an increase in the percentages of MART-1
homolog reactive WT TCR expressing T cells. The Y-intercept of 3.5174 indicates that
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on average, 3.5% of αD26Y/βL98W TCR expressing T cells were cross-reactive when
0% of WT TCR expressing T cells were cross-reactive. Overall, these data indicated in
terms of the number of occurrences and the Y-intercept, the αD26Y/βL98W TCR
mutation enhanced cross-reactivity compared to the WT TCR. However, in terms of the
magnitudes of overall cross-reactivity, the αD26Y/βL98W TCR mutations decreased
cross-reactivity compared to the WT TCR. In the fifth graph, CD8+ T cells expressing
the αD26Y/αY50A/βL98W TCR demonstrated an increased percentage of MART-1
homolog reactive T cells in 37% (20/54) of responses compared to the WT TCR (Table
7). However, a majority of the cross-reactive values that were enhanced with the
αD26Y/αY50A/βL98W TCR were very similar to the WT TCR values and were under
4%. The close proximity of some these values is therefore, unseen with this frequency
quantification, but rather is more apparent in the stark decrease in the slope.
Specifically, this result is further supported by the observation of the slope far below 1
(0.1356) in the calculated linear regression. The Y-intercept of 0.6643 indicates that on
average, 0.67% of αD26Y/αY50A/βL98W TCR expressing T cells were cross-reactive
when 0% of WT TCR expressing T cells were cross-reactive. Overall, these data
quantitatively demonstrate the αD26Y/αY50A/βL98W TCR mutations elicited a
decrease in the level of cross-reactivity compared to the WT TCR. Lastly, CD8+ T cells
expressing αD26Y/αY50V/βL98W TCR demonstrated an increased percentage of
MART-1 homolog reactive T cells in 54.9% (28/51) of responses compared to the WT
TCR (Table 7). However, the slope of the linear regression line (0.7047) implicated
when taking magnitudes into account, cross-reactivity was reduced with the
αD26Y/αY50V/βL98W TCR compared to the WT TCR. The Y-intercept of 0.9032 that
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on average, 0.9% of αD26Y/αY50V/βL98W TCR expressing T cells were cross-reactive
when 0% of WT TCR expressing T cells were cross-reactive. Overall, these data
indicated in terms of the number of occurrences, the αD26Y/αY50V/βL98W TCR
mutations enhanced cross-reactivity compared to the WT TCR. However, in terms of
the magnitudes of overall cross-reactivity, the αD26Y/αY50V/βL98W TCR mutation
decreased cross-reactivity compared to the WT TCR.
In totality, these results exemplify the different conclusions that can be inferred
about cross-reactivity based upon the occurrences of cross-reactivity or the magnitudes
of cross-reactivity. It is plausible that both of these conclusions have biological
implications for cross-reactivity in a human. Conclusively, these results quantitatively
imply that overall cross-reactivity against MART-1 homologs was enhanced in CD8+ T
cells expressing the αD26Y TCR and was decreased in CD8+ T cells expressing the
αD26Y/αY50A/βL98W TCR compared to CD8+ T cells expressing the WT DMF5 TCR.
Thus far we have determined how mutations in the DMF5 TCR altered crossreactivity in CD4+ and CD8+ T cells by observing recognition of sequence homologous
MART-1 peptides. We have also observed how mutations in the DMF5 TCR affect
cross-reactivity in totality, compared to the WT TCR. It would be beneficial to elucidate if
there were any correlations between the structural aspects of the introduced DMF5 TCR
mutations and changes observed in MART-1 homolog reactivity compared to the WT
DMF5 TCR. To do this we individually compared each of the average percentages of
MART-1 and MART-1 homolog reactive CD4+ and CD8+ T cells between each modified
DMF5 TCR with the WT DMF5 TCR. Specifically, we listed the peptides in descending
order based on the percent antigen reactive T cells to compare differences in the order
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of recognition between the WT DMF5 TCR and a modified DMF5 TCR. For this
analysis, recognition of a peptide by less than 2% of TCR transduced T cells and
differences of less than 2% amongst two different TCRs, were not considered for
comparative analysis. Since the percentages of antigen reactive T cells are the
averages of six experiments, these thresholds allowed us to better compare overall
trends in the altered recognition of the MART-1 homologs. Table 8 represents the
percentages of reactive T cells expressing either the WT TCR or αD26Y TCR in CD4+
and CD8+ T cells. As previously described, the percent antigen reactive T cells
expressed any one or more functional markers (CD107A or cytokines). In CD4+ T cells,
T cells expressing the αD26Y TCR exhibited enhanced reactivity against every MART-1
homolog compared to T cells expressing the WT TCR. Consequently, it is difficult to
make specific comparisons as T cells expressing the WT TCR hardly recognized the
MART-1 homologs. Specifically, only two out of the eleven MART-1 homologs elicited
reactivity in more than 1% of WT TCR expressing CD4+ T cells and these two MART-1
homologs elicited reactivity in less than 2% of WT TCR expressing CD4+ T cells.
However, there are a few points to make in regards to the order of MART-1 homologs
recognized by αD26Y TCR expressing CD4+ T cells. The most highly recognized
MART-1 homolog maintained homology in the peptide core, HSV-1 glycoprotein III
(GIGI). This hydrophobic “GIGI” at positions 3 through 6 has been shown to be
important for DMF5 TCR recognition [404, 423]. Secondly, CD4+ T cells expressing the
αD26Y TCR recognized the ADP-ribose diphosphatase peptide. This was most likely
due to the removal of unfavorable charge repulsed with the WT DMF5 TCR and the
aspartic acid at position two of the peptide.
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Table 8. Summary of Percentage of MART-1 Homolog Reactive T Cells Expressing
the WT or αD26Y TCR. The differences in sequence homology with the MART-1 9mer
is in bold and underlined. The percent reactive T cells are the average of six
independent experiments. The percent reactive T cells was determined following
background subtraction, as described in Chapter Two. Antigen reactive T cells
expressed any one or more functional marker.
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Lastly, this tyrosine TCR mutation at position 26 in the TCR alpha chain was proposed
to have an effect on the N-terminal region of the peptide. However, there appears to be
no apparent preference for N-terminal peptide residues. Specifically, the top four
recognized MART-1 homologs each contain a different amino acid at position one. This
indicated the tyrosine mutation non-specifically enhanced recognition of the MART-1
homologs. Overall, αD26Y TCR mutation in the DMF5 TCR non-specifically enhanced
the percentages of CD4+ reactive T cells against all of the MART-1 homologs compared
to T cells expressing the WT TCR.
We next examined how the presence of the CD8 co-receptor affected any
structural correlations between the αD26Y TCR mutation and recognition of MART-1
homologs. In the CD8+ T cells, T cells expressing the αD26Y TCR again demonstrated
an increase in all the percentages of MART-1 homolog reactive T cells compared to T
cells expressing the WT TCR. One notable difference in recognition was with the GPCR
3 peptide, as it was not recognized by CD8+ T cells expressing the WT TCR. The stark
increase in the percent αD26Y TCR expressing reactive CD8+ T cells could be due to
enhanced binding with the N-terminal end of the peptide or an overall favorable
antigenic surface due to the four mutations (positions 2, 4, 6, and 8) in the GPCR 3
peptide. Like in the CD4+ T cells, there appears to be no apparent preference for Nterminal peptide residues by CD8+ T cells expressing the αD26Y TCR. Overall, the
αD26Y mutation non-specifically enhanced the percentages of MART-1 homolog
reactive T cells compared to T cells expressing the WT TCR in both CD4+ and CD8+ T
cells. Moreover, CD8 augmented the magnitudes of cross-reactivity.
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We subsequently elucidated any structural correlations between MART-1
homolog recognition and the tryptophan mutation at position 98 in the TCR beta chain.
Table 9 represents the percentage of antigen reactive T cells expressing either the WT
TCR or βL98W TCR in TCR transduced CD4+ and CD8+ T cells. Contributions of the
tryptophan substitution in the βL98W TCR are hard to elucidate in CD4+ T cells because
as like CD4+ T cells expressing the WT TCR, they were not very reactive against the
MART-1 homologs. Specifically, seven MART-1 homologs were recognized by less than
2% of βL98W TCR expressing CD4+ T cells. However, the percentage of βL98W TCR
expressing ADP-ribose diphosphatase reactive CD4+ T cells was enhanced compared
to CD4+ T cells expressing the WT TCR (5.9% vs. 1.67%). This could be attributed to
the leucine at position 7 because the βL98W mutation enhanced shape
complementarity with position 7 in the MART-1 9mer peptide. Albeit, this is not
reproducible in other MART-1 homologs with that contain a leucine at position 7 (HSV-1
glycoprotein III, GPCR 3, β-endoxylanase). Overall, the tryptophan mutation at position
98 in the TCR beta chain did not preferentially enhance recognition of MART-1
homologs with a leucine at position 7.
We next examined how the presence of the CD8 co-receptor affected any
structural correlations between the βL98W mutation and recognition of MART-1
homologs. The percentages and order of MART-1 homolog reactive CD8+ T cells is
fairly similar between CD8+ T cells expressing the WT TCR or βL98W TCR. One
notable difference was the increase in the percentage of human CD9 reactive T cells in
T cells expressing the βL98W TCR compared to the WT TCR (9.43% vs. 3.02%).
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Table 9. Summary of Percentage of MART-1 Homolog Reactive T Cells Expressing
the WT or βL98W TCR. The differences in sequence homology with the MART-1 9mer
is in bold and underlined. The percent reactive T cells are the average of six
independent experiments. The percent reactive T cells was determined following
background subtraction, as described in Chapter Two. Antigen reactive T cells
expressed any one or more functional marker.
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Human CD9 contains an alanine at position 7, and thus, it is possible that the
tryptophan in the βL98W TCR enhanced binding with the small nonpolar alanine.
Overall, the tryptophan in the βL98W TCR did not significantly affect the pattern of
recognition against the MART-1 homologs compared to T cells expressing the WT TCR.
Furthermore, the tryptophan mutation at position 98 in the TCR beta chain did not
preferentially enhance recognition of MART-1 homologs with a leucine at position 7 in
CD4+ or CD8+ T cells.
We next elucidated any structural correlations between MART-1 homolog
recognition and the combination of the αD26Y TCR and βL98W TCR mutations. Table
10 represents the percentage of antigen reactive T cells expressing either the WT TCR
or αD26Y/βL98W TCR in CD4+ and CD8+ T cells. In CD4+ T cells, the αD26Y/βL98W
TCR generally enhanced the percentage of MART-1 homolog reactive T cells compared
to T cells expressing the WT TCR. In αD26Y/βL98W TCR expressing CD4+ T cells, the
MART-1 homologs that elicited the highest percentages of reactive T cells were similar
to T cells expressing the αD26Y TCR (M. tuberculosis protein I, HSV-1 glycoprotein III,
ADP-ribose diphosphatase, human CD9, HREEP 5). These results implicated the
structural effect of the αD26Y TCR mutation. Surprisingly, 6.8% of αD26Y TCR
expressing CD4+ T cells recognized the lmrA MART-1 homolog, while only 1.23% of
αD26Y/βL98W TCR expressing CD4+ T cells recognized lmrA. However, as discussed
previously, it is possible that the affinity of the αD26Y/βL98W TCR is too high and thus,
T cell function has reached its maximum threshold, or has been arrested. Moreover, 3D
αD26Y/βL98W TCR affinity measurements with the MART-1 10mer indicated a
nanomolar value.
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Table 10. Summary of Percentage of MART-1 Homolog Reactive T Cells
Expressing the WT or αD26Y/βL98W TCR. The differences in sequence homology
with the MART-1 9mer is in bold and underlined. The percent reactive T cells are the
average of six independent experiments. The percent reactive T cells was determined
following background subtraction, as described in Chapter Two. Antigen reactive T cells
expressed any one or more functional marker.
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This indicated anchor residues could very much affect 3D TCR affinity. Therefore, it is
difficult to correlate αD26Y/βL98W TCR structure with T cell responses against the
MART-1 homologs if the T cell functional output has been subsequently affected due to
the supraphysiological high affinity. Patterns of the percentages of MART-1 homolog
reactive αD26Y/βL98W TCR expressing CD8+ T cells generally coincided with the
hypothesis associated with TCR affinity being too high and subsequently arresting T cell
function. For example, 7.73% of αD26Y TCR expressing CD8+ T cells recognized the
HREEP 5 peptide, while only 1.2% αD26Y/βL98W TCR expressing CD8 + T cells
recognized the HREEP 5 peptide. However, we would expect a higher percentage of
reactive T cells with higher affinity TCR. Furthermore, CD4+ and CD8+ αD26Y/βL98W
TCR expressing T cells recognized ADP-ribose diphosphatase with the same
percentage of T cells (5.2% vs. 5.25%). A similar trend was observed in CD4+ T cells vs
CD8+ T cells with HSV-1 glycoprotein III (10.18% vs. 13.33%) and M. tuberculosis
protein I (10.57% vs 10.68%) peptides. These results indicated the addition of CD8 had
no effect on the percentage of reactive T cells. Overall, these results suggested specific
patterns of MART-1 homolog recognition observed in αD26Y/βL98W TCR expressing
CD4+ and CD8+ T cells and how they structurally correlate with the TCR mutations are
difficult to elucidate because the supraphysiological affinity is most likely affecting T cell
function.
We next elucidated any structural correlations between MART-1 homolog
recognition and the introduction of a MHC weakening TCR mutation, αY50A, with the
αD26Y and βL98W TCR mutations. Table 11 represents the percentage of antigen
reactive T cells expressing either the WT TCR or αD26Y/αY50A/βL98W TCR in CD4 +

and

CD8+
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T cells. Structural contributions of the αD26Y/αY50A/βL98W TCR mutations

are hard to make in CD4+ T cells, because as observed with T cells expressing the WT
TCR, they are minimally reactive against the MART-1 homologs. Specifically, only one
MART-1 homolog (HREEP 5) was recognized by over 2% of αD26Y/αY50A/βL98W
TCR expressing CD4+ T cells, at 2.13%. Overall, the introduction of the
αD26Y/αY50A/βL98W TCR mutations did not affect MART-1 homolog recognition in
CD4+ T cells compared to the WT TCR.
In αD26Y/αY50A/βL98W TCR expressing CD8+ T cells, only a small percentage
of MART-1 homolog reactive T cells were observed. The three peptides recognized by
over 2% of αD26Y/αY50A/βL98W TCR expressing CD8+ T cells were the same top
three recognized by CD8+ T cells expressing the WT TCR (ADP-ribose diphosphatase,
M. tuberculosis protein I, HSV-1 glycoprotein III). These peptides reveal sequence
homology with the MART-1 9mer at positions 3 through 6. In summary, T cells
expressing the αD26Y/αY50A/βL98W TCR exhibited a reduction in the percentages of
MART-1 homolog reactive T cells, indicating the αY50A TCR mutation counterbalanced
the αD26Y and βL98W TCR mutations. Moreover, the structure of the
αD26Y/αY50A/βL98W TCR had no impact on the patterns of MART-1 homolog
recognition compared to the WT TCR.
We next elucidated any structural correlations between MART-1 homolog
recognition and the introduction of a different MHC weakening TCR mutation, αY50V,
with the αD26Y TCR and βL98W TCR mutations. Table 12 represents the percentage
of antigen reactive T cells expressing either the WT TCR or αD26Y/αY50V/βL98W TCR
in CD4+ and CD8+ T cells.
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Table 11. Summary of Percentage of MART-1 Homolog Reactive T Cells
Expressing the WT or αD26Y/αY50A/βL98W TCR. The differences in sequence
homology with the MART-1 9mer is in bold and underlined. The percent reactive T cells
are the average of six independent experiments. The percent reactive T cells was
determined following background subtraction, as described in Chapter Two. Antigen
reactive T cells expressed any one or more functional marker.
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Table 12. Summary of Percentage of MART-1 Homolog Reactive T Cells
Expressing the WT or αD26Y/αY50V/βL98W TCR. The differences in sequence
homology with the MART-1 9mer is in bold and underlined. The percent reactive T cells
are the average of six independent experiments. The percent reactive T cells was
determined following background subtraction, as described in Chapter Two. Antigen
reactive T cells expressed any one or more functional marker.

Contributions of the αD26Y/αY50V/βL98W TCR mutations are hard to make in

CD4+
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cells, as with T cells expressing the WT TCR, they are minimally reactive against the
MART-1 homologs. However, HREEP 5 and ADP-ribose diphosphatase elicited the
highest percentages of αD26Y/αY50V/βL98W CD4+ reactive T cells (4.88% and 4.07%).
The percentage of HREEP 5 reactive CD4+ T cells was similar between
αD26Y/αY50V/βL98W TCR and αD26Y/βL98W TCR expressing CD4+ T cells (4.88%
vs. 4.07%), but less than αD26Y TCR expressing T cells (9.07%). This again suggested
the αD26Y/βL98W TCR affinity was too high, thus attenuating T cell potency, but the
addition of the αY50V mutation could offset the effect of the other MART-1 targeting
mutations. It was interesting that the MART-1 homolog, HREEP 5, elicited the highest
percentages of reactive CD4+ T cells with the αD26Y/αY50A/βL98W TCR and
αD26Y/αY50V/βL98W TCR, but none of the other TCRs. HREEP 5 only shares
sequence homolog with the MART-1 9mer at positions 4 and 5. These results implicate
that the addition of a TCR mutation that eliminates or weakens binding with three
residues in the MHC to the αD26Y/ βL98W TCR, could have less of an effect on
recognition of HREEP 5 compared to the other MART-1 homologs. This could be due to
the structural, antigenic surface of HREEP 5 in the MHC. In summary, the introduction
of the αD26Y/αY50V/βL98W TCR mutations had minimal overall effects on the patterns
in recognition of the MART-1 homologs compared to the WT TCR in CD4+ T cells.
We next examined how the presence of the CD8 co-receptor affected any
structural correlations between the αD26Y/αY50V/βL98W TCR mutations and
recognition of MART-1 homologs. In the αD26Y/αY50V/βL98W TCR expressing CD8+ T
cells, the order of MART-1 homolog recognition was the same, for MART-1 homologs
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that elicited reactivity, compared to T cells expressing the WT TCR. In summary, these
results indicated that these three TCR mutations did not significantly affect structural
recognition of the MART-1 homologs compared to T cells expressing the WT TCR.
These results of this analysis highlight a few key points in regards to TCR
structure and antigen recognition. First, CD8 generally augments antigen recognition.
Secondly, recognition of MART-1 homologs did not always align with predictions based
upon the structural impact of the introduced DMF5 TCR mutations. Specifically, the
αD26Y TCR mutation non-specifically enhanced all MART-1 homolog recognition and
the βL98W TCR mutation did not specifically enhance recognition of MART-1 homologs
with a leucine at position 7. Conclusively, this analysis indicated the net antigenic
surface of the whole pMHC complex is more important than individual or specific
alterations in peptide residues.
Impact of Mutant DMF5 TCRs on Polyfunctional T cell Phenotypes
Our conclusions about cross-reactivity thus far have been based solely on
reactive T cells determined by expression of any one or more functional markers
(CD107A, IFN-γ, TNF-α, IL-17A, IL-2, IL-4, or IL-22). However, it has been shown that
polyfunctional phenotypes are important in different effector T cell functions. Therefore,
we sought to determine how mutations in the DMF5 TCRs altered polyfunctional
phenotypes of TCR transduced T cells. Since seven functional markers were evaluated
(CD107A, IFN-γ, TNF-α, IL-17A, IL-2, IL-4, and IL-22), there was a potential for each T
cell to exhibit 1 of 128 (27) possible functional phenotypes. “Cool plots” were generated
to display how mutations in the DMF5 TCR altered functional phenotypes compared to
the WT DMF5 TCR in different donors. We first focused on the CD4+ T cells to
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determine how the structure of the TCR/pMHC interaction affected polyfunctional T cell
responses. A representative example of the CD4+ reactivity against T2 cells loaded with
the MART-1 9mer is shown in Figure 22. The percentage of reactive CD4+ T cells
expressing a specific functional phenotype ranged from 0% to about 6.5%. As described
in Chapter Two, reactivity is defined after background subtraction (subtraction of the
background immunofluorescence observed with T2 cells loaded with an irrelevant, HCV,
peptide). Specifically, any phenotype expressed by over 0.1% of TCR transduced T
cells were defined as reactive. Previous studies performing this analysis focused on
phenotypes elicited by over 0.25% of TCR transduced T cells [95]. Thus, we decided to
be more conservative by examining phenotypes elicited by over 0.1% of any DMF5
TCR transduced T cell population. Here, among six TCR transduced CD4+ T cell
populations, 25 out of the potential 128 polyfunctional phenotypes were detected in at
least one DMF5 TCR transduced T cell population, by over 0.1% of TCR transduced
CD4+ T cells. It is evident that individual TCR transduced CD4+ T cells are very
polyfunctional and are capable of producing Th1 (IFN-γ, TNF-α, IL-2), Th2 (IL-4), and
Th17 (IL-17A and IL-22) cytokines [424, 425]. Th1, Th2, and Th17 cytokine producing TCR
transduced CD4+ T cells are also capable of lysis, as measured by CD107A.
Furthermore, the production of Th1, Th2, and Th17 cytokines are not mutually exclusive,
meaning TCR transduced T cells produced combinations of cytokines from the different
T cell subsets. Overall, these results indicated TCR transduced CD4+ T cells were
capable of exhibiting functional phenotypes comprised of lysis and Th 1, Th2, and Th17
cytokines.
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We subsequently observed how the distribution of functional phenotypes was
altered amongst T cells expressing each of the different DMF5 TCRs when stimulated
with the MART-1 9mer. It is evident that there is variability in the CD107A and cytokine
responses amongst the different DMF5 TCRs even when presented with the same
ligand in the same donor and the same experiment (Figure 22). For example, the first
listed polyfunctional phenotype consisted of CD107A+, IFN-γ+, TNF-α+, IL-4+ TCR
transduced CD4+ T cells. This phenotype consisted of both type 1 and type 2 cytokines
and lysis. This phenotype was exhibited in less than 0.5% of αD26Y TCR, βL98W TCR,
and αD26Y/αY50V/βL98W TCR expressing T cells but absent in T cells expressing the
other DMF5 TCRs. In a second example, the second functional phenotype consisted of
CD107A+, IFN-γ+, TNF-α+ TCR transduced CD4+ T cells. This phenotype was present in
about 2% to 3% of T cells expressing the WT TCR, βL98W TCR, and
αD26Y/αY50V/βL98W TCR, less than 0.5% of T cells expressing the αD26Y TCR, and
was not exhibited in T cells expressing the αD26Y/βL98W TCR or
αD26Y/αY50A/βL98W TCR. Another example of this variability between the different
DMF5 TCRs was observed in the TNF-α+ only phenotype. This phenotype was present
in around 1% to 2% of T cells expressing the WT TCR, αD26Y TCR, and
αD26Y/αY50V/βL98W TCR, less than 0.5% of T cells expressing the
αD26Y/αY50A/βL98W TCR, and was not present in T cells expressing the
αD26Y/βL98W TCR or βL98W TCR. Overall, these are a few of many examples of how
the polyfunctional phenotypes expressed are TCR dependent in the same donor and
experiment when presented with the same ligand.
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Figure 22. Impact of DMF5 Mutations in TCR Transduced CD4+ T cells on
Polyfunctional Responses against MART-1 (Donor One). The data indicate reactivity
against T2 cells loaded with the MART-1 9mer peptide in donor one, experiment one.
“Cool plots” were generated to include any functional phenotype present over 0.1%. In
the functional phenotypes listed, “+” indicates positive for the marker and “-“ indicates
negative for the marker. As described in Chapter Two, reactivity is defined after
background subtraction and specifically, any phenotype expressed by over 0.1% of
TCR transduced T cells (subtraction of the background immunofluorescence observed
with T2 cells loaded with an irrelevant, HCV, peptide). The color depicted in the “cool
plot” correlates to the scale on the right. An “X” indicates no T cells were positive
(<0.1% after background subtraction) for given functional phenotype. The color white for
a given functional phenotype indicates a percentage less than 0.5%.

Despite the variability in the magnitudes of responses and in the polyfunctional
phenotypes amongst T cells expressing each of the different DMF5 TCRs, there are two
functional phenotypes reproducibly exhibited with T cells expressing each of the DMF5
TCRs when stimulated with the MART-1 9mer (Figure 22). These two phenotypes are
IFN-γ+, TNF-α+ and TNF-α+, IL-4+. TNF-α is type 1 cytokine while IL-4 is type 2 cytokine,
thus exemplifying the ability for the T cells to commonly express cytokines that have
been previously categorized into different T cell subsets. Overall, this experiment
demonstrated the polyfunctionality of TCR transduced CD4+ T cells and the variability in
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the functional phenotypes demonstrated in T cells expressing different DMF5 TCRs
despite presentation of the same ligand. Despite variability in the patterns of
polyfunctional phenotypes, two phenotypes were reproducibly exhibited by T cells
expressing each of the DMF5 TCRs in response to the MART-1 9mer.
It is well appreciated that polyclonal PBL-derived T cells will not function in the
exact same manner when stimulated on different days after previous activations.
Specifically, the duration of in vitro cell culture after T cell activation can affect the
expansion of different T cell populations [426]. Furthermore, one study indicated four
day anti-CD3 T cell activation only induced proliferation of 60% of T cells, depending
upon T cell populations [427]. It has also been shown that T cells will become less
functional, the longer they are cultured in vitro [428]. Consequently, proportions of T cell
populations and overall T cell function could vary depending upon the duration of in vitro
cell culture. Therefore, we determined if the patterns described above were reproducible
in a second repeat in donor one, with the same TCR transduced T cell culture, four days
later (Figure 46, in the appendix). In the repeat of donor one among six TCR transduced
CD4+ T cell populations, 31 out of the potential 128 polyfunctional phenotypes were
detected in at least one DMF5 TCR transduced T cell population, by over 0.1% of TCR
transduced CD4+ T cells. Six more phenotypes were represented in the second
experiment, but the percentage of reactive CD4+ T cells expressing a specific functional
phenotype decreased from a maximum of 6.5% to a maximum of 2.5%. These findings
indicated the polyfunctional patterns are not completely reproducible in this donor. For
example, the IFN-γ+, TNF-α+ and TNF-α+, IL-4+ phenotypes were exhibited by T cells
expressing each DMF5 TCR in the first experiment. In the second experiment, the IFN-

γ+,

TNF-α+ phenotype
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was exhibited by T cells expressing each DMF5 TCR. However,

the second phenotype exhibited by T cells expressing each DMF5 TCR was CD107A+,
IL-4+, rather than the TNF-α+, IL-4+ phenotype. In summary, these two repeats indicated
that functional phenotypes are not completely reproducible in the same donor when
observed in two independent experiments. However, one functional phenotype was
reproducibly exhibited by CD4+ T cells expressing each of the DMF5 TCRs in both
experiments in response to the MART-1 9mer.
Donor variability occurs in human polyclonal PBL-derived T cells. This
phenomenon has been observed both in vitro and in vivo. Therefore, we performed this
analysis in another donor to determine how mutations in the DMF5 TCR altered
polyfunctional phenotypes in polyclonal PBL-derived T cells from a different donor when
stimulated with the MART-1 9mer. A representative cool plot for the second donor is
shown in Figure 23. In this experiment, the percentage of reactive CD4+ T cells
expressing a specific functional phenotype ranged from 0% to around 9%. Among six
TCR transduced CD4+ T cell populations, 71 out of the potential 128 polyfunctional
phenotypes were detected in at least one DMF5 TCR transduced population, by over
0.1% of TCR transduced CD4+ T cells. It is evident that the TCR transduced T cells are
again, very polyfunctional. Furthermore, phenotypes consisting of lysis and
combinations of Th1, Th2 and Th17 cytokines were exhibited. Overall, these results
indicated that this donor and experiment exhibited more functional phenotypes than
donor one, and included functional phenotypes consisting of combinations of lysis and
Th1, Th2 and Th17 cytokines.

137
Next, we examined how the distribution of functional phenotypes changed
amongst T cells expressing each of the different DMF5 TCRs when stimulated with the
MART-1 9mer. As observed with donor one, different polyfunctional phenotypes were
exhibited by T cells expressing the different DMF5 TCRs despite presentation of the
same ligand (Figure 23). For example, the first functional phenotype listed consisted of
CD107A+, IFN-γ+, TNF-α+, IL-22+, IL-17A+, IL-2+ TCR transduced CD4+ T cells. This
phenotype is exhibited in less than 0.5% of αD26Y TCR expressing T cells but absent in
T cells expressing each of the other DMF5 TCRs. In another example, the last
phenotype in the first row consisted of CD107A+ TCR transduced CD4+ T cells. This
phenotype is exhibited in 2% of WT TCR and αD26Y/βL98W TCR expressing T cells,
but absent in T cells expressing each of the other DMF5 TCRs. Overall, these are a few
of the many examples of how the polyfunctional phenotypes expressed are TCR
dependent in the same donor and experiment despite presentation of the same ligand.
Despite the variability in polyfunctional phenotypes exhibited amongst T cells
expressing each of the different DMF5 TCRs, there are 14 functional phenotypes that
are reproducibly exhibited by T cells expressing each DMF5 TCR when stimulated with
the MART-1 9mer (Figure 23). This observation indicated this donor, in this experiment,
exhibited functional phenotypes consisting of lysis and cytokines from combinations of
different T cell subsets. Overall, this experiment demonstrated the polyfunctionality of
TCR transduced CD4+ T cells and the variability in the functional phenotypes
demonstrated in T cells expressing each of the different DMF5 TCRs despite
presentation of the same ligand. Nonetheless, 14 phenotypes were reproducibly
exhibited by T cells expressing each of the DMF5 TCRs in this experiment.
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Figure 23. Impact of DMF5 Mutations in TCR Transduced CD4+ T cells on
Polyfunctional Responses against MART-1 (Donor Two). The data indicate reactivity
against T2 cells loaded with the MART-1 9mer peptide in donor two, experiment one.
“Cool plots” were generated to include any functional phenotype present over 0.1%. In
the functional phenotypes listed, “+” indicates positive for the marker and “-“ indicates
negative for the marker. As described in Chapter Two, reactivity is defined after
background subtraction and specifically, any phenotype expressed by over 0.1% of
TCR transduced T cells (subtraction of the background immunofluorescence observed
with T2 cells loaded with an irrelevant, HCV, peptide). The color depicted in the “cool
plot” correlates to the scale on the right. An “X” indicates no T cells were positive
(<0.1% after background subtraction) for given functional phenotype. The color white for
a given functional phenotype indicates a percentage less than 0.5%.

We observed variability and similarity within the patterns of polyfunctionality
when we compared two independent repeats in the first donor. Therefore, we
determined if the patterns described above were reproducible in a second repeat in
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donor two, with the same TCR transduced T cell culture, four days later (Figure 47, in
the appendix). In the repeat of donor two among six TCR transduced CD4 + T cell
populations, 67 out of the potential 128 polyfunctional phenotypes were detected in at
least one DMF5 TCR transduced T cell population, by over 0.1% of TCR transduced
CD4+ T cells. Four fewer phenotypes were represented in the second experiment and
the percentage of reactive CD4+ T cells expressing a specific functional phenotype
decreased from a maximum of 9% to a maximum of 7%. This indicated the patterns
were not completely reproducible in this donor. For example, the IL-4+ only phenotype is
exhibited by T cells expressing each DMF5 TCR in the second experiment, but only by
T cells expressing the αD26Y TCR in the first experiment. However, nine functional
phenotypes were reproducibly exhibited by T cells expressing each of DMF5 TCRs in
the two experiments. These functional phenotypes included 1.) CD107A+, IFN-γ+, TNFα+, 2.) CD107A+, IL-17A+, 3.) IFN-γ+, TNF-α+, IL-17+, 4.) IFN-γ+, TNF-α+, 5.) IFN-γ+, 6.)
TNF-α+, IL-22+, IL-17A+, 7.) TNF-α+, IL-17A+, 8.) TNF-α+, and 9.) IL-17A+. These results
indicated that in this donor, T cells expressing each of the DMF5 TCRs exhibited
phenotypes consisting of combinations of lysis and Th1 and Th17 cytokines. In summary,
these two repeats indicated that functional phenotypes are not completely reproducible
in the same donor when observed in two independent repeats. However, nine functional
phenotypes were reproducibly exhibited by T cells expressing each of the DMF5 TCRs
in response to the MART-1 9mer in both experiments.
It would be important to observe the differences and similarities in patterns of
polyfunctional phenotypes amongst the first two donors. However, to first determine if
variability was reproducibly observed in more than two donors, we performed this
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analysis in a third donor. A representative cool plot for the third donor is shown in Figure
24. In this donor, the percentage of antigen reactive CD4+ T cells expressing a specific
functional phenotype ranged from 0% to about 12%. Among six TCR transduced CD4+
T cell populations, 44 out of the potential 128 polyfunctional phenotypes were detected
in at least one DMF5 TCR transduced T cell population, by over 0.1% of TCR
transduced CD4+ T cells. It is evident that the TCR transduced T cells are again, very
polyfunctional. Overall, these results indicated in this donor and experiment, TCR
transduced T cells exhibited functional phenotypes comprised of lysis and Th1, Th2, and
Th17 cytokines.
We next examined how the distribution of functional phenotypes changed
amongst T cells expressing each of the different DMF5 TCRs when stimulated with the
MART-1 9mer. As with donors one and two, different polyfunctional phenotypes were
exhibited by T cells expressing the different DMF5 TCRs despite presentation of the
same ligand (Figure 24). For example, the first functional phenotype listed consisted of
CD107A+, IFN-γ+, TNF-α+, IL-17A+, IL-2+ TCR transduced CD4+ T cells. This phenotype
was exhibited by less than 0.5% of αD26Y/βL98W TCR expressing T cells but absent in
T cells expressing each of the other DMF5 TCRs. In another example, the second
functional phenotype listed consisted of CD107A+, IFN-γ+, TNF-α+, IL-2+ TCR
transduced CD4+ T cells. This phenotype was expressed by less than 0.5% of
αD26Y/αY50V/βL98W TCR expressing T cells, but absent in T cells expressing each of
the other DMF5 TCRs. If we move further down the cool plot to the CD107A +, IL-4+
phenotype, this phenotype is expressed by less than 0.5% of αD26Y/αY50V/βL98W
TCR expressing T cells, 6% of αD26Y TCR expressing T cells, about 2.5% of βL98W
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TCR and αD26Y/βL98W TCR expressing T cells, and absent in WT TCR and
αD26Y/αY50A/βL98W TCR expressing T cells. Overall, these results demonstrated that
the exhibited polyfunctional phenotypes are TCR dependent within the same donor and
the same experiment despite presentation of the same ligand.
Despite the variability in polyfunctional phenotypes amongst T cells expressing each of
the different DMF5 TCRs, there were seven functional phenotypes that were
reproducibly exhibited by T cells expressing each of the DMF5 TCRs (Figure 24). These
functional phenotypes included 1.) CD107A+, IFN-γ+, TNF-α+, 2.) CD107A+, IFN-γ+, 3.)
IFN-γ+, TNF-α+, IL-2+, 4.) IFN-γ+, TNF-α+, IL-4+, 5.) IFN-γ+, TNF-α+, 6.) IFN-γ+, and 7.)
TNF-α+, IL-2+. These results implicated that Th1 and Th2 cytokines were commonly
expressed amongst in T cells expressing each different DMF5 TCR. Furthermore,
combinations of lysis, Th1, or Th2 cytokines were sometimes expressed in the same
phenotype. Overall, this experiment demonstrated the polyfunctionality of TCR
transduced CD4+ T cells and the variability of the functional phenotypes demonstrated
in T cells expressing different DMF5 TCRs despite presentation of the same ligand.
Nonetheless, seven phenotypes were reproducibly exhibited by T cells expressing each
of the DMF5 TCRs in response to the MART-1 9mer in this experiment.
We observed variability and similarity within the patterns of polyfunctionality
when comparing two independent repeats in the first two donors. Therefore, we
determined if the patterns described above were reproducible in a second repeat in the
third donor, with the same TCR transduced T cell culture, four days later (Figure 48, in
the appendix).
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Figure 24. Impact of DMF5 Mutations in TCR Transduced CD4+ T cells on
Polyfunctional Responses against MART-1 (Donor Three). The data indicate
reactivity against T2 cells loaded with the MART-1 9mer peptide in donor three,
experiment one. “Cool plots” were generated to include any functional phenotype
present over 0.1%. In the functional phenotypes listed, “+” indicates positive for the
marker and “-“ indicates negative for the marker. As described in Chapter Two,
reactivity is defined after background subtraction, specifically, any phenotype expressed
by over 0.1% of TCR transduced T cells (subtraction of the background
immunofluorescence observed with T2 cells loaded with an irrelevant, HCV, peptide).
The color depicted in the “cool plot” correlates to the scale on the right. An “X” indicates
no T cells were positive (<0.1% after background subtraction) for given functional
phenotype. The color white for a given functional phenotype indicates a percentage less
than 0.5%.
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In the repeat of donor three among six TCR transduced T cell populations, 27 out of the
potential 128 polyfunctional phenotypes were detected in over 0.1% of TCR transduced
CD4+ T cells in this donor and this experiment. Seventeen fewer phenotypes were
exhibited in the second experiment compared to the first experiment, indicating the
patterns were not completely reproducible in this donor. For example, the TNF-α+ only
phenotype was exhibited by T cells expressing the αD26Y TCR in the second
experiment, but not in the first experiment. However, four functional phenotypes were
reproducibly exhibited by T cells expressing each of DMF5 TCRs in the two
experiments. These exhibited phenotypes included 1.) CD107A+, IFN-γ+, 2.) IFN-γ+,
TNF-α+, 3.) IFN-γ+, and 4.) TNF-α+, IL-2+. These results indicated that in this donor, T
cells expressing each of the DMF5 TCRs exhibited phenotypes consisting of lysis
and/or Th1 and Th2 cytokines in response to the MART-1 9mer. In summary, these two
repeats indicated that functional phenotypes are not completely reproducible in the
same donor when observed in two independent repeats. However, four functional
phenotypes were reproducibly exhibited by T cells expressing each of the DMF5 TCRs
in both experiments.
Thus far, we have demonstrated that TCR transduced CD4+ T cells were lytic
and polyfunctional. Furthermore, in CD4+ T cells there is no CD8 co-receptor and thus,
interactions are dependent upon the TCR/pMHC. There are a few overarching
conclusions that can be made based upon the polyfunctional responses of T cells
expressing each of the DMF5 TCRs against the MART-1 9mer in different experiments
and donors. The first set of conclusions encompassed variability and similarity amongst
polyfunctional patterns between donors and experiments. Table 13 depicts a numerical
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summary of the number of functional phenotypes observed and their reproducibility
amongst each experiment and donor. First, the number of polyfunctional patterns
exhibited was donor and experiment dependent. For example, donor two was more
polyfunctional than donors one and three. Furthermore, no two experimental repeats
exhibited the same number of functional phenotypes. Secondly, the number of
reproducible patterns of polyfunctional phenotypes amongst T cells expressing each of
the DMF5 T cells was experiment dependent. For example, in donor one, experiment
one, one reproducible functional phenotype was exhibited with T cells expressing each
of the DMF5 TCRs, whereas in experiment two, two reproducible functional phenotypes
were exhibited. Thirdly, the number of reproducible patterns of functional phenotypes
exhibited in T cells expressing each of the DMF5 TCRs was donor dependent. For
example, the number of unique reproducible functional phenotypes in T cells expressing
each of the DMF5 TCRs was different in every donor (donor 1 – one, donor 2 – nine,
donor 3 – four). Fourthly, one functional phenotype was exhibited by CD4 + T cells
expressing each of the DMF5 TCRs in every donor and in every experiment. This was a
Th1 cytokine pattern, IFN-γ+, TNF-α+. This makes sense as expression of these two
cytokines can be mediated by the same transcription factors (STAT1 and NF-κB) [424,
429-432]. Furthermore, IFN-γ is considered an early response cytokine and shown to be
important to modulate the adaptive immune response [433-435]. In summary, these
data indicated polyfunctional responses of CD4+ T cells are dependent upon the TCR,
experiment, and donor. However, we demonstrated that in response to the MART-1
9mer, T cells expressing each of the DMF5 TCRs always exhibited the IFN-γ+, TNF-α+
phenotype.
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Table 13. Summary of Polyfunctional Phenotypes in TCR Transduced CD4+ T cells
amongst Six Experiments. *Reproducible phenotypes with every DMF5 TCR indicate
that within a specific experiment, all six TCR transduced CD4+ T cell populations (WT
DMF5 TCR and each mutant DMF5 TCR) exhibited the functional phenotype.
**Reproducible phenotypes with every DMF5 TCR within donor indicate that within a
specific donor, all six TCR transduced CD4+ T cell populations (WT DMF5 TCR and
each mutant DMF5 TCR) exhibited the functional phenotype in both experimental
repeats.

The second set of conclusions encompassed variability and similarity amongst
polyfunctional patterns between donors and experiments in regards to each of the
DMF5 TCRs. Table 14 depicts a numerical summary of the number of functional
phenotypes observed amongst T cells expressing each of the DMF5 TCRs in each
experiment and donor. First, the number of polyfunctional phenotypes exhibited is
DMF5 TCR dependent. For example, in donor one and experiment one, T cells
expressing each of the DMF5 TCRs exhibited a different number of polyfunctional
phenotypes. Secondly, the number of polyfunctional phenotypes exhibited amongst T
cells expressing any given DMF5 TCR is experiment and donor dependent. For
example, T cells expressing the WT DMF5 TCR exhibited a different number of
polyfunctional phenotypes in five out of the six experiments. Thirdly, the total number
and the average number of functional phenotypes amongst the six experiments,
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generally trends towards a correlation between number of polyfunctional phenotypes
and the overall percentages of antigen reactive TCR transduced CD4+ T cells. For
example, in Figure 19, CD4+ T cells expressing the αD26Y TCR and the βL98W TCR
exhibited a trend towards an increase in the percentage of MART-1 9mer reactive T
cells, compared to T cells expressing the WT TCR, in the six experiments. Herein, CD4+
T cells expressing the αD26Y TCR and the βL98W TCR exhibited a trend towards an
increase in the average and total number of functional phenotypes exhibited in the six
experiments, compared to T cells expressing the WT TCR. Conversely, in Figure 19,
CD4+ T cells expressing the αD26Y/βL98W TCR and the αD26Y/αY50A/βL98W TCR
exhibited a trend towards (statistically significant in T cells expressing the
αD26Y/αY50A/βL98W TCR) a reduction in the percentage of MART-1 9mer reactive T
cells, compared to T cells expressing the WT TCR, in the six experiments. Herein, CD4 +
T cells expressing the αD26Y/βL98W TCR and the αD26Y/αY50A/βL98W TCR
exhibited a trend towards a reduction in the average and total number of functional
phenotypes exhibited in the six experiments, compared to T cells expressing the WT
TCR. The one exception to this correlation is T cells expressing the
αD26Y/αY50V/βL98W TCR exhibited a comparable percentage of MART-1 9mer
reactive T cells but exhibited an increase in the average and total number of functional
phenotypes, compared to T cells expressing the WT TCR. Conclusively, these results
indicated polyfunctional phenotypes exhibited amongst T cells expressing each of the
DMF5 TCRs is TCR, experiment, and donor dependent. However, CD4+ T cells
expressing each of the DMF5 TCRs always exhibited the IFN-γ+, TNF-α+ functional
phenotype in response to the MART-1 9mer.
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Table 14. Summary of Polyfunctional Phenotypes in TCR Transduced CD4+ T cells
amongst Six Experiments per each of the DMF5 TCRs.

Lastly, the number of different functional phenotypes exhibited generally correlated to
the overall pattern in the percentages of MART-1 9mer reactive TCR transduced CD4+
T cells. Specifically, the greater the percentage of antigen reactive TCR transduced T
cells, the more functional phenotypes exhibited.
The analysis of TCR transduced CD4+ T cells allowed us to examine how the
structure of the TCR/pMHC altered polyfunctional T cell responses. However, as
mentioned previously, CD8 has been shown to affect antigen recognition and T cell
function. Therefore, we next examined how mutations in the DMF5 TCR altered the
polyfunctional responses of CD8+ T cells. A representative example of the CD8+
reactivity against T2 cells loaded with the MART-1 9mer is shown in Figure 25. In the
first donor, the percentage of reactive CD8+ T cells expressing a specific functional
phenotype ranged from 0% to around 20%.
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Figure 25. Impact of DMF5 Mutations in Transduced CD8+ T cells on
Polyfunctional Responses against MART-1 (Donor One). The data indicate reactivity
against T2 cells loaded with the MART-1 9mer peptide in donor one, experiment one.
“Cool plots” were generated to include any functional phenotype present over 0.1%. In
the functional phenotypes listed, “+” indicates positive for the marker and “-“ indicates
negative for the marker. As described in Chapter Two, reactivity is defined after
background subtraction, specifically, any phenotype expressed by over 0.1% of TCR
transduced T cells (subtraction of the background immunofluorescence observed with
T2 cells loaded with an irrelevant, HCV, peptide). The color depicted in the “cool plot”
correlates to the scale on the right. An “X” indicates no T cells were positive (<0.1%
after background subtraction) for given functional phenotype. The color white for a given
functional phenotype indicates a percentage less than 0.5%. Five prominent
phenotypes are highlighted with red boxes.
Among six TCR transduced CD8+ T cell populations, 17 out of the potential 128
polyfunctional phenotypes were detected in at least one DMF5 TCR transduced T cell
population, by over 0.1% of TCR transduced CD8+ T cells. Combinations of lysis and
Th1, Th2, and Th17 cytokines are all exhibited, except for phenotypes including IL-22. As
observed with the CD4+ T cells, differences in the patterns of polyfunctional phenotypes
are evident among T cells expressing the different DMF5 TCRs despite seeing the
same ligand. For example, the first functional phenotype listed consisted of CD107A+,

IFN-γ+,

TNF-α+,

IL-17A+ TCR

transduced

CD8+
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T cells. This phenotype was exhibited by

less than 0.5% of WT TCR, αD26Y TCR, βL98W TCR and αD26Y/αY50A/βL98W TCR
expressing T cells, but absent in T cells expressing the αD26Y/βL98W TCR and
αD26Y/αY50V/βL98W TCR expressing T cells. Despite the differences observed in
polyfunctional patterns amongst the DMF5 TCRs, there were nine functional
phenotypes that were reproducibly exhibited by T cells expressing each of the DMF5
TCRs. However, it was notable that a majority of the functional T cells exhibited five
prominent functional phenotypes. These five prominent phenotypes (highlighted in red
boxes) were comprised of combinations of CD107A, IFN-γ, and TNF-α. Overall, these
results indicated in this donor and experiment, TCR transduced T cells exhibited
functional phenotypes comprised of lysis and Th1, Th2, and Th17 cytokines.
Furthermore, five distinct functional phenotypes were reproducibly exhibited by T cells
expressing each of the DMF5 TCRs in response to the MART-1 9mer.
We observed variability and similarity within patterns of polyfunctionality when we
compared two independent repeats within the same donor in the TCR transduced CD4 +
T cells when stimulated with the MART-1 9mer.Therefore, we determined if the patterns
described above were reproducible or inconsistent in a second repeat in donor one, with
the same TCR transduced CD8+ T cell culture, four days later (Figure 49, in the
appendix). In the repeat of donor one among six TCR transduced CD8+ T cell
populations, 21 out of the potential 128 polyfunctional phenotypes were detected in at
least one DMF5 TCR transduced T cell population, by over 0.1% of transduced CD8+ T
cells. Four more phenotypes were exhibited in the second experiment and the
percentage of reactive CD8+ T cells was reduced from a maximum of 20% to a

150
maximum of 11%. This indicated the patterns are not completely reproducible in this
donor. For example, the IL-4+ only phenotype is exhibited in experiment two and not in
experiment one. Furthermore, IL-22 is exhibited in two functional phenotypes, whereas
it was absent in experiment one. Despite differences, the five predominant functional
phenotypes that were exhibited previously, are reproducibly exhibited in this experiment
in T cells expressing each of the DMF5 TCRs. In summary, these two experiments
indicated that functional phenotypes are not completely reproducible in the same donor
when observed in two independent repeats. Moreover, the five predominant functional
phenotypes that were exhibited previously, are reproducibly exhibited by T cells
expressing each of the DMF5 TCRs in both experiments.
To determine if donor variability reproducibly occurred in polyclonal PBL-derived
CD8+ T cells, we performed this analysis in multiple donors. A representative cool plot
for the second donor is shown in Figure 26. In this experiment, the percentage of
reactive CD8+ T cells expressing a specific functional phenotype ranged from 0% to
around 12%. Among six TCR transduced CD8+ T cell populations, 26 out of the
potential 128 polyfunctional phenotypes were detected in at least one DMF5 TCR
transduced T cell population, by over 0.1% of TCR transduced CD8+ T cells.
Combinations of lysis and Th1, Th2, and Th17 cytokines are all represented, except for
phenotypes including IL-22. As observed in the transduced CD4+ T cells, the patterns of
polyfunctional phenotypes exhibited was TCR dependent. For example, the first
functional phenotype listed consisted of CD107A+, IFN-γ+, TNF-α+, IL-17A+, IL-2+
transduced CD8+ T cells.
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Figure 26. Impact of DMF5 Mutations in Transduced CD8+ T cells on
Polyfunctional Responses against MART-1 (Donor Two). The data indicate reactivity
against T2 cells loaded with the MART-1 9mer peptide in donor two, experiment one.
“Cool plots” were generated to include any functional phenotype present over 0.1%. In
the functional phenotypes listed, “+” indicates positive for the marker and “-“ indicates
negative for the marker. As described in Chapter Two, reactivity is defined after
background subtraction, specifically, any phenotype expressed by over 0.1% of TCR
transduced T cells (subtraction of the background immunofluorescence observed with
T2 cells loaded with an irrelevant, HCV, peptide). The color depicted in the “cool plot”
correlates to the scale on the right. An “X” indicates no T cells were positive (<0.1%
after background subtraction) for given functional phenotype. The color white for a given
functional phenotype indicates a percentage less than 0.5%. Five prominent
phenotypes are highlighted with red boxes.

This phenotype was exhibited by less than 0.5% of αD26Y/αY50A/βL98W TCR and
αD26Y/αY50V/βL98W TCR expressing T cells, and not exhibited by T cells expressing
each of the other DMF5 TCRs. The five prominent phenotypes (highlighted in red
boxes) comprised of combinations of CD107A, IFN-γ, and TNF-α were also observed in
this donor and experiment. Overall, these results indicated transduced T cells were
capable of exhibiting functional phenotypes comprised of lysis and Th1, Th2, and Th17
cytokines. Moreover, five functional phenotypes were reproducibly exhibited by T cells
expressing each of the DMF5 TCRs in response to the MART-1 9mer.
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When previously comparing two independent repeats in the same donors, we
observed variability and similarity within patterns of polyfunctionality elicited by TCR
transduced CD4+ T cells when stimulated with the MART-1 9mer. Therefore, we
determined if the patterns described above were reproducible in a second repeat in
donor two, with the same TCR transduced CD8+ T cell culture, four days later (Figure
50, in the appendix). In the repeat of donor two among six TCR transduced CD8+ T cell
populations, 48 out of the potential 128 polyfunctional phenotypes were detected in at
least one DMF5 TCR transduced T cell population, by over 0.1% of transduced CD8+ T
cells. 21 more phenotypes were represented in the second experiment. This indicated
the patterns are not completely reproducible in this donor. Here, the five predominant
functional phenotypes that were exhibited in the first experiment are reproducibly
exhibited. However, in addition to these five, there are additional polyfunctional
phenotypes exhibited by the transduced T cells expressing each of the DMF5 TCRs.
Furthermore, IL-22 is exhibited in functional phenotypes, whereas it was not in
experiment one. In summary, these two repeats indicated that functional phenotypes
are not completely reproducible in the same donor when observed in two independent
repeats. However, the five predominant functional phenotypes that were exhibited in the
first experiment are reproducibly exhibited by T cells expressing each of the DMF5
TCRs.
To determine if donor variability was again observed with another donor in TCR
transduced CD8+ T cells when stimulated with the MART-1 9mer, we performed this
analysis in a third donor. A representative cool plot for the third donor is shown in Figure
27.
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Figure 27. Impact of DMF5 Mutations in Transduced CD8+ T cells on
Polyfunctional Responses against MART-1 (Donor Three). The data indicate
reactivity against T2 cells loaded with the MART-1 9mer peptide in donor three,
experiment one. “Cool plots” were generated to include any functional phenotype
present over 0.1%. In the functional phenotypes listed, “+” indicates positive for the
marker and “-“ indicates negative for the marker. As described in Chapter Two,
reactivity is defined after background subtraction, specifically, any phenotype expressed
by over 0.1% of TCR transduced T cells (subtraction of the background
immunofluorescence observed with T2 cells loaded with an irrelevant, HCV, peptide).
The color depicted in the “cool plot” correlates to the scale on the right. An “X” indicates
no T cells were positive (<0.1% after background subtraction, as described in Chapter
Two) for given functional phenotype. The color white for a given functional phenotype
indicates a percentage less than 0.5%. Five prominent phenotypes are highlighted with
red boxes.

In donor three, the percentage of reactive CD8+ T cells expressing a specific functional
phenotype ranged from 0% to around 13%. Among six TCR transduced CD8 + T cell
populations, 30 out of the potential 128 polyfunctional phenotypes were detected in at
least one DMF5 TCR transduced T cell population, by over 0.1% of TCR transduced
CD8+ T cells. Differences in polyfunctional phenotypes are evident among T cells
expressing the different DMF5 TCRs despite seeing the same ligand. For example, the
first phenotype consisted of CD107A+, IFN-γ+, TNF-α+, IL-22+ CD8+ transduced T cells.
This phenotype was exhibited by less than 0.5% of βL98W TCR expressing T cells, but
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absent in T cells expressing each of the other DMF5 TCRs. Despite the differences
among T cells expressing each of the DMF5 TCRs, the five prominent phenotypes
(highlighted in red boxes) comprised of combinations of CD107A, IFN-γ, and TNF-α
were also observed in this donor and experiment (except in T cells expressing the
αD26Y/βL98W TCR). Overall, this experiment demonstrated the polyfunctionality of
transduced CD8+ T cells and the variability of the functional phenotypes demonstrated
in T cells expressing different DMF5 TCRs despite presentation of the same ligand.
Furthermore, the five predominant functional phenotypes that were exhibited in the first
donor are reproducibly exhibited.
We observed variability and similarity within patterns of polyfunctionality elicited
by TCR transduced T cells when stimulated with the MART-1 9mer when we compared
two independent repeats in the first two donors. Therefore, we determined if the
patterns described above were reproducible in a second repeat in the third donor, with
the same TCR transduced T cell culture, four days later (Figure 51, in the appendix). In
the repeat of donor three among six TCR transduced T cell populations, 42 out of the
potential 128 polyfunctional phenotypes were detected in over 0.1% of TCR transduced
CD8+ T cells in this donor and this experiment. 21 more phenotypes were represented
in the second experiment and the maximum percentage of reactive CD8+ T cells was
increased from a maximum of 13% to about 16%. This indicated the patterns are not
completely reproducible in this donor. For example, the IFN-γ+, TNF-α+, IL-2+ phenotype
is exhibited by T cells expressing each DMF5 TCR in the second experiment, but is only
exhibited by T cells expressing the WT TCR, βL98W TCR, and αD26Y/αY50V/βL98W
TCR in experiment one. Despite differences in the patterns amongst the different DMF5
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TCRs, the five predominant functional phenotypes that were exhibited previously are
reproducibly exhibited in this second experiment. In summary, these two repeats
indicated that functional phenotypes are not completely reproducible in the same donor
when observed in two independent repeats. Moreover, the five predominant functional
phenotypes that were exhibited previously, are reproducibly exhibited in T cells
expressing each of the DMF5 TCRs.
Thus far, we demonstrated that transduced CD8+ T cells were polyfunctional
against the MART-1 9mer. There are a few overarching conclusions that were made
based upon the polyfunctional responses of T cells expressing each of the DMF5 TCRs
against the MART-1 9mer in different experiments and donors. The first set of
conclusions encompassed variability and similarity amongst polyfunctional patterns
between donors and experiments. Table 15 depicts a numerical summary of the number
of functional phenotypes observed and their reproducibility amongst each experiment
and donor. First, as with the CD4+ T cells, the number of polyfunctional phenotypes
exhibited was donor and experiment dependent. Secondly, as with the CD4+ T cells, the
number of reproducible polyfunctional phenotypes amongst T cells expressing each of
the DMF5 T cells were experiment dependent. Thirdly, the number of reproducible
functional phenotypes exhibited in T cells expressing each of the DMF5 TCRs was
donor dependent. For example, the number of unique reproducible functional
phenotypes in T cells expressing each of the DMF5 TCRs was different in every donor
(donor 1 – five, donor 2 – eight, donor 3 – five). Fourthly, five functional phenotypes
were exhibited by CD8+ T cells expressing each of the DMF5 TCRs in every donor and
in every experiment (except with one TCR in donor three, experiment one).
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Table 15. Summary of Polyfunctional Phenotypes in TCR Transduced CD8+ T cells
amongst Six Experiments. *Reproducible phenotypes with every DMF5 TCR indicate
that within a specific experiment, all six TCR transduced CD8+ T cell populations (WT
DMF5 TCR and each mutant DMF5 TCR) exhibited the functional phenotype.
**Reproducible phenotypes with every DMF5 TCR within donor indicate that within a
specific donor, all six TCR transduced CD8+ T cell populations (WT DMF5 TCR and
each mutant DMF5 TCR) exhibited the functional phenotype in both experimental
repeats.

The five phenotypes identified are: 1.) CD107A+, IFN-γ+, TNF-α+, 2.) IFN-γ+, TNF-α+, 3.)
CD107A+, IFN-γ+, 4.) IFN-γ+ only, and 5.) CD107A+ only. This indicated that in CD8+ T
cells expressing each of the DMF5 TCRs will be lytic, produce type 1 cytokines, or do
both in response to the MART-1 9mer. In summary, these data indicated polyfunctional
responses of CD8+ T cells are dependent upon the TCR, experiment, and donor.
However, we demonstrated that in response to the MART-1 9mer, T cells expressing
each of the DMF5 TCRs almost always exhibited a lytic and/or IFN-γ+ and TNF-α+
phenotype.
The second set of conclusions encompassed variability and similarity amongst
polyfunctional patterns between donors and experiments in regards to each of the
DMF5 TCRs. Table 16 depicts a numerical summary of the number of functional
phenotypes observed amongst T cells expressing each of the DMF5 TCRs in each

157
experiment and donor. First, the number of polyfunctional phenotypes exhibited is
DMF5 TCR dependent. Secondly, the number of polyfunctional phenotypes exhibited
amongst T cells expressing any given DMF5 TCR is experiment and donor dependent.
For example, T cells expressing the WT DMF5 TCR exhibited a different number of
polyfunctional phenotypes in each of the six experiments. Thirdly, like the CD4+ T cells,
the total number and the average number of functional phenotypes amongst the six
experiments, generally trends towards a correlation between number of polyfunctional
phenotypes and the overall percentages of reactive TCR transduced CD8+ T cells. For
example, in Figure 20, CD8+ T cells expressing each of the DMF5 TCRs exhibited a
trend towards a reduction (statistically significant in T cells expressing the
αD26Y/βL98W TCR or αD26Y/αY50A/βL98W TCR) in the percentage of MART-1 9mer
reactive T cells compared to T cells expressing the WT TCR. With the one exception of
T cells expressing the αD26Y/αY50V/βL98W TCR, the total number and the average
number of polyfunctional phenotypes exhibited by T cells expressing each of the DMF5
TCRs trends towards a reduction compared to T cells expressing the WT TCR amongst
the six experiments. Conclusively, these results indicated polyfunctional phenotypes
exhibited amongst T cells expressing each of the DMF5 TCRs is TCR, experiment, and
donor dependent. However, CD8+ T cells expressing each of the DMF5 TCRs nearly
always exhibited the same five functional phenotypes in response to the MART-1 9mer.
Lastly, the number of different functional phenotypes exhibited generally correlated to
the overall patterns observed with the percentages of MART-1 9mer reactive TCR
transduced CD8+ T cells.
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Table 16. Summary of Polyfunctional Phenotypes in TCR Transduced CD8+ T cells
amongst Six Experiments per each of the DMF5 TCRs.
We have independently concluded that the polyfunctional responses of CD4 + and
CD8+ T cells expressing either the WT DMF5 or each of the mutant DMF5 TCRs
against the MART-1 9mer. Many of the conclusions remained consistent between CD4 +
and CD8+ T cells. However, there are also some notable differences. For example, the
magnitudes of the percentages of T cells expressing a given phenotype in CD8+ T cells
was increased compared to the CD4+ T cells. This was expected due to the contribution
of CD8 in stabilization and in signaling. Secondly, with the one exception of T cells
expressing the αD26Y/αY50A/βL98W TCR, on average, TCR transduced CD4+ T cells
exhibited more polyfunctional phenotypes than TCR transduced CD8 + T cells. This
indicated that the response of CD8+ T cells are less heterogeneous than CD4+ T cells.
Additionally, different polyfunctional phenotypes were reproducibly exhibited in T cells
expressing each of the DMF5 TCRs between the CD4+ and CD8+ T cells. Notably,
CD107A+ only phenotypes were more prevalent in the CD8+ T cells than the CD4+ T
cells. This is consistent with the knowledge in the field that CD8 + T cells are generally

more lytic than

CD4+

T cells [436]. Overall,

CD4+

and

CD8+
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T cells were polyfunctional

and the polyfunctional phenotypes displayed were dependent upon the donor,
experiment, and DMF5 TCR. Lastly, the number of polyfunctional phenotypes exhibited
against the MART-1 9mer with a given DMF5 TCR, generally correlated to the pattern
associated with the percentages of MART-1 9mer reactive T cells.
Thus far we have focused on polyfunctional responses against the MART-1 9mer
peptide. Furthermore, we observed five prominent and reproducible functional patterns
in CD8+ T cells expressing each of the DMF5 TCRs. However, altered-peptide ligands
have been shown to elicit different polyfunctional phenotypes in CD8+ T cells [95].
Therefore, we wanted to determine if these five prominent functional patterns were
observed amongst T cells expressing each of the different DMF5 TCRs. Polyfunctional
responses would be important in CD4+ T cells, however, since only T cells expressing
the αD26Y TCR and αD26Y/βL98W TCR elicited significant reactivity against the
MART-1 homologs in CD4+ T cells (based on Figure 19), we focused our attention on
the CD8+ T cells. Therefore, we sought to determine how the DMF5 TCRs altered
polyfunctional phenotypes against the MART-1 homologs in DMF5 TCR transduced
CD8+ T cells. These five functional phenotypes were also apparent in polyfunctional
responses against the MART-1 homologs amongst T cells expressing the different
DMF5 TCRs in different donors and experiments. For proof of concept, representative
cool plots from the three donors depicting polyfunctional responses against M.
tuberculosis I protein, HSV-1 glycoprotein III, and ADP-ribose diphosphatase are shown
in Figures 28-30. These three peptides were chosen as examples for proof of concept
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because they were the top three most recognized MART-1 homologs (based on Figure
20).
Reproducible conclusions are evident when observing the polyfunctional
responses against the M. tuberculosis protein I (Figure 28). Specifically, the TCR
transduced CD8+ T cells are polyfunctional, and polyfunctional responses are DMF5
TCR and donor dependent. However, the five prominent phenotypes previously
described in CD8+ T cell responses against the MART-1 9mer, are evident here, with
the different ligand. These results indicated a reproducible pattern of polyfunctional
responses with different ligands. Furthermore, CD8+ T cells expressing the WT TCR
exhibited 11, 11, and 12 functional phenotypes against the M. tuberculosis protein I, per
each donor, respectively. CD8+ T cells expressing the αD26Y TCR exhibited more
functional phenotypes compared to T cells expressing the WT TCR at 13, 19, and 18
functional phenotypes per each donor, respectively. CD8+ T cells expressing the
αD26Y/αY50A/βL98W TCR exhibited fewer functional phenotypes than T cells
expressing the WT TCR at 3, 7, and 2 functional phenotypes per each donor,
respectively. These results coincided with the results in Figure 20 depicting a
statistically significant increase and decrease in the percentages of M. tuberculosis
protein I reactive CD8+ T cells in T cells expressing the αD26Y TCR and
αD26Y/αY50A/βL98W TCR, respectively, compared to T cells expressing the WT TCR.
Specifically, these results indicated that a greater percentage of TCR transduced M.
tuberculosis protein I reactive CD8+ T cells correlates to a greater number of functional
phenotypes exhibited.
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Figure 28. Impact of DMF5 Mutations in TCR Transduced
T cells on
Polyfunctional Responses against M. tuberculosis protein I. “Cool plots” were
generated to include any functional phenotype present over 0.1%. In the functional
phenotypes listed, “+” indicates positive for the marker and “-“ indicates negative for the
marker. As described in Chapter Two, reactivity is defined after background subtraction,
specifically, any phenotype expressed by over 0.1% of TCR transduced T cells
(subtraction of the background immunofluorescence observed with T2 cells loaded with
an irrelevant, HCV, peptide). The color depicted in the “cool plot” correlates to the scale
on the right. An “X” indicates no T cells were positive (<0.1% after background
subtraction) for given functional phenotype. The color white for a given functional
phenotype indicates a percentage less than 0.2% (a) or 0.5% (b and c). Five prominent
phenotypes are highlighted with red boxes. (a) donor one (b) donor two (c) donor three.

Overall, T cell polyfunctionality and the five predominant polyfunctional phenotypes
were observed with CD8+ T cells expressing each of the different DMF5 TCRs against a
different ligand.
We next observed the polyfunctional patterns demonstrated in response to the
HSV-1 glycoprotein III. Polyfunctional responses against the HSV-1 glycoprotein III
indicated reproducible observations that have been previously described (Figure 29).
Moreover, the TCR transduced CD8+T cells are polyfunctional, and polyfunctional
responses are DMF5 TCR and donor dependent. Nonetheless, the five prominent
phenotypes previously described in CD8+ T cell responses against the MART-1 9mer,
are evident here, with the different ligand. Furthermore, CD8 + T cells expressing the WT
TCR exhibited 7, 10, and 13 functional phenotypes against the HSV-1 glycoprotein III,
per each donor, respectively. CD8+ T cells expressing the αD26Y TCR exhibited more
functional phenotypes compared to T cells expressing the WT TCR at 10, 20, and 36
functional phenotypes per each donor, respectively.
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Figure 29. Impact of DMF5 Mutations in TCR Transduced
T cells on
Polyfunctional Responses against HSV-1 glycoprotein III. “Cool plots” were
generated to include any functional phenotype present over 0.1%. In the functional
phenotypes listed, “+” indicates positive for the marker and “-“ indicates negative for the
marker. As described in Chapter Two, reactivity is defined after background subtraction,
specifically, any phenotype expressed by over 0.1% of TCR transduced T cells
(subtraction of the background immunofluorescence observed with T2 cells loaded with
an irrelevant, HCV, peptide). The color depicted in the “cool plot” correlates to the scale
on the right. An “X” indicates no T cells were positive (<0.1% after background
subtraction) for given functional phenotype. The color white for a given functional
phenotype indicates a percentage less than (a) 0.2% or (b and c) 0.5%. Five prominent
phenotypes are highlighted with red boxes. (a) donor one (b) donor two (c) donor three.
CD8+ T cells expressing the αD26Y/αY50A/βL98W TCR exhibited fewer functional
phenotypes than T cells expressing the WT TCR at 2, 4, and 6 functional phenotypes
per each donor, respectively. These results coincided with the results in Figure 20
depicting a statistically significant increase and decrease in the percentages of HSV-1
glycoprotein III reactive CD8+ T cells in T cells expressing the αD26Y TCR and
αD26Y/αY50A/βL98W TCR, respectively, compared to T cells expressing the WT TCR.
Specifically, these results indicated that a greater percentage of TCR transduced HSVglycoprotein III reactive CD8+ T cells correlates to a greater number of functional
phenotypes exhibited. Overall, T cell polyfunctionality and the five predominant
polyfunctional phenotypes were observed with CD8+ T cells expressing each of the
different TCRs against a different ligand.
Lastly, we demonstrated that polyfunctional responses against the ADP-ribose
diphosphatase are dependent upon the DMF5 TCR and the donor (Figure 30).
However, the five prominent phenotypes previously described in CD8+ T cell responses
are evident here, with the different MART-1 homolog.
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Figure 30. Impact of DMF5 Mutations in TCR Transduced
T cells on
Polyfunctional Responses against ADP-ribose diphosphatase. “Cool plots” were
generated to include any functional phenotype present over 0.1%. In the functional
phenotypes listed, “+” indicates positive for the marker and “-“ indicates negative for the
marker. As described in Chapter Two, reactivity is defined after background subtraction,
specifically, any phenotype expressed by over 0.1% of TCR transduced T cells
(subtraction of the background immunofluorescence observed with T2 cells loaded with
an irrelevant, HCV, peptide). The color depicted in the “cool plot” correlates to the scale
on the right. An “X” indicates no T cells were positive (<0.1% after background
subtraction) for given functional phenotype. The color white for a given functional
phenotype indicates a percentage less than 0.2%. Five prominent phenotypes are
highlighted with red boxes. (a) donor one (b) donor two (c) donor three.
Furthermore, CD8+ T cells expressing the WT TCR exhibited 7, 14, and 11 functional
phenotypes against the ADP-ribose diphosphatase, per each donor, respectively. CD8+
T cells expressing the αD26Y TCR exhibited an equal number or more functional
phenotypes compared to T cells expressing the WT TCR at 7, 16, and 27 functional
phenotypes per each donor, respectively. CD8+ T cells expressing the
αD26Y/αY50A/βL98W TCR exhibited fewer functional phenotypes than T cells
expressing the WT TCR at 4, 11, and 4 functional phenotypes per each donor,
respectively. These results coincided with the results in Figure 20 depicting a trend
towards an increase and decrease in the percentages of ADP-ribose diphosphatase
reactive CD8+ T cells in T cells expressing the αD26Y TCR and αD26Y/αY50A/βL98W
TCR, respectively, compared to T cells expressing the WT TCR. As observed with the
MART-1 9mer, M. tuberculosis protein I, and HSV-1 glycoprotein III, these results
indicated that a greater percentage of TCR transduced ADP-ribose diphosphatase
reactive CD8+ T cells correlates to a greater number of functional phenotypes exhibited.
Overall, T cell polyfunctionality and the five predominant polyfunctional phenotypes
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were observed with

CD8+

T cells expressing each of the different TCRs against a

different ligand.
In light of all the polyfunctional results against different ligands from CD8 + T cells
expressing each of the DMF5 TCRs in different experiments and donors, there are
reproducible and overarching conclusions that can be made. First, it is evident that
polyfunctional responses are DMF5 TCR, experiment, donor, and ligand dependent.
However, amongst the variability, five reproducible functional phenotypes are frequently
exhibited by T cells expressing each of DMF5 TCRs against different ligands, in
different donors and experiments. Secondly, the number of polyfunctional phenotypes
exhibited against a given ligand, generally correlated to the patterns observed in the
percentages of ligand reactive T cells. This indicated the more antigen reactive T cells
there are, the more polyfunctional phenotypes they will exhibit. Overall, these data
suggested that patterns in polyfunctionality are evident, but specific functional
phenotypes are ultimately dependent upon the TCR, ligand, experiment, and donor.
Impact of Mutant DMF5 TCRs on Cross-Reactivity within Major Polyfunctional
Phenotypes
Thus far, we have described patterns of polyfunctionality in CD8+ T cells against
four targets in the form of cool plots. Analysis via cool plots is advantageous to visually
examine all the polyfunctional phenotypes exhibited and to visually examine how
mutations in the DMF5 TCR altered polyfunctional phenotypes against a specific ligand.
However, cool plots did not feasibly allow us to quantitatively determine how mutations
in the DMF5 TCR altered cross-reactivity patterns against all the MART-1 homologs
within specific functional phenotypes. Nonetheless, this analysis is of importance, since
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our previous conclusions on cross-reactivity were centered on antigen reactivity based
upon expression of any one or more functional marker. Through the analysis of cool
plots, we have identified five functional phenotypes that were predominantly expressed
among CD8+ T cells expressing each of the DMF5 TCRs, against different ligands, and
in different experiments and donors. The five phenotypes identified were: 1.) CD107A+,
IFN-γ+, TNF-α+, 2.) IFN-γ+, TNF-α+, 3.) CD107A+, IFN-γ+, 4.) IFN-γ+ only, and 5.)
CD107A+ only. Seven potential combinations of functional phenotypes were possible
with these three functional markers. CD107A+, TNF-α+ and TNF-α+ only are the two
phenotypes missing from these combinations. However, these two phenotypes were not
reproducibly exhibited in our analysis. This indicated that generally, if TNF-α was
produced, IFN-γ was also produced. Based upon these reproducible findings, we next
determined if the cross-reactive patterns observed against the MART-1 homologs in
Figure 20 were reproducible when focusing on each of these five predominant
functional phenotypes. We first examined TCR transduced CD8+ T cells expressing
CD107A, IFN-γ, and TNF-α (Figure 31). The average of six experiments found 9.2% of
T cells expressing the WT TCR exhibited the CD107A+, IFN-γ+, TNF-α+ polyfunctional
phenotype in response to targets loaded with the MART-1 9mer. Furthermore, T cells
expressing the WT TCR recognized four of the MART-1 homologs, ranging between 1%
and 2.6% reactive T cells. We observed similar patterns in reactivity against MART-1
and the MART-1 homologs with T cells expressing the mutant DMF5 TCRs that were
previously observed when examining reactivity based on any one or more functional
marker.
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Figure 31. Impact of DMF5 Mutations on Cross-Reactivity in TCR Transduced
CD8+ T cells Expressing the CD107A+, IFN-γ+, TNF-α+ Phenotype. Percent reactive
CD8+ T cells expressing the CD107A+, IFN-γ+, TNF-α+ functional phenotype were
determined using data generated from the six cool plots. Self-peptides are indicated by
a black triangle. Data represent the average of 6 experiments (three donors, two
independent repeats) and error bars represent the standard error of the mean. As
described in Chapter Two, reactivity is defined after background subtraction,
specifically, any phenotype expressed by over 0.1% of TCR transduced T cells
(subtraction of the background immunofluorescence observed with T2 cells loaded with
an irrelevant, HCV, peptide) . **** P <0.0001; ***P < 0.001; **P < 0.01; *P < 0.05 when
the percentage of antigen reactive T cells against each peptide with a given TCR was
compared to the percentage of antigen reactive T cells to the respective peptide with
the WT TCR by two-way ANOVA using Sidak’s multiple comparisons tests.

Specifically, the percentage of MART-1 9mer reactive T cells was comparable between
T cells expressing the αD26Y TCR and T cells expressing the WT TCR (9.6% vs.
9.2%). Furthermore, the percentages of αD26Y TCR expressing MART-1 homolog
reactive T cells was increased compared to T cells expressing the WT TCR. Statistical
significance was reached in HSV-1 glycoprotein III (10%), M. tuberculosis protein I
(8.3%), human CD9 (3.4%) and GPCR 3 (4.5%). In T cells expressing the βL98W TCR,
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the percentage of MART-1 9mer (9.1% vs. 9.2%) and MART-1 homolog (0.1% - 2.6%
vs. 1% - 2.6%) reactive T cells was comparable to T cells expressing the WT TCR.
However, there was one apparent exception, although not significant, the percentage of
antigen reactive βL98W TCR expressing T cells was increased against human CD9,
compared to T cells expressing the WT TCR (1.4% vs. 0%). This coincided with our
previous conclusions made in Figure 20. T cells expressing the αD26Y/βL98W TCR
demonstrated a statistically significant reduction in the percentage of MART-1 9mer
reactive T cells compared to T cells expressing the WT TCR (2% vs. 9.2%), consistent
with previous findings. There were no statistically significant changes in the percentage
of MART-1 homolog reactive T cells, consistent with previous findings. Although not
statistically significant compared to T cells expressing the WT TCR, T cells expressing
the αD26Y/αY50A/βL98W TCR exhibited a trend towards a reduction in the percentage
of MART-1 9mer reactive T cells (9.2% vs. 6.5%). and MART-1 homolog reactive T cells
(1% to 2.6% vs. 0.28% to 1.1%). Lastly, there were no statistically significant differences
between the WT TCR and the αD26Y/αY50V/βL98W TCR in terms of the percentages
of MART-1 9mer (9.2% vs. 7.7%) and MART-1 homolog reactive (1% to 2.6% vs. 0.1%
to 2.5%) TCR transduced CD8+ T cells, consistent with previous findings in Figure 20.
Overall, when examining the percentages of MART-1 and MART-1 homolog reactive T
cells exhibiting the CD107A+, IFN-γ+, TNF-α+ polyfunctional phenotype, we generated
conclusions that were similar to the conclusions we generated from Figure 20. Mainly,
the percentages of MART-1 homolog reactive TCR transduced CD8+ T cells were
generally enhanced with the αD26Y TCR and reduced with the αD26Y/αY50A/βL98W
TCR, compared to the WT DMF5 TCR. Furthermore, T cells expressing the
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αD26Y/αY50A/βL98W TCR exhibited a trend towards a reduction in the percentage of
MART-1 9mer and MART-1 homolog reactive T cells compared to T cells expressing
the WT TCR. These results indicated that patterns in MART-1 9mer and MART-1
homolog reactivity were comparable when observing the overall percentages of antigen
reactive TCR transduced CD8+ T cells (Figure 20), or the percentages of antigen
reactive TCR transduced CD8+ T cells expressing a specific polyfunctional phenotype
(Figure 31). We next determined if the patterns observed in MART-1 9mer and MART-1
homolog reactivity were reproducible in the other four functional phenotypes: IFN-γ+,
TNF-α+ (Figure 32), CD107A+, IFN-γ+ (Figure 33), IFN-γ+ only (Figure 34), and
CD107A+ only (Figure 35).
Our observations from these data indicated that patterns in antigen recognition
among different DMF5 TCR transduced CD8+ T cell populations are frequently
reproducible when examining antigen reactivity in terms of the total percentage of
antigen reactive T cells (Figure 20), or when examining antigen reactivity in terms of
expressing individual functional phenotypes (Figures 31-35). Moreover, CD8+ T cells
expressing the WT TCR are cross-reactive, as they recognized between four and nine
MART-1 homologs within each functional phenotype (Figures 31-35). Overall, CD8+ T
cells expressing each of the mutant DMF5 TCRs generally exhibited similar patterns in
the percentages of MART-1 9mer and MART-1 homolog reactive T cells among the five
specific functional phenotypes, compared to T cells expressing the WT TCR.
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Figure 32. Impact of DMF5 Mutations on Cross-Reactivity in TCR Transduced
CD8+ T cells Expressing the IFN-γ+, TNF-α+ Phenotype. Percent reactive CD8+ T
cells expressing the IFN-γ+, TNF-α+ functional phenotype were determined using data
generated from the six cool plots. Self-peptides are indicated by a black triangle. Data
represent the average of 6 experiments (three donors, two independent repeats) and
error bars represent the standard error of the mean. As described in Chapter Two,
reactivity is defined after background subtraction, specifically, any phenotype expressed
by over 0.1% of TCR transduced T cells (subtraction of the background
immunofluorescence observed with T2 cells loaded with an irrelevant, HCV, peptide).
**** P <0.0001; ***P < 0.001; **P < 0.01; *P < 0.05 when the percentage of antigen
reactive T cells against each peptide with a given TCR was compared to the percentage
of antigen reactive T cells to the respective peptide with the WT TCR by two-way
ANOVA using Sidak’s multiple comparisons tests.
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Figure 33. Impact of DMF5 Mutations on Cross-Reactivity in TCR Transduced
CD8+ T cells Expressing the CD107A+, IFN-γ+ Phenotype. Percent reactive CD8+ T
cells expressing the CD107A+, IFN-γ+ functional phenotype were determined using data
generated from the six cool plots. Self-peptides are indicated by a black triangle. Data
represent the average of 6 experiments (three donors, two independent repeats) and
error bars represent the standard error of the mean. As described in Chapter Two,
reactivity is defined after background subtraction, specifically, any phenotype expressed
by over 0.1% of TCR transduced T cells (subtraction of the background
immunofluorescence observed with T2 cells loaded with an irrelevant, HCV, peptide).
**** P <0.0001; ***P < 0.001; **P < 0.01; *P < 0.05 when the percentage of antigen
reactive T cells against each peptide with a given TCR was compared to the percentage
of antigen reactive T cells to the respective peptide with the WT TCR by two-way
ANOVA using Sidak’s multiple comparisons tests.
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Figure 34. Impact of DMF5 Mutations on Cross-Reactivity in TCR Transduced
CD8+ T cells Expressing the IFN-γ+ only Phenotype. Percent reactive CD8+ T cells
expressing the IFN-γ+ only functional phenotype were determined using data generated
from the six cool plots. Self-peptides are indicated by a black triangle. Data represent
the average of 6 experiments (three donors, two independent repeats) and error bars
represent the standard error of the mean. As described in Chapter Two, reactivity is
defined after background subtraction, specifically, any phenotype expressed by over
0.1% of TCR transduced T cells (subtraction of the background immunofluorescence
observed with T2 cells loaded with an irrelevant, HCV, peptide). **** P <0.0001; ***P <
0.001; **P < 0.01; *P < 0.05 when the percentage of antigen reactive T cells against
each peptide with a given TCR was compared to the percentage of antigen reactive T
cells to the respective peptide with the WT TCR by two-way ANOVA using Sidak’s
multiple comparisons tests.
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Figure 35. Impact of DMF5 Mutations on Cross-Reactivity in TCR Transduced
CD8+ T cells Expressing the CD107A+ only Phenotype. Percent reactive CD8+ T
cells expressing the CD107A+ only functional phenotype were determined using data
generated from the six cool plots. Self-peptides are indicated by a black triangle. Data
represent the average of 6 experiments (three donors, two independent repeats) and
error bars represent the standard error of the mean. As described in Chapter Two,
reactivity is defined after background subtraction, specifically, any phenotype expressed
by over 0.1% of TCR transduced T cells (subtraction of the background
immunofluorescence observed with T2 cells loaded with an irrelevant, HCV, peptide).
**** P <0.0001; ***P < 0.001; **P < 0.01; *P < 0.05 when the percentage of antigen
reactive T cells against each peptide with a given TCR was compared to the percentage
of antigen reactive T cells to the respective peptide with the WT TCR by two-way
ANOVA using Sidak’s multiple comparisons tests.
Specifically, T cells expressing the αD26Y TCR exhibited more MART-1 homolog
reactive T cells compared to T cells expressing the WT TCR, with statistical significance
reached with some MART-1 homologs in four of the five functional phenotypes (Figures
31 and 33-35). It was notable that T cells expressing the αD26Y TCR exhibited
significantly more MART-1 9mer reactive T cells in the CD107A+ only (Figure 35) and
CD107A+, IFN-γ+ (Figure 33) phenotype. This was not observed in Figure 20 when
examining the total percentage of MART-1 9mer reactive CD8+ T cells. This indicated
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that these patterns of MART-1 9mer reactivity are not 100% reproducible within
individual phenotypes. Overall, these results indicated that the tyrosine mutation at
position 26 in the TCR alpha chain did not enhance MART-1 9mer antigen specificity in
TCR transduced CD8+ T cells expressing specific functional phenotypes. However,
compared to the WT TCR, a statistically significant increase in the percentages of
MART-1 9mer reactive CD8+ T cells was observed in αD26Y TCR transduced CD8+ T
cells expressing the CD107A+ only and CD107A+, IFN-γ+ phenotypes.
We next examined reproducible patterns in MART-1 9mer and MART-1 homolog
reactivity with CD8+ T cells expressing the βL98W TCR. Specifically, the percentages of
MART-1 9mer reactive T cells were comparable between βL98W TCR and WT TCR
expressing CD8+ T cells amongst the five functional phenotypes (Figures 31-35).
Additionally, the percentages of MART-1 homolog reactive T cells were comparable
between βL98W TCR and WT TCR expressing CD8+ T cells amongst the five functional
phenotypes (Figures 31-35). Although not significant, one notable difference was a
trend towards an increase in human CD9 reactive T cells expressing the βL98W TCR
compared to T cells expressing the WT TCR amongst the five functional phenotypes
(Figures 31-35). This was also previously demonstrated in Figure 20. Overall, these
results indicated that the tryptophan mutation at position 98 in the TCR beta chain did
not enhance MART-1 9mer antigen specificity in TCR transduced CD8+ T cells
expressing specific functional phenotypes.
We next elucidated reproducible patterns in MART-1 9mer and MART-1 homolog
reactivity with T cells expressing the αD26Y/βL98W TCR. Specifically, the percentages
of MART-1 9mer reactive T cells were statistically significantly reduced in T cells
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expressing the αD26Y/βL98W TCR compared to T cells expressing the WT TCR in four
of the five functional phenotypes (Figures 31-34). Furthermore, the percentages of
MART-1 homolog reactive T cells were comparable, with no statistically significant
differences (Figures 31-35). Overall, the combination of the αD26Y and βL98W TCR
mutations did not enhance MART-1 9mer antigen specificity and attenuated MART-1
reactivity in TCR transduced CD8+ T cells expressing specific functional phenotypes.
We next examined comparable patterns in MART-1 9mer and MART-1 homolog
reactivity with T cells expressing the αD26Y/αY50A/βL98W TCR. Specifically, T cells
expressing the αD26Y/αY50A/βL98W TCR significantly reduced the percentages of
MART-1 reactive CD8+ T cells in two of the five functional phenotypes, compared to the
WT TCR (Figures 33-34). Furthermore, T cells expressing the αD26Y/αY50A/βL98W
TCR exhibited a trend towards a reduction in the percentages of MART-1 homolog
reactive T cells compared to T cells expressing the WT TCR (Figures 31-32, and 35),
reaching statistical significance with some of the MART-1 homologs in two of the five
functional phenotypes (Figures 33-34). In summary, the addition of the alanine TCR
mutation at position 50 in the TCR alpha chain to the αD26Y/βL98W TCR resulted in an
overall trend in reduced MART-1 9mer and MART-1 homolog reactivity in TCR
transduced CD8+ T cells expressing specific functional phenotypes.
Lastly, there were no significant differences in the percentages of MART-1 9mer
and MART-1 homolog reactive αD26Y/αY50V/βL98W TCR or WT TCR expressing T
cells amongst the five functional phenotypes (Figures 31-35). Overall, the valine TCR
mutation at position 50 in the TCR alpha did not have as much as an impact on MART-1

178
9mer and MART-1 homolog reactivity as the alanine TCR mutation in TCR transduced
CD8+ T cells expressing specific functional phenotypes.
Based on all the data observing antigen specificity and cross-reactivity in DMF5
TCR transduced CD8+ T cells expressing specific functional phenotypes, a few
comprehensive conclusions were generated. First, trends in MART-1 9mer and MART-1
homolog recognition amongst T cells expressing each of the DMF5 TCRs were
commonly reproducible whether examining the total percentages of antigen reactive
CD8+ T cells (Figure 20), or the percentages of antigen reactive CD8+ T cells
expressing a specific functional phenotype (Figures 31-35). However, these trends were
not 100% reproducible with each DMF5 TCR in each individual phenotype. This
suggested that observing antigen reactivity in regards to exhibiting any functional
phenotype (Figure 20) gives a baseline for the total percentage of antigen reactive T
cells. Subsequently, it is plausible to observe minor variation around that baseline within
individual functional phenotypes (Figures 31-35). In summary, these results indicated
the patterns of MART-1 and MART-1 homolog reactivity elicited with T cells expressing
each of the different DMF5 TCRs are generally or broadly reproducible when comparing
the total percentage of antigen reactive T cells or the percentage of antigen reactive T
cells within an individual phenotype.
It was of interest to determine if the patterns of the CD107A+ only phenotype
(Figure 35) in response to the MART-1 9mer correlated to patterns in lysis of MEL 624
in Figure 17. Our results indicated that the percentages of CD107A+ only CD8+ T cells in
response to the MART-1 9mer generally correlated with cytotoxicity. For example,
compared to T cells expressing the WT TCR, αD26Y TCR expressing T cells exhibited
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a statistically significant increase in MEL 624 killing (Figure 17) and exhibited a
statistically significant increase in the percentage of CD107A+ only CD8+ T cells in
response to the MART-1 9mer (Figure 35). Furthermore, compared to T cells
expressing WT TCR, T cells expressing the βL98W TCR, αD26Y/αY50A/βL98W TCR,
or αD26Y/αY50V/βL98W TCR exhibited comparable, or a trend towards an increase in
MEL 624 killing (Figure 17) and exhibited similar percentages of CD107A+ only CD8+ T
cells in response to the MART-1 9mer (Figure 35). However, there was one exception to
this correlation. αD26Y/βL98W TCR expressing T cells exhibited a statistically
significant increase in MEL 624 killing (Figure 17), but exhibited a trend towards a
decrease in the percentages of CD107A+ only CD8+ T cells compared to CD8+ T cells
expressing the WT TCR (Figure 35). One caveat is that the percentage of CD107A+
only CD8+ T cells was much lower than the percentages of functional phenotypes
exhibiting both CD107A and cytokines. This indicated CD107A+ T cells, or T cells that
have potentially killed, generally also expressed cytokines. Therefore, we examined the
total percentages of CD107A+ T cells against the MART-1 9mer to determine if there
was a correlation with MEL 624 lysis (Figure 36). In CD8+ T cells, T cells expressing the
αD26Y/βL98W TCR exhibited a statistically significantly lower percentage of MART-1
9mer reactive CD107A+ T cells compared to T cells expressing the WT TCR (Figure
36A). This did not correlate with lysis of MEL 624 in Figure 17. Although not statistically
significant compared to CD8+ T cells expressing the WT TCR, T cells expressing the
αD26Y exhibited a trend towards an increase in the percentage of CD107A + MART-1
9mer reactive T cells (Figure 36A), corresponding to the statistically significant increase
in MEL 624 lysis (Figure 17).
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Figure 36. Percentage of Total CD107A+ CD8+ and CD4+ MART-1 9mer Reactive T
cells. The percentages of MART-1 9mer reactive (a) CD8+ and (b) CD4+ T cells
expressing CD107A is displayed. Data represent the average of 6 experiments (three
donors, two independent repeats) and error bars represent the standard error of the
mean. As described in Chapter Two, reactivity is defined after background subtraction,
specifically, any CD107A+ T cells expressed by over 0.1% of TCR transduced T cells
(subtraction of the background immunofluorescence observed with T2 cells loaded with
an irrelevant, HCV, peptide). **P < 0.01; *P < 0.05 when the percentage of antigen
reactive T cells given with a given modified DMF5 TCR was compared to the
percentage of antigen reactive T cells expressing the WT TCR by one-way ANOVA.

Although not statistically significant compared to

CD8+
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T cells expressing the WT TCR,

T cells expressing the αD26Y/αY50A/βL98W TCR exhibited a trend towards a decrease
in the percentage of CD107A+ MART-1 9mer reactive T cells (Figure 36A) despite
exhibiting comparable levels of MEL 624 lysis (Figure 17). Lastly, although not
statistically significant compared to CD8+ T cells expressing the WT TCR, T cells
expressing the αD26Y/αY50V/βL98W TCR or βL98W TCR exhibited comparable
percentages of CD107A+ MART-1 9mer reactive T cells (Figure 36A) despite exhibiting
a trend towards an increase in MEL 624 killing (Figure 17). Overall, the percentages of
CD107A+ MART-1 9mer reactive CD8+ T cells roughly followed to the patterns observed
in MEL 624 lysis. The one drastic exception was observed with T cells expressing the
αD26Y/βL98W TCR.
TCR transduced T cells expressing either the WT DMF5 TCR or each of the
mutant DMF5 TCRs used in the MEL 624 lysis assay were comprised of both CD4 + and
CD8+ T cells. Therefore, we determined if the percentages of MART-1 9mer reactive
CD4+ T cells expressing CD107A correlated to MEL 624 lysis (Figure 36B). Although
not significant compared to CD4+ T cell expressing the WT TCR, CD4+ T cells
expressing the αD26Y TCR or βL98W TCR exhibited a trend towards an increase in the
percentages of CD107A+ MART-9mer reactive T cells (Figure 36B), coinciding with their
significant or trend towards an increase in MEL 624 lysis (Figure 17), respectively.
Compared to CD4+ T cell expressing the WT TCR, CD4+ T cells expressing the
αD26Y/βL98W TCR exhibited a comparable percentage of CD107A+ MART-9mer
reactive T cells (Figure 36B), despite their significant increase in MEL 624 lysis (Figure
17). Lastly, CD4+ T cells expressing the αD26Y/αY50A/βL98W TCR or
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αD26Y/αY50V/βL98W TCR exhibited comparable or a trend towards an increase in the
percentages of CD107A+ MART-9mer reactive T cells (Figure 36B), coinciding with their
comparable or a trend towards an increase in MEL 624 lysis (Figure 17), respectively. In
summary, the percentages of CD107A+ MART-1 9mer reactive CD4+ T cells
corresponded to patterns in MEL 624 lysis. One exception was observed in CD4+ T
cells expressing the αD26Y/βL98W TCR.
A few conclusions can be made based on the correlations between CD107A +
9mer reactive CD4+ and CD8+ T cells and MEL 624 lysis. First, the lysis assays were
done using CD4+ and CD8+ pooled T cells. As previously stated, the proportion of CD4 +
T cells ranged between 27% and 35% and the proportion of CD8+ T cells ranged
between 65% and 73% amongst the TCR transduced T cells populations. Therefore, we
can draw overarching conclusions from the data (as we did previously), but we cannot
directly compare lysis without performing the lysis assay with only CD4+ T cells or only
CD8+ T cells. However, if we observe overall trends in the patterns, it is evident that the
percentages of CD107A+ T cells generally correlated to the patterns observed in MEL
624 lysis. The one exception was observed with T cells expressing the αD26Y/βL98W
TCR. There a few possible explanations for this result. Notably, the αD26Y/βL98W TCR
harbors the supraphysiological 3D TCR affinity. It is possible that with this level of
affinity, CD107A expression is not reflective of lysis. Additionally, at this level of affinity,
it is possible that CD107A expression is antigen density dependent. In summary,
patterns observed in CD107A expression in response to the MART-1 9mer were
generally correlative with patterns observed in MEL 624 lysis, except with T cells
expressing a TCR harboring a supraphysiological 3D TCR affinity. Based on all the data

observing antigen specificity and cross-reactivity in DMF5 TCR transduced

CD8+
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T cells

expressing specific functional phenotypes, a few comprehensive conclusions were
generated. First, trends in MART-1 9mer and MART-1 homolog recognition amongst T
cells expressing each of the DMF5 TCRs were commonly reproducible whether
examining the total percentages of antigen reactive CD8+ T cells (Figure 20), or the
percentages of antigen reactive CD8+ T cells expressing a specific functional phenotype
(Figures 31-35). However, these trends were not 100% reproducible with each DMF5
TCR in each individual phenotype. This suggested that observing antigen reactivity in
regards to exhibiting any functional phenotype (Figure 20) gives a baseline for the total
percentage of antigen reactive T cells. Subsequently, it is plausible to observe minor
variation around that baseline within individual functional phenotypes (Figures 31-35). In
summary, these results indicated the patterns of MART-1 and MART-1 homolog
reactivity elicited with T cells expressing each of the different DMF5 TCRs are generally
or broadly reproducible when comparing the total percentage of antigen reactive T cells
or the percentage of antigen reactive T cells within an individual phenotype.
Impact of Single MHC Targeted Mutations on Cross-Reactivity in DMF5 TCR
Our findings indicated that in combination with the αD26Y and βL98W TCR
mutations that target the MART-1 peptide, the addition of the αY50V mutation could
reduce the cross-reactivity to levels similar to the WT TCR. Furthermore, the addition of
the αY50A mutation reduced cross-reactivity lower than that of the WT TCR. We
therefore determined if these mutations that weaken TCR binding to the MHC could
reduce cross-reactivity while maintaining reactivity against MART-1 expressing targets.
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Figure 37. Impact of Single, MHC Weakening, TCR Alpha Chain Mutations in the
DMF5 TCR. Human T cells expressing either WT or mutated DMF5 TCRs were
stimulated with T2 cells loaded with the control HCV NS3 peptide (KLVALGINAV),
MART-1 9mer peptide (AAGIGILTV), or MART-1 homologs. Cells were incubated with
CD3/CD28 Dynabeads in a 1:1 bead to cell ratio for positive control. IFN-γ release was
measured by ELISA in triplicate wells. Error bars represent the standard error of the
mean from three independent repeats of one representative donor. Antigen reactivity is
defined as a T cell culture that secretes twice background, or twice the amount of IFN-γ
produced against T2 cells loaded with the HCV peptide, and greater than 200 pg/mL.
Mutant DMF5 TCRs were constructed with only the αY50A TCR mutation or the αY50V
TCR mutation. Human T cells were transduced to express either the WT, αY50A, or
αY50V DMF5 TCRs. T cells expressing the single mutant DMF5 TCRs eliminated all
recognition of MART-1 and MART-1 homologs (Figure 37). Furthermore, activation with
CD3/CD28 beads indicated that these T cells were capable of secreting IFN-γ. These
results indicated that in the DMF5 TCR, αY50 binding to HLA-A2 is essential for antigen
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recognition. However, when αY50 TCR mutations are counterbalanced with TCR
mutations that enhance binding to the MART-1 peptide, the reduced αY50 TCR and
HLA-A2 binding is permissible. Overall, these results exemplify the importance of this
TCR/pMHC contact site for antigen recognition.
Impact of Single MHC Targeted Mutations on Cross-Reactivity in HCV 1406 TCR
In our structure-guided design strategy, positive TCR mutations that target the
peptide would be TCR and ligand specific. However, it is plausible that the negative
mutations that weaken binding with the MHC could be translatable to other TCRs if they
were introduced at evolutionarily conversed residues or binding sites. The αY50 residue
makes contact with an evolutionarily conserved region of HLA-A2 [37]. Therefore, we
determined how the single MHC weakening mutations affected antigen recognition in
another TCR. Herein, we utilized our previously described HLA-A2 restricted hepatitis C
(HCV) NS3:1406-1415-reactive TCR because this TCR recognized a number of NS3
mutant epitopes [437, 438]. Mutations were made in the alpha chain to that same
tyrosine that contacts the same conserved region of HLA-A2, αY59A or αY59V. A panel
of naturally occurring mutant epitopes of the HCV NS3 protein were used to measure
cross-reactivity [438]. Human T cells were transduced to express either the WT, αY59A,
or αY59V HCV 1406 TCRs. We first determined how T cells expressing the WT HCV
1406 TCR recognized the mutant NS3 epitopes. T cells expressing the WT HCV TCR
are cross-reactive against all of the mutant epitopes except 8S/9G/12L (Figure 38).
After determining which mutant NS3 epitopes were recognized by T cells expressing the
WT HCV 1406 TCR, we determined how the mutant HCV 1406 TCRs affected
recognition of the WT and mutant NS3 epitopes.
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Figure 38. Impact of Single, MHC Weakening, TCR Alpha Chain Mutations in the
HCV 1406 TCR. Human T cells expressing either WT or mutated HCV 1406 TCRs were
stimulated with T2 cells loaded with the control MART-1 9mer peptide (AAGIGILTV),
HCV NS3 peptide (KLVALGINAV), or mutant NS3 peptides. Cells were incubated with
CD3/CD28 Dynabeads in a 1:1 bead to cell ratio for positive control. IFN-γ release was
measured by ELISA in triplicate wells. Error bars represent the standard error of the
mean from three independent repeats of one representative donor. Black triangles
indicate CD8 dependent epitopes. Antigen reactivity is defined as a T cell culture that
secretes twice background, or twice the amount of IFN-γ produced against T2 cells
loaded with the MART-1 peptide, and greater than 200 pg/mL.
The αY59A TCR mutation in the HCV 1406 TCR eliminated detectable all detectable
recognition of the WT NS3 HCV peptide and all HCV NS3 peptide mutants. Activation
with CD3/CD28 beads indicated that these T cells were capable of secreting IFN-γ.
Dissimilar to the single mutations in the DMF5 TCR, the αY59V TCR mutation in the
HCV 1406 TCR reduced reactivity against the WT NS3 peptide compared to the T cells
expressing the WT HCV 1406 TCR. The αY59V TCR mutation in the HCV 1406 TCR
reduced cross-reactivity against three mutant epitopes (V1408L, I1412L, I1412V) even
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eliminating detectable cross-reactivity against four (A1409T, I1412N, V1408T,
8S/9G/12L/14S), compared to T cells expressing the WT HCV 1406 TCR. More
specifically, recognition of epitopes previously determined to be CD8 dependent
(A1409T, I1412N, and 8S/9G/12L/14S) were no longer recognized [438, 439]. While the
3D affinity of the DMF5 TCR is around 37 μM, the HCV 1406 TCR has a higher 3D
affinity, around 16.8 μM [439]. It is possible that this increase in TCR affinity contributes
to the ability of the αY59V HCV TCR to recognize the WT NS3 peptide and some of the
mutant NS3 epitopes. In summary, these results indicated this conserved MHC contact
residue in the TCR could be a potential site for mutation in order to reduce potential
cross-reactivity of high affinity TCRs.
Impact of Mutant DMF5 TCRs on Recognition of Processed Antigens
Thus far, we have observed how T cells expressing each of the mutant DMF5
TCRs alter antigen recognition and cross-reactivity by recognition of T2 cells loaded
with a peptide panel comprised of MART-1 homologs. However, many peptide reactive
T cells do not recognize the processed antigen. Therefore, we sought to determine if the
four human MART-1 homologs (human CD9, human elongation factor 1α, G-protein
coupled receptor 3, and human receptor expression enhancing protein 5) were
processed and presented by HLA-A2, and recognized by TCR transduced T cells
expressing the WT or modified DMF5 TCRs. To answer this, we planned to transfect
COS-A2 cells with cDNAs encoding the full length MART-1, human CD9, human
elongation factor 1α, G-protein coupled receptor 3, and human receptor expression
enhancing protein 5. However, preliminary experiments comparing COS cells, COS-A2
cells, and COS-A2 cells loaded with the MART-1 9mer revealed an unexpected result.

IFN- Release (pg/mL)

188
25000
20000
15000

WT
aD26Y

8000

aD26Y/L98W

6000

aD26Y/Y50V/L98W

4000
2000

T-

1

2
A

S

C

O

S-

A

2

C

M

O

A

R

S-

O
C

m

ed

ia

0

Figure 39. Impact of DMF5 TCRs on COS-A2 Cell Recognition. Human T cells
expressing either WT or a mutant DMF5 TCR were stimulated with COS cells, COS-A2
cells, or COS-A2 cells loaded with the MART-1 9mer peptide (AAGIGILTV) for 18 hours.
Antigen reactivity is as defined as a T cell culture that secretes twice background (COS
cells) and greater than 200 pg/mL IFN-γ. IFN-γ release was measured by ELISA in
triplicate wells. One representative experiment from is shown.
First, T cells expressing the WT DMF5 TCR did not recognize COS cells or COS-A2
cells, but did recognize MART-1 loaded COS-A2 cells (Figure 39). Surprisingly, T cells
expressing the αD26Y, αD26Y/βL98W, and αD26Y/αY50V/βL98W TCRs recognized
COS-A2 cells and MART-1 loaded COS-A2 cells, but not COS cells. The recognition of
COS-A2 cells by T cells expressing the modified DMF5 TCRs suggested HLA-A2
restricted recognition of other antigens. This observation led us to determine if COS-A2
MART-1- recognition was unique, or if COS-A2 MART-1- recognition was due to broad
cross-reactivity. Therefore, we composed a panel of tumors derived from a variety of
tissues to examine potential cross-reactivity with naturally processed self-antigens
(Table 2, Chapter Two - Methods).
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Human T cells transduced to express the WT DMF5 TCR or each modified DMF5 TCR
were used as effector T cells and stimulated with the tumor panel in cytokine release
assays. Of note, included in this panel was A375, an HLA-A2+ MART-1- melanoma cell
line. One representative donor and experiment is shown in Figure 40. First, two patterns
of cross-reactivity were observed. The first pattern was mutant DMF5 TCRs that were
highly cross-reactive compared to the WT TCR (generally, three times as reactive as
the WT TCR) (Figure 40A). The second pattern was mutant DMF5 TCRs that were
modestly cross-reactive compared to the WT TCR (generally, less than two times as
reactive as the WT TCR) (Figure 40B). T cells expressing WT TCR were cross-reactive
against the HLA-A2+ off-target tumors (Figure 40A). Somewhat surprisingly, T cells
expressing either the αD26Y TCR or αD26Y/βL98W TCR were reactive against all the
HLA-A2+ off-target tumors, more than T cells expressing the WT TCR (Figure 40A).
Furthermore, T cells expressing the αD26Y/αY50V/βL98W TCR were reactive against
all the HLA-A2+ off-target tumors, although not as reactive as T cells expressing the
αD26Y or αD26Y/βL98W TCRs, but more reactive than T cells expressing the WT TCR
(except with A375) (Figure 40A). Lastly, T cells expressing the βL98W TCR or
αD26Y/αY50A/βL98W TCR exhibited enhanced cross-reactivity against some, but not
all of the HLA-A2+ off-target tumors, compared to T cells expressing the WT TCR
(Figure 40B). It was interesting to note that off-target tumor recognition was tumor
specific within each mutant DMF5 TCR. Variability in recognition and potential off-target
tumor antigens being recognized will be discussed in further detail in a subsequent
section.
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Figure 40. Impact of DMF5 Mutations on Cross-Reactivity Using Multi-Tissue
Tumor Panel. Human T cells expressing either WT or a mutant DMF5 TCR were
stimulated with tumor cell lines (see Table 2 – Chapter Two, Methods). IFN-γ release
was measured by ELISA in triplicate wells. SAUJ and MEL 624-28 are HLA-A2-, all
other tumors are HLA-A2+. Two patterns of off-target tumor recognition were observed.
(a) Highly cross-reactive TCRs compared to the WT TCR (generally, three times as
reactive as the WT TCR). (b) Modestly cross-reactive TCRs compared to the WT TCR
(generally, less than two times as reactive as the WT TCR). One representative
experiment and donor is shown. Reactivity is defined as a T cell culture that secretes
twice background, or twice the amount of IFN-γ produced as against MEL 624-28, and
greater than 200 pg/mL.
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Additionally, it was surprising when T cells expressing the βL98W TCR or
αD26Y/αY50A/βL98W TCR were cross-reactive, T cells expressing the
αD26Y/αY50A/βL98W TCR generally exhibited higher magnitudes of reactivity. These
results would not have been predicted based upon 3D affinity or our conclusions from
MART-1 homolog peptide loaded targets, where T cells expressing the
αD26Y/αY50A/βL98W TCR reduced cross-reactivity. In summary, T cells expressing
each of the mutant DMF5 TCRs were generally more cross-reactive against the offtarget, HLA-A2+ tumors than T cells expressing the WT TCR. Furthermore, the DMF5
WT TCR is cross-reactive.
Our previous results have indicated that donor variability occurs in polyclonal
PBL-derived T cells. Therefore, it was of importance to analyze this off-target crossreactivity in multiple donors. All individual experiments and donors are shown in Figures
52-58, in the appendix. In all the individual experiments, we observed variability in the
patterns of recognition, magnitudes of responses, and magnitudes in background
amongst T cells expressing each of the DMF5 TCRs. Thus, instead of averaging
together experiments, we developed a scoring index to examine how mutations in the
DMF5 TCR altered recognition of the off-target tumors compared to the WT DMF5 TCR
among different donors and experiments. We based this index off of our standard of
defining antigen reactivity as twice over background and greater than 200 pg/mL.
Therefore, we examined each experiment and allocated a score to each mutant DMF5
TCR in response to each off-target tumor. A score of 1 indicated IFN-γ production
against an off-target tumor was twice over the IFN-γ production against MEL 624-28
within the respective mutant DMF5 TCR, AND twice over the IFN-γ production exhibited
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by the WT DMF5 TCR, AND over 200 pg/mL. A score of 0 was given if ANY of the three
criteria were NOT met. This scoring was completed in each experiment in each donor.
We used MEL 624-28 as the negative control because this is a relevant MART-1+
melanoma, but it is HLA-A2-. We used the WT DMF5 TCR in the scoring index so that
we could compare off-target tumor recognition by each modified DMF5 TCR compared
to the WT DMF5 TCR. Overall, with this scoring index we could examine both
differences in recognition over background (MEL 624-28) within a respective mutant
DMF5 TCR and differences in recognition compared to the WT DMF5 TCR. Table 17
specifies the scores given to each modified DMF5 TCR, in each experiment, against
each off-target tumor. These scores were based on the raw data shown in Figures 5258 in the appendix. We subsequently averaged the scores together and obtained an
index that demonstrated the frequency at which T cells expressing each mutant DMF5
TCR exhibited twice the level of recognition against an off-target tumor as T cells
expressing the WT TCR (Figure 41). The criteria for comparing to the WT DMF5 TCR is
just classified as twice over recognition by the WT DMF5 TCR, and thus, we understand
this index does not take into account the magnitude in which a response is greater than
twice of the WT TCR. However, this index gives us an objective way to compare
experiments given the donor and experimental variability. These results indicated T
cells expressing the αD26Y TCR recognized the off-target A375, UOK131, SW480,
SKGT5, and U251 tumors more than T cells expressing the WT TCR in every
experiment. Furthermore, T cells expressing the αD26Y TCR recognized the off-target
SKOV3, CAPAN 1, MDA 231, and HEPG2 tumors more than T cells expressing the WT
TCR with a frequency between 0.83 and 0.86.
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Table 17. Scoring Index for DMF5 TCRs against Off-Target Tumors. Experiment 1 in
donor 1 was not included in analysis because a minimal off-target tumor panel was used.
A blank space indicates off-target tumor was not used in that experiment. A score of 1
indicated IFN-γ production against an off-target tumor was twice over IFN-γ production
against MEL 624-28 within the respective mutant DMF5 TCR, AND twice over IFN-γ
production exhibited by the WT DMF5 TCR, AND over 200 pg/mL. A score of 0 was given
if ANY of the three criteria were NOT met. Shown are scores from four donors, including
1-2 experiments, were averaged for each off-target tumor with each DMF5 TCR.
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Figure 41. Frequency Mutant DMF5 TCRs Exhibited Enhanced Recognition of OffTarget Tumors Compared WT DMF5 TCR. Given experimental variability, a reactivity
score was developed to enable a direct comparison of experiments. Recognition of
each off-target tumor by each mutant DMF5 TCR was given a score of 1 or 0 in every
experiment. A score of 1 indicated IFN-γ production was twice over IFN-γ production
against MEL 624-28 (HLA-A2-) within respective mutant DMF5 TCR, AND twice over
IFN-γ production exhibited by the WT DMF5 TCR, AND over 200 pg/mL. A score of 0
was given if ANY of the three criteria were NOT met. Scores from each experiment
were averaged for each mutant DMF5 TCR and off-target tumor. Data indicate the
averages of seven experiments and error bars indicate the standard error of the mean.
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T cells expressing the βL98W TCR recognized the off-target tumors more than T cells
expressing the WT TCR with a frequency between 0.14 and 0.33. T cells expressing the
αD26Y/βL98W TCR recognized the off-target SKOV3, MDA 231, SW480, HEPG2,
SKGT5, and U251 tumors more than T cells expressing the WT TCR in every
experiment. Furthermore, T cells expressing the αD26Y/βL98W TCR recognized the offtarget A375, UOK131, and CAPAN 1 tumors with frequencies between 0.83 and 0.85. T
cells expressing the αD26Y/αY50A/βL98W TCR did not recognize the off-target
UOK131 or HEPG2 tumor more than T cells expressing the WT TCR in any experiment.
Moreover, T cells expressing the αD26Y/αY50A/βL98W TCR recognized the other offtarget tumors more than T cells expressing the WT TCR with frequencies between 0.14
and 0.71, with U251 yielding the highest frequency. Lastly, T cells expressing the
αD26Y/αY50V/βL98W TCR recognized the off-target tumors more than T cells
expressing the WT TCR with frequencies between 0.33 and 0.71. Overall, these results
coincided with the two patterns of off-target recognition we previously described in
Figure 40. Specifically, T cells expressing the αD26Y TCR and αD26Y/βL98W TCR
exhibited greater off-target tumor recognition in nearly all the experiments compared to
T cells expressing the WT TCR. T cells expressing the αD26Y/αY50V/βL98W TCR
frequently exhibited greater off-target tumor recognition compared to T cells expressing
the WT TCR. Lastly, T cells expressing the βL98W TCR and αD26Y/αY50A/βL98W
TCR sometimes exhibited greater off-target tumor recognition compared to T cells
expressing the WT TCR, but demonstrated the lowest frequencies amongst the mutant
DMF5 TCRs.
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Creating the previous index allowed us to examine the frequency at which T cells
expressing a given mutant DMF5 TCR exhibited greater recognition of an off-target
tumor than T cells expressing the WT TCR in a yes/no manner. While this provided
valuable conclusions based upon all the experiments and donors, it is important to also
note conclusions that were revealed based upon the magnitudes and patterns of offtarget tumor recognition. First, off-target recognition was not completely reproducible
among experiments. For example, in donor three, T cells expressing the αD26Y TCR
exhibited comparable recognition of SKOV3 (3, 128 pg/mL) and UOK131 (3,671 pg/mL)
in experiment one (Figure 55, in the appendix), but were 4.5 times more reactive
against UOK131 (17,469 pg/mL) than SKOV3 (3,854 pg/mL) in experiment two (Figure
56, in the appendix). Secondly, off-target recognition was donor dependent. For
example, T cells expressing the αD26Y/αY50V/βL98W exhibited similar levels of
recognition of the off-target U251 tumor compared to T cells expressing the WT TCR in
donor two (Figures 53-54, in the appendix) but increased recognition in donor four
(Figures 57-58, in the appendix). Thirdly, T cells expressing the WT DMF5 TCR
recognized at least one off-target tumor in every experiment. This occurred against
MDA 231 and CAPAN 1 (Figure 52, in the appendix), CAPAN 1 (Figure 53, in the
appendix), CAPAN 1 and SW480 (Figure 54, in the appendix), CAPAN 1 (Figure 55, in
the appendix), A375, SCOV 3, UOK131, CAPAN 1, MDA 231, and SW480 (Figure 56,
in the appendix), A375, SKOV3, CAPAN 1, and MDA 231 (Figure 57, in the appendix),
and A375, SKOV3, UOK131, CAPAN 1, MDA 231, SW480, HEPG2, SKGT5, and U251
(Figure 58, in the appendix). Specifically, T cells expressing the WT TCR recognized
the CAPAN 1 tumor in every experiment. Conclusively, all of these results suggested
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off-target tumor recognition was generally experiment and donor dependent. Despite
donor and experimental variability, a few overarching conclusions in regards to offtarget tumor recognition can be made. First, the observed cross-reactivity was HLA-A2
restricted. Secondly, T cells expressing the WT DMF5 TCR are cross-reactive. Thirdly,
T cells expressing the αD26Y TCR or αD26Y/βL98W TCR are highly cross-reactive
against all the tumors. T cells expressing the αD26Y/αY50V/βL98W TCR are frequently
cross-reactive against all the tumors. T cells expressing the βL98W TCR are mildly
cross-reactive against the tumors and sometimes this recognition is above the level of
recognition by T cells expressing the WT TCR. Lastly, T cells expressing the
αD26Y/αY50A/βL98W TCR are mildly cross-reactive against the tumors and sometimes
this recognition is above the level of recognition by T cells expressing the WT TCR or
βL98W TCR.
Impact of Mutant DMF5 TCRs on 2D Affinity
It was very interesting that the patterns of cross-reactivity against the HLA-A2+
tumors did not coincide with the DMF5 TCRs measured 3D affinity. More recently, it has
been demonstrated that 2D affinity measurements can better predict T cell functional
outcomes compared to 3D affinity measurements [162, 170, 172]. This is most likely
due to the fact that 2D affinity measurements account for aspects unique to membranebound proteins, where 3D affinity measurements are strictly dependent upon the
TCR/pMHC. We measured the 2D affinity of the WT DMF5 TCR and each of the mutant
DMF5 TCRs to determine if these measurements correlated to the observed patterns in
off-target tumor reactivity. To eliminate the variability associated with polyclonal PBLderived T cells, we utilized Jurkat E6.1 cells transduced with the WT DMF5 TCR or
each of the mutant DMF5 TCRs for this experiment. The 2D affinity measurements of
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the DMF5 TCRs with the MART-1 10mer peptide/HLA-A2 complex are shown in Figure
42. The observed patterns of cross-reactivity against the off-target tumor panel better
correlated with 2D affinity measurements. Specifically, T cells expressing the αD26Y
TCR or the αD26Y/βL98W TCR exhibited the highest 2D affinity, corresponding to their
high levels of cross-reactivity against the off-target tumors. Most notably, the
αD26Y/αY50A/βL98W TCR and αD26Y/αY50V/βL98W TCR revealed higher affinities
compared to the βL98W or WT TCR, which coincided with their enhanced crossreactivity against the off-target tumor lines. One explanation for the disconnect between
3D and 2D affinity measurements could be due to differences in TCR affinity when
using purified proteins or membrane-bound interactions. In conclusion, 2D affinity
measurements correlated better to the cross-reactivity observed against the off-target
tumor panel than the 3D affinity measurements.
Potential DMF5 TCR Targets in Off-Target Tumors
In was interesting that the patterns of recognition against the MART-1 homologs
and off-target tumors were not consistent amongst each of the different DMF5 TCRs.
Thus, we began to hypothesize what targets these TCRs were recognizing on the offtarget tumor cells. First, we knew that they recognized specific peptides, or a class of
peptides in the context of HLA-A2, because T2 cells loaded with negative control
peptides and some of the MART-1 homolog peptides revealed no detectable reactivity.
We refocused our attention on the human self-peptides, MART-1, human CD9, human
elongation factor 1α, G-protein coupled receptor 3, and human receptor expression
enhancing protein 5. We initially hypothesized it was possible that the T cells were
recognizing one or more of these proteins on the off-target tumor cells.
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Figure 42. Relative 2D Affinity of DMF5 TCRs. Adhesion frequencies of TCR
transduced Jurkat E6.1 cells were determined using a two-dimensional micropipette
adhesion frequency assay with TCR transduced Jurkat E6.1 cells expressing each
DMF5 TCR and MART-1 10mer/HLA-A2-coated RBCs. Relative 2D affinities were
calculated using the specific adhesion frequency (Pa) along with the surface pMHC (m l)
and TCRβ (mr) densities, as determined by flow cytometry. For each TCR, 50 Jurkat
E6.1 cell-RBC pairs were used to obtain Pa values from which the affinity was
calculated as: AcKa = −ln [1−Pa(1)]/mrml. The geometric mean of affinities and
normalized adhesion bonds are reported ± standard error of the mean. 2D affinity
measurements were completed in the Evavold lab.
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We utilized “The Human Protein Atlas” to determine if these proteins were expressed in
the tissues from which our off-target tumors were derived. Aside from MART-1
expression being limited to only melanocytes, the other four self-proteins were
expressed either at high, medium, or low levels in a majority of tissues throughout the
human body (Table 18). One caveat here is that we do not know the expression of the
proteins in our specific tumors. However, these results implicated there was a possibility
that some of these self-proteins could be expressed in the tumors. Since human CD9 is
expressed on the cell surface, we immunofluorescently labeled the tumors with an antiCD9 mAb to determine if CD9 was expressed on the tumor cells. We confirmed
expression of CD9 on all the tumor cell lines (Figure 43). Specifically, human CD9
expression on the tumors ranged between 44% and 100%. Human elongation factor 1α,
G-protein coupled receptor 3, and human receptor expression enhancing protein 5 are
not expressed on the surface and thus, could not be immunofluorescently labeled.
Other assays such as RT-PCR could confirm mRNA transcripts or western blot could
confirm protein expression. However, once we knew the off-target tumors were CD9+,
expression of one of more of the other three self-proteins would still not directly
elucidate what antigens were being recognized. Although it was that plausible that CD9
was being recognized on the off-target tumor cells by the DMF5 TCR transduced T
cells, we believed we had thorough evidence to suggest the cross-reactivity was due to
multiple different antigens, and was most likely DMF5 TCR dependent. Variability in the
recognition of the off-target tumors between DMF5 TCRs, donors, and experiments
indicated a few possibilities in regards to the antigens being recognized.
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Table 18. Levels of MART-1 and Self-MART-1 Homolog Protein Expression in
Normal Tissues. “X” indicates not expressed. These data were generated from The
Human Protein Atlas.
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Figure 43. Human CD9 Expression on Tumor Panel. 1x106 tumor cells were stained
for surface expression of HLA-A2 and CD9. (a) PG13 cells (murine leukemia cell line)
were used as a negative control. SAUJ tumor cells show an example of an HLA-A2CD9+ tumor line while A375 tumor cells (MART-1-) show an example of an HLAA2+CD9+ tumor line. (b) Summary of surface CD9 expression on tumor cell lines. Data
represent the averages of two independent experiments and error bars indicate the
standard error of the mean.
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The highly cross-reactive TCRs (αD26Y TCR and αD26Y/βL98W TCR) could be
eliciting low levels of cross-reactivity to numerous antigens being broadly recognized, or
could be eliciting high levels of cross-reactivity to one or a few antigens. Variability in
recognition of the different off-target tumors by even the same DMF5 TCR transduced T
cell population indicated is it unlikely the off-target tumors are processing and
presenting the same antigen or antigens. Furthermore, it is possible the DMF5 TCRs
are recognizing the same set of antigens on the off-target tumor cells, just at different
levels of magnitudes. Conversely, it is possible the DMF5 TCRs are each recognizing a
completely different spectrum of antigens. In summary, it is possible that human CD9
was recognized on the off-target tumor cells, but we believe this was not the sole
potentially recognized antigen.
We believed our data thus far indicated that T cells expressing each of the
mutated DMF5 TCRs were recognizing multiple different peptides on the off-target
tumors. Therefore, it was of interest to expand the number of targets, but also
categorize the targets we were examining in order to narrow down potential targets. We
elucidated potential targets by utilizing combinatorial peptide libraries in positional
scanning format [440, 441]. In combinatorial peptide libraries in positional scanning
format, each pool contains contain a mixture of peptides where one or more of the
peptide residues’ is fixed at a specific amino acid and the remaining peptide residues
include a mixture of amino acids. This method allowed us to examine reactivity against
millions of peptides and highlight favorable amino acids at specific sites in the peptide
for recognition. In this analysis we utilized TCR transduced Jurkat 76 cells to limit the
donor variability observed in polyclonal T cell populations. The Jurkat 76 cell line is TCR

α-β-
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and therefore, we eliminated off-target recognition due to TCR chain mispairing in

using this cell line. For this analysis, we compared Jurkat 76 cells expressing the WT
DMF5 TCR with Jurkat 76 cells expressing the highly cross-reactive αD26Y/βL98W
TCR, or Jurkat 76 cells expressing the unexpectedly, off-target tumor cross-reactive,
αD26Y/αY50A/βL98W TCR (Figure 44) [350]. Jurkat 76 cells expressing the WT DMF5
TCR exhibit recognition of nearly all the sub-libraries, supporting the notion that this WT
DMF5 TCR is inherently cross-reactive. Jurkat 76 cells expressing the αD26Y/βL98W
TCR exhibited enhanced recognition against the sub-libraries compared to the WT
DMF5 TCR expressing Jurkat 76 cells. Lastly, Jurkat 76 cells expressing the
αD26Y/αY50A/βL98W TCR exhibited a reduction in recognition against the sub-libraries
compared to the WT DMF5 TCR expressing Jurkat 76 cells. Overall, these data support
our conclusions based on the MART-1 homolog peptide data, where the αD26Y/βL98W
TCR enhanced cross-reactivity and the αD26Y/αY50A/βL98W TCR reduced crossreactivity compared to the WT TCR.
This approach of using a combinatorial peptide library, has been utilized to
identify recognition of an off-target, altered-peptide ligand of an antigen specific TCR
[442]. Albeit, in our model it would be difficult to identify important residues at specific
peptide positions for antigen recognition because recognition generally occurred across
all peptide pools with the WT TCR and αD26Y/βL98W TCR. However, the
αD26Y/αY50A/βL98W TCR largely reduced Jurkat 76 cell potency against the peptide
pools compared to the WT TCR and displayed a less permissive pattern of reactivity
against the peptide pools. One notable difference was observed in the recognition of the
peptide pool containing a fixed aspartic acid at position 5.
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Figure 44. Combinatorial Peptide Library Scans. Combinatorial peptide library scans
of WT (top), αD26Y/βL98W (middle), and αD26Y/αY50A/βL98W (bottom) TCRs. For
each experiment, TCR transduced Jurkat 76 cells were incubated with equal numbers
of T2 cells loaded with 152 sub-libraries where each position of the peptide (excluding
primary anchors) was fixed with each of the naturally occurring amino acids (excluding
cysteine). Reactivity was assessed by measuring IL-2 release in triplicate wells, as
indicated by the heat map scales on the right. Results are the average of three
independent experiments with each TCR. This experiment was completed in the Baker
lab [350].
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Reactivity was about doubled with cells expressing the αD26Y/αY50A/βL98W TCR
compared to Jurkat 76 cells expressing the WT DMF5 TCR. This suggested that despite
generally reducing overall cross-reactivity compared to the WT DMF5 TCR, there were
possibly a small number of peptides that elicited an increase in reactivity with Jurkat 76
cells expressing the αD26Y/αY50A/βL98W TCR. This idea would support our findings
as to why T cells expressing the αD26Y/αY50A/βL98W TCR were sometimes more
cross-reactive against the off-target tumors than T cells expressing the WT DMF5 TCR.
This pool (fixed aspartic acid at position 5) is also notable because it was demonstrated
that the WT DMF5 TCR also recognizes epitopes containing a “DRG” charged core
[404, 423]. In summary, the potential number of targets recognized on the tumor cells is
seemingly vast, however, recognition via the αD26Y/αY50A/βL98W TCR could be the
result of enhanced reactivity against a few targets compared to the WT TCR.
In summary, in collaboration with the Baker’s laboratory, we have developed a
novel structure guided approach to enhance antigen specificity and reduce crossreactivity. We generated five modified DMF5 TCRs and sought to determine how
structure-guided mutations in the DMF5 TCR altered tumor lysis, polyfunctional T cell
responses, cross-reactivity, antigen specificity, and recognition of processed antigens.
When measuring polyfunctional T cell responses against a panel of MART-1 homologs,
the structure guided approach appeared to be promising, with T cells expressing the
αD26Y/αY50A/βL98W TCR exhibiting reduced percentages of MART-1 homolog
reactive T cells compared to T cells expressing the WT TCR (Figure 20). Conversely,
when observing T cell responses against processed antigens on a variety of different
tissues, this trend did not remain consistent (Figure 40). Our results demonstrated that
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sequence homology is not the sole factor in cross-reactivity, and 3D affinity against the
“cognate” antigen is not always correlative to all-encompassing cross-reactivity.
Furthermore, T cell responses vary due to biophysical properties/kinetics of the
TCR/pMHC interaction and the polyclonal PBL-derived T cell population. Our structurebased designed strategy could be utilized in the future, as it is more meticulous and
specific than random mutation through yeast or phage display. Specifically, we also
elucidated the critical role of the MHC weakening TCR mutation and how it could
potentially be translatable to other TCRs. Overall, it is important to understand how
alterations in the TCR/pMHC interface can affect functional T cell phenotypes to
maximize the efficacy and safety of TCRs to be used in gene modified T cells in
adoptive cell transfer.
Second Round of DMF5 TCR Mutations
The goal of designing the first round of DMF5 mutations (DMF5 TCRs described
thus far) was to determine which TCR mutations enhanced MART-1 specificity while
reducing off-target cross-reactivity. Our objective was to take the information we learned
from the first generation of mutant DMF5 TCRs and subsequently optimize the results
through the generation of a second round of mutant DMF5 TCRs. Based on information
elucidated from the functional results, the Baker lab subsequently designed a second
round of DMF5 TCRs. In αD26Y/αY50A/βL98W TCR expressing CD8+ T cells, a
reduction in the percentage of MART-1 homolog reactive T cells was observed
compared to T cells expressing the WT TCR, but a reduction in MART-1 potency was
also observed. The objective with this next round of DMF5 TCRs was to better maintain
MART-1 potency while also maintaining a reduction in cross-reactivity compared to the
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WT TCR, similar to the level observed with the αD26Y/αY50A/βL98W TCR against the
MART-1 homologs. Our results indicated the αY50 residue was critical for antigen
recognition. Specifically, the alanine mutation was more effective than the valine
mutation at reducing MART-1 reactivity and cross-reactivity. In collaboration with the
Baker lab, we hypothesized the αY50 residue was too close to the MART-1 peptide
(about 5 Ä away). Therefore, the mutation of a tyrosine to an alanine at position 50 in
the TCR alpha chain weakened bonds with the MHC, but also likely weakened bonds
with the MART-1 peptide. Specifically, it is possible that the αY50A TCR mutation may
not be solely “MHC binding” specific. This could be an explanation for the reduction
observed in MART-1 specific reactivity. Thus, we wanted to examine other TCR
mutations at different TCR/MHC binding residues that might not interfere with MART1/TCR binding interactions. The Baker lab identified four residues in the DMF5 TCR that
interacted with HLA-A2, but were more than 10 Ä away from the MART-1 peptide.
These residues included αN52, αK68, βN52, and βT57 [443]. Each residue was
mutated to an alanine because the alanine mutation in the αY50 mutations was more
effective than the valine mutation. Four DMF5 TCRs were made:
αD26Y/αN52A/βL98W, αD26Y/βN52A/βL98W, αD26Y/αK68A/βL98W, and
αD26Y/βT57A/βL98W. Each new negative mutation replaced the previous αY50
mutation. The second round of DMF5 TCRs was further used in functional T cell
assays.
The objective was to determine how this second round of DMF5 mutations
altered MART-1 and MART-1 homolog reactivity compared to the WT TCR. However,
findings from the first round of DMF5 TCR mutations demonstrated unexpected off-
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target tumor cross-reactivity that did not correlate with recognition of the MART-1
homologs. Thus, we believed we should first examine recognition of our tumor panel
before examining polyfunctional T cell responses. Our preliminary experiment in one
donor is shown in Figure 59, in the appendix. T cells expressing the WT DMF5 TCR are
cross-reactive against HLA-A2+ tumors as previously observed. We next determined
how T cells expressing the newly designed mutant DMF5 TCRs altered the recognition
of the off-target tumors compared to the WT TCR. T cells expressing each mutant
DMF5 TCR exhibited more cross-reactivity against all the HLA-A2+ tumors compared to
T cells expressing the WT TCR. The αD26Y/αN52A/βL98W, αD26Y/βN52A/βL98W, and
αD26Y/βT57A/βL98W TCR expressing T cells were more reactive against MEL 624
compared to T cells expressing the WT TCR, but were extremely more cross-reactive.
Our previous findings indicated the presence of the αD26Y mutation in a mutant TCR
enhanced cross-reactivity against the off-target tumors amongst all the DMF5 TCRs. It
is possible that same phenomenon is occurring with these TCR mutations as well.
These mutant DMF5 TCRs appear to be extremely cross reactive compared to the WT
TCR, whereas the αD26Y/αY50A/βL98W TCR was mildly cross-reactive compared to
the WT TCR. This indicated it was possible that the proximity of the αY50A mutation
with the peptide was important to counterbalance the effects of the αD26Y mutation.
Thus, these new negative mutations do not counterbalance the effect of the αD26Y
mutation as efficiently. Overall, these results indicate this second round of TCR
mutations did not reduce the cross-reactivity of the WT TCR.
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In vivo Model
All of the experiments thus far have examined antigen specificity and crossreactivity in vitro. It was important to next determine if these results were reproducible in
vivo. However, in vitro findings do not always translate in vivo [444]. Therefore, we
wanted to determine if the first round of DMF5 mutations could have anti-tumor activity
in a murine model. Namely, we wanted to determine if the high affinity (3D) TCRs
(αD26Y and αD26Y/βL98W) could control tumor growth better than the WT TCR and if
the low affinity (3D) TCR (αD26Y/αY50A/βL98W) could control tumor growth. We chose
to use a NSG A2+ mouse model for multiple reasons. First, an immunodeficient host
allowed us to use a xenograft model. This was beneficial for examining the efficiency of
human TCR transduced T cells against a human tumor in vivo [384, 445]. Furthermore,
HLA-A2+ mice allowed us to examine any signs of autoimmunity due to the introduction
of the TCR transduced T cells. Mice do not share complete homology with humans,
however, three of the four self-MART-1 homologs in the peptide panel (CD9, elongation
factor 1α, and receptor expression enhancing protein 5) are completely homologous in
the mouse. In summary, we believed the NSG A2+ mice were an advantageous model
to use to examine the anti-tumor efficacy of TCR transduced T cells and observe
potential autoimmunity.
Despite the advantages of the xenograft model, there are a few drawbacks. First,
due to the lack of a host immune system, there is no cytokine or chemokine support to
assist in T cell function, persistence, and trafficking to the tumor [446-448]. Furthermore,
in our hands and in other studies, human T cells expressing the DMF5 TCR fail to
control tumor growth in NSG mice [449]. Therefore, we explored additional mechanisms
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to support the persistence, function and trafficking of the introduced TCR transduced T
cells. Herein, those mechanisms included prior PBMC engraftment, cytokine support,
and checkpoint blockade.
The immunodeficiency of NSG mice is advantageous for xenograft models but
disadvantageous for the support of the introduced human T cells. To overcome this,
previous studies have generated humanized NSG mice in order to reconstitute a human
immune system in the mice and support introduced T cells [450]. Thus, xenografts could
be examined in the presence of a human immune system. This has been commonly
done by engrafting human bone marrow-derived or umbilical cord blood-derived CD34+
hematopoietic stem cells into the mice [450-453]. We believed we could recapitulate this
via the engraftment of human PBMCs. We first determined if human PBMCs could
persist weeks after engraftment and determined if intraperitoneal or retro-orbital route of
injection affected engraftment (Figure 60, in the appendix). These results indicated
human CD3+ T cells could be detected in the blood of mice 72 days post engraftment.
Furthermore, retro-orbital route of injection persisted better than the intraperitoneal
route of injection, meaning the intravenous route of injection was superior for
engraftment. Consistent with previous studies, mice demonstrated signs of GVHD
around nine weeks post engraftment, indicating xeno-cross-reactivity occurred. In
summary, these results indicated human T cells can persist 72 days post engraftment in
the NSG A2+ mice.
We confirmed engrafted human T cells could persist in the blood of NSG A2+
mice and retro-orbital route of injection was superior to intraperitoneal route of injection
(Figure 60, in the appendix). We next determined if the engrafted T cells could support
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the persistence and function of the introduced TCR transduced T cells. Mice were
engrafted with human PBMC 7 days prior to MEL 624 tumor challenge (Figure 61, in the
appendix). Mice were treated with TCR transduced T cells 17 days post tumor
challenge. For this pilot experiment, we only used T cells transduced with either the WT
TCR, the αD26Y TCR, or the αD26Y/αY50A/βL98W TCR. These results indicated that
the engraftment prior to tumor challenge did not affect the anti-tumor activity of the TCR
transduced T cells, as there were no differences between treated and untreated mice.
Additionally, no signs of autoimmunity were observed in these mice throughout the
duration of this experiment. This indicated that the introduced T cells did not elicit offtumor off-target damage that could be observed. To determine if engraftment supported
the introduced T cells, we monitored the persistence of the TCR transduced T cells post
injection. It was interesting that on day 13, no CD34+ T cells were found in the blood of
treated mice, despite 66-76% CD34 expression amongst the TCR transduced T cell
groups prior to injection (Figure 62, in the appendix). Specifically, in one mouse, only
0.57% of cells in blood were CD3+CD34+. There was a large population of human CD3+
T cells in the blood, however, we are unable to distinguish engrafted T cells from T cells
that have lost the CD34 transgene expression. Transgene expression has been shown
to decrease over time in vivo but it has been shown that cytokines can help maintain
transgene expression [275, 454]. Because the TCR transduced T cells are cultured ex
vivo in IL-2 and IL-15, then enter the in vivo environment with no cytokine support, we
hypothesized additional cytokine support would enhance the transgene expression and
T cell function.
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IL-2 and IL-15 are important for T cell activation, proliferation, and function [455460]. Furthermore, IL-2 and IL-15 have been shown to promote long-term survival and
function of adoptively transferred T cells in vivo [461-466]. We therefore determined if
IL-2 or IL-15 support would enhance the anti-tumor activity of TCR transduced T cells in
vivo (Figure 63, in the appendix). In this pilot experiment, we compared T cells
expressing the WT DMF5 TCR with untransduced T cells, with or without IL-2 or IL-15
cytokine support. There were no differences between treatments with untransduced and
WT TCR transduced T cells, with or without cytokine support. These results indicated
that cytokine support did not enhance the anti-tumor activity of the TCR transduced T
cells. Furthermore, on day 10 post therapy, there were no differences in the
percentages of CD3+CD34+ human T cells in the blood of mice treated with IL-2 or IL-15
(Figure 64, in the appendix). One mouse treated with WT TCR transduced T cells
actually exhibited 1.88% CD3+CD34+ human T cells in the blood compared to 0.39%
and 0.49% of IL-2 and IL-15 treated mice, respectively. These results indicated that
cytokine support did not enhance transgene expression in vivo. One explanation for this
could be that the TCR transduced T cells did not traffic to the tumor. To examine this,
on day 16 post treatment, we determined if there were TCR transduced T cells in the
tumor (Figure 65, in the appendix). Compared to untransduced T cells, there were no
CD3+CD34+ T cells found in the tumors of mice treated with DMF5 WT TCR transduced
T cells with or without IL-2 and IL-15. These results indicated that cytokine support did
not enhance the trafficking of TCR transduced T cells to the tumor or the survival of
TCR transduced T cell in the tumor. On day 16, we also determined if the TCR
transduced T cells had homed and remained in the spleen (Figure 66, in the appendix).

No human

CD3+

or human

CD3+CD34+
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T cells were found in the spleens of mice from

each treatment group. Conclusively, our results suggested the introduced TCR
transduced T cells were unable to survive in vivo despite IL-2 or IL-15 cytokine support.
Our results thus far have demonstrated that engraftment of human T cells prior to
treatment or cytokine support did not enhance the anti-tumor efficacy, persistence, or
trafficking of TCR transduced T cells in vivo. The TCR transduced T cells underwent ex
vivo activation for up to three weeks prior to injection in vivo and thus, exhaustion could
be limiting their effector function in vivo [467-469]. Therefore, we determined if anti-PD1 treatment with adoptively TCR transduced T cells could enhance their anti-tumor
efficacy [470, 471]. In this experiment, we compared the anti-tumor efficacy of
untransduced or WT DMF5 TCR transduced T cells with or without anti-PD-1 (Figure
67, in the appendix). These results indicated that treatment with anti-PD-1 did not
enhance the anti-tumor efficacy of WT DMF5 TCR transduced T cells, as they did not
control tumor growth better than no treatment or untransduced T cells. In summary,
anti-PD-1 treatment did not enhance the anti-tumor efficacy of DMF5 TCR transduced T
cells in vivo.
Our in vivo data thus far suggested that TCR transduced T cells did not control
MEL 624 tumor growth and were not found in the tumor after treatment. Furthermore,
anti-PD-1 treatment did not affect the anti-tumor efficacy of the TCR transduced T cells,
indicating that PD-1 dependent exhaustion was most likely not the sole reason.
Conclusively, these results suggested loss of transgene expression and inability to
traffic to the tumor potentially limited the TCR transduced T cells anti-tumor efficacy. To
determine if inability of trafficking to the tumor was contributing to this, we performed an
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in vivo cytotoxic T lymphocyte (CTL) assay [472]. This assay allowed us to determine if
TCR transduced T cells could kill MART+ target cells in vivo without needing to traffic to
the site of a tumor. A schematic of this assay is depicted in Figure 68, in the appendix. If
DMF5 TCR transduced T cells killed MART-1 9mer pulsed PBMCs in vivo, we would
expect to see an increase in the proportion of CFSE low (PBMCs) cells because the
CFSE high cells (MART-1 9mer pulsed PBMCs) were killed. An example of the
proportion of CFSE high and CFSE low cells from the spleen two days after injection is
shown in Figure 69, in the appendix. In PBS treated mice, the proportion of CFSE high
to CFSE lows cells remains even, at 7.04% high and 6.83% low, indicating no specific
lysis occurred. In mice treated with WT DMF5 TCR transduced T cells, the proportion of
CFSE high to CFSE low cells is skewed, at 11.8% low and 6.49% high. These results
indicated that MART-1 9mer pulsed PBMCs (CFSE high) were killed. The % MART-1
lysis is shown in Figure 70, in the appendix. These results indicated that WT DMF5 TCR
transduced T cells killed about 41% of the MART+ target cells, compared to 5% with
PBS treatment. These results suggested WT DMF5 TCR transduced T cells can kill
MART+ targets in vivo. Since these T cells did not have to traffic to encounter these
MART+ target cells in vivo, it is plausible that we previously did not observe anti-tumor
activity of the TCR transduced T cells due to their inability to traffic to the site of the
tumor or suppressive mechanisms in the tumor microenvironment.

CHAPTER FOUR
DISCUSSION
Introduction
The use of TCR gene-modified T cells for adoptive T cell transfer is an evolving
and promising form of immunotherapy. However, the use of TCRs that target selfantigens involve the caveat of bearing a low affinity for the targeted antigen. TCR affinity
enhancement via methods such as yeast or phage display have been utilized to
enhance anti-tumor efficacy of TCR transduced T cells, but have resulted in patient
fatalities [5, 6, 298, 299]. Therefore, reducing potential off-target cross-reactivity while
maintaining or enhancing the anti-tumor activity of TCR gene-modified T cells is of
upmost importance for both safety and efficacy. Herein, we developed a novel structureguided approach designed to fine-tune the antigen specificities of the DMF5 TCR.
Numerous factors can impact the functional response of T cells. These factors include
structural components in the TCR/pMHC interface, kinetic factors, and cellular factors.
In this dissertation we focused on how these factors influence the on-target and offtarget responses of T cells engineered to express the WT or mutated DMF5 TCRs.
Furthermore, our findings emphasize the importance of rigorous preclinical testing of
modified TCRs and the need for advancement in modeling/prediction tools for protein
interactions. Overall, this is important in order to better design TCRs that will be safe
and more efficient in patients.
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How DMF5 Mutations Affect Recognition of MART-1 Homologs
Correlation to Alanine Scan
The alanine scan method was utilized to determine that Titin was the target of the
affinity enhanced MAGE-A3 TCR, causing lethal adverse events. Two sets of alanine
substituted or glycine substituted peptide panels elucidated critical residues for
recognition of MAGE-A3 by T cells expressing the affinity enhanced TCR. Searches for
protein sequences with epitope homology resulted in three clinically relevant potential
targets aside from MAGE: one was Titin, two were pathogenic [299]. Overall, this
method was suitable for predicting a critical cross-reactive peptide with this modified
TCR, and if completed prior to therapeutic treatments, the authors could have identified
the target that led to lethal adverse events.
We utilized a panel of MART-1 nonameric alanine substituted peptides to
determine how mutations in the DMF5 TCR affected recognition of a structurally altered
MART-1 peptide. The alanine scan method can be a suitable method for making a
general prediction about the importance of an individual residue in the peptide for
recognition, and furthermore, it was an adequate tool for predicting the lethal off-target
peptide in the MAGE-A3 clinical trial. However, our results indicated that this method is
not always an adequate predictor for potential off-target, altered-peptide ligand
reactivity. Since the alanine scan data were generated in TCR transduced CD8- Jurkat
E6.1 cells, the results must be compared with the reactivity of TCR transduced CD4+ T
cells. Specifically, the alanine scan demonstrated the importance of positions 4 and 6 in
the MART-1 9mer peptide for recognition by αD26Y TCR expressing cells. However,
αD26Y TCR expressing CD4+ T cells recognized all of the seven MART-1 homologs
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that did not display sequence homology with the MART-1 9mer peptide at position 4
and/or position 6. The alanine scan is a low throughput screen that only allows for
determination of a residue’s importance for TCR recognition when mutated to an
alanine, and when mutated individually. Therefore, this method lacks the ability to
account for the effects of non-alanine mutations in the peptide and the effects of
multiple mutations in the peptide.
It has been shown that the conformational adaptability of TCRs is important for
the ability to recognize multiple different ligands [473, 474]. As a result, recognition of a
peptide is more dependent upon the net effect of all the individual residues and the
TCR’s ability to conform to that pMHC structure. For instance, one amino acid
substitution could result in an unfavorable interaction with the TCR, but another amino
acid substitution elsewhere, in the same peptide, could result in a favorable interaction
with the TCR. Therefore, different interactions between the peptide and the MHC and
between the peptide and the TCR can offset each other differently. These interactions
will be both ligand and TCR dependent. In summary, recognition of the alanine
substituted MART-1 peptides did not entirely predict recognition of different MART-1
homologs because each amino acid in a given peptide will contribute differently to
binding in the MHC and to binding with the TCR to subsequently affect T cell activation
and T cell function.
Correlation to Structure
Our results indicated that the structural effects of the introduced DMF5 TCR
mutations did not always correlate to the predicted recognition of MART-1 homologs.
The αD26Y TCR mutation was designed to enhance charge complementarity with the
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N-terminal region of the MART-1 peptide, as previously described in Chapter Three
[350, 351]. However, this TCR mutation also eliminated charge repulsion with a
negatively charged glutamic acid in the HLA-A2 α1 helix [349]. This illustrates the
difficulty associated with identifying TCR residues that will only impact binding with the
peptide when mutated to a different amino acid. With the αD26Y TCR mutation, it is not
easy to distinguish the influence of the favorable HLA-A2 binding interaction with the
influence of the favorable peptide binding interaction. It is plausible that both factors
were contributing to the enhanced cross-reactivity.
Our data suggested that the tyrosine mutation at position 26 in the TCR alpha
chain non-specifically enhanced recognition of the MART-1 homologs. We will again
focus on the CD4+ T cells for this part of the discussion because the structure-guided
mutations were designed in the absence of CD8. Although not statistically significant,
the percentages of MART-1 9mer and 10mer reactive T cells was modestly enhanced
with T cells expressing the αD26Y TCR vs. the WT TCR, as predicted (Figure 19). The
percent reactive CD4+ T cells was enhanced against every MART-1 homolog (reaching
statistical significance in two) in αD26Y expressing T cells compared WT expressing T
cells (Figure 19). The replacement of a charged aspartic acid with a bulky and
amphipathic tyrosine enhances surface area and allows for increased involvement in
van der Waals forces [395]. Therefore, the αD26Y TCR mutation seemingly enhanced
non-specific binding to nonpolar, hydrophobic residues at position 2 in the 9mer
peptides. In the MART-1 homologs, all residues at position two are a hydrophobic
amino acid, except for in one MART-1 homolog. In ADP-ribose diphosphatase there is a
charged aspartic acid at position two. ADP-ribose diphosphatase was minimally
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recognized by T cells expressing the WT TCR (1.67%) but there was a stark increase in
the percentage of αD26Y TCR expressing reactive T cells (16.47%). This result was
most likely due to the elimination of the charge repulsion between the negatively
charged aspartic acids associated with the WT DMF5 TCR and ADP-ribose
diphosphatase by the tyrosine TCR alpha chain mutation. There is no clear importance
or ranking of preferred hydrophobic residues at position two in the peptide with the
αD26Y TCR. This suggested that the tyrosine mutation enhanced non-specific binding.
Overall, the αD26Y TCR mutation resulted in non-specific cross-reactivity with all the
MART-1 homologs, indicating its lack of specificity for the MART-1 peptide.
The second MART-1 targeting TCR mutation, βL98W, was designed to enhance
shape complementarity with the leucine at position 7 in the MART-1 9mer peptide, as
previously described in Chapter Three [350, 351]. Although not statistically significant,
the percentages of MART-1 9mer and 10mer reactive CD4+ T cells was modestly
enhanced with T cells expressing the βL98W TCR vs. the WT TCR, as predicted
(Figure 19). There were only minor increases observed (averaging between 0.64% and
4.3%) in the percentages of MART-1 homolog reactive CD4+ T cells between the WT
TCR and βL98W TCR, with none reaching statistical significance (Figure 19). Although
the βL98W TCR mutation enhanced binding to the MART-1 9mer via the leucine at
position 7, increased percentages of reactive βL98W TCR expressing CD4+ T cells
were only notable against one out of the four MART-1 homologs that contained a
leucine at position 7, ADP-ribose diphosphatase (5.9% vs. 1.6%) (Figure 19). This could
also be due to the valine N-terminal anchor in this peptide, as valines are superior HLAA2 anchors [404]. Like tyrosine, tryptophan is also commonly used to enhance binding
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due to their rigid, bulky, and amphipathic nature [72]. Position 7 in other MART-1
homologs is generally also very hydrophobic, and thus the tryptophan mutation
seemingly remains unable to discern differences between the hydrophobic residues.
There is also no pattern in preference for specific residues at position 7 in the peptide
with the βL98W TCR. In conclusion, the tryptophan TCR mutation at position in 98 in
the TCR beta chain was not entirely specific for the MART-1 peptide, but was more
specific than the αD26Y TCR mutation.
The field generally considers high affinity TCRs are optimal for T cell function and
therapeutic efficacy [180, 396]. However, our results did not entirely correlate with this
assumption when combining the αD26Y TCR and βL98W TCR mutations. The
correlation with affinity will be discussed in the next section. CD4+ T cells expressing the
αD26Y/βL98W TCR starkly reduced the percentage of MART-1 9mer and 10mer
reactive T cells compared to T cells expressing the WT TCR (Figure 19). This results
indicated that the combination of the two MART-1 targeting mutations was not additive,
although affinity is dramatically increased. T cells expressing the αD26Y/βL98W TCR
exhibited in a trend towards an increase in the percentages of MART-1 homolog
reactive T cells compared to T cells expressing the WT TCR, with statistical significance
reached with two MART-1 homologs (Figure 19). We would have expected to see more
considerable differences in the recognition of the MART-1 homologs, based upon the
recognition of the MART-1 homologs by T cells expressing the αD26Y TCR. Therefore,
these results were most likely due to the supraphysiological high affinity of the
αD26Y/βL98W TCR. This will be discussed in the next section. Consequently, it is
difficult to accurately determine the structural effects of the αD26Y/βL98W TCR on
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recognition of MART-1 and the MART-1 homologs since the affinity of this TCR most
likely affected T cell function. Overall, the combination of the αD26Y TCR mutation and
the βL98W TCR mutation in the αD26Y/βL98W TCR did not enhance MART-1
specificity.
Our positive and negative design strategy hypothesized that introduction of a
TCR mutation that weakened TCR binding with the MHC would reduce off-target crossreactivity. As predicted, the addition of the αY50A mutation to the αD26Y/βL98W TCR
reduced the percentages of MART-1 homolog CD4+ reactive αD26Y/αY50A/βL98W
TCR expressing T cells compared to αD26Y/βL98W TCR expressing T cells (Figure
19). However, compared to the T cells expressing the WT TCR, the percentages of
MART-1 9mer and 10mer CD4+ reactive αD26Y/αY50A/βL98W TCR expressing T cells
was significantly reduced (Figure 19). These results indicated that even though MART-1
homolog recognition was comparable, MART-1 specific reactivity was reduced.
However, these results were different with the introduction of a different MHC
weakening TCR mutation, αY50V. T cells expressing the αD26Y/αY50V/βL98W TCR
exhibited comparable percentages of MART-1 9mer and 10mer reactive CD4+ T cells
compared to T cells expressing the WT TCR (Figure 19). Also, there were no significant
changes in the percentages of MART-1 homolog reactive T cells, however, minor
increases were observed. These results indicated the introduction of a valine mutation
at position 50 in the TCR alpha chain could offset the effects of the αD26Y/βL98W TCR
and restore MART-1 reactivity to similar levels observed with the WT TCR. These
results also indicated the importance of eliminating contact with positions 154, 155, and
158 in the HLA-A2 with the alanine mutation, to result in reduced T cell reactivity
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compared to the WT TCR levels. Overall, these results demonstrated the combination
of the MHC weakening TCR mutations with peptide binding TCR mutations could alter
on-target and off-target antigen recognition.
The effects of these structure-guided TCR mutations are generally described in a
very linear fashion, based on their impact on the MART-1 decamer/HLA-A2 complex.
However, the TCR/pMHC interaction includes only a small subset of all the membranebound proteins on a T cell and the APC. Thus, this interaction is very dynamic and fluid
complex. It is clear from our data that structural predictions based on this complex, do
not always directly correlate with recognition of altered-peptide ligands and crossreactive peptides. This is likely due to multiple factors involved in the TCR/pMHC
interaction. For example, it has been shown that anchor residues can alter TCR binding
and specificity [475-478]. Therefore, it is possible that a peptide with little core sequence
homology but an optimal anchor residue could impact TCR binding and recognition
differently than a peptide with more core sequence homology but a suboptimal anchor
residue. Specifically, it has been demonstrated that different anchor modifications of the
MART-1 9mer and 10mer peptides elicited different cytokine responses [479]. Also, as
already mentioned above, multiple favorable and non-favorable interactions within the
TCR/pMHC complex will affect binding and subsequent signaling. These interactions
will be different with each TCR and each ligand. Overall, these results emphasized the
idea that the net effect of individual interactions within the TCR/pMHC complex dictates
binding and peptide recognition.

225
Correlation to 3D Affinity
The structure-guided DMF5 TCR mutations altered the binding affinity compared
to the WT DMF5 TCR. The DMF5 TCR 3D affinity measurements generally correlated
to the percentages of reactive CD4+ T cells against MART-1 and the MART-1
homologs. One exception is the comparable percentages of reactive T cells between
the WT TCR and αD26Y/αY50V/βL98W TCRs despite the αD26Y/αY50V/βL98W
harboring a much lower affinity. Albeit, this result coincided with our goal in that using
this strategy was not necessarily to enhance TCR affinity, but rather to redistribute the
TCR’s free binding energy. Moreover, these results begin to elucidate the limitations
associated with using the 3D affinity measurement against the target antigen as a
predictor for cross-reactivity against altered-peptide ligands. For example, 4.9% of CD4+
T cells expressing the αD26Y/αY50V/βL98W recognized the MART-1 homolog, HREEP
5, whereas only 2.5% of T cells expressing the βL98W TCR recognized HREEP5. Their
3D affinities with the MART-1 9mer are 140 μM and 12 μM, respectively. Despite the
decrease in 3D affinity against the MART-1 9mer, the structural interaction between the
αD26Y/αY50V/βL98W TCR and the HREEP 5/HLA-A2 complex elicited a better T cell
response than with the βL98W TCR. The 3D affinity measurement is based upon the
net interaction between the TCR/pMHC. However, it is possible that strongly enhanced
binding, or strong favorable interactions at certain TCR/pMHC residues can heavily
influence a T cell response, despite the presence of unfavorable interactions at other
TCR/pMHC residues. Specifically, the net interactions will influence 3D affinity, but
interactions at different TCR/pMHC residues could differentially influence
conformational changes within the TCR/CD3 complex and subsequent signaling and T

226
cell function. In summary, the 3D affinity measured with the targeted ligand can
correlate to functional outcomes with the targeted ligand and with altered-peptide
ligands, but as demonstrated here, that is not always the case.
The field generally considers high affinity TCRs are optimal for T cell function and
therapeutic efficacy. However, more recently it has been demonstrated when TCR
affinity is too high, reduced T cell function is observed [146, 480-483]. This was
exhibited in T cells expressing the αD26Y/βL98W TCR, as high TCR 3D affinity does
not always yield enhanced T cell function. The lack of rational correlation between 3D
affinity and T cell function in T cells expressing the αD26Y/βL98W TCR can be
attributed to its supraphysiological high affinity. It has been demonstrated when a TCR’s
3D affinity approaches 5 - 1 μM, a decline in TCR signaling, in expression of activating
and co-stimulatory molecules, and in T cell function is observed [146, 480-483]. SHP-1
negatively regulates TCR signaling and has been shown to be upregulated in an affinitydependent manner [419, 484]. The highest levels of SHP-1 have been observed in T
cells with supraphysiological TCR affinities [419]. Therefore, it would be of interest to
determine the levels of SHP-1 in T cells expressing the αD26Y/βL98W TCR in response
to MART-1 and the MART-1 homologs compared to T cells expressing the other DMF5
TCRs. Additionally, prolonged half-lives of TCRs have also been associated with a
decrease in T cell function [485-488]. Serial triggering is important for full T cell
activation and can be limited by prolonged half-lives [147]. It has also been shown that
dissociation rates better correlate to T cell potency than TCR affinity [489-491]. Kon and
Koff rates of the αD26Y/βL98W TCR could help elucidate some of the kinetic factors
attributing to the observed decline in on-target T cell function. Additionally, we might
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expect stark enhancements in the percentages of MART-1 homolog reactive
αD26Y/βL98W TCR expressing T cells compared to the αD26Y TCR if we used 3D
affinity as a predictor. Lastly, the 3D affinity measured with the αD26Y/βL98W TCR and
the MART-1 decamer/HLA-A2 was in the nM affinity range. Therefore, MART-1
homologs harboring a superior anchor residue or other favorable interactions could
again, result in an attenuated T cell responses with a high affinity TCR. In conclusion,
these results suggested the supraphysiological 3D affinity of the αD26Y/βL98W TCR
attenuated its on-target, and possibly off-target T cell potency in αD26Y/βL98W TCR
expressing T cells.
It is well appreciated that higher affinity TCRs can be more cross-reactive [179,
483]. High affinity TCRs can tolerate significant changes in the peptide and still induce T
cell activation, whereas these peptide changes with a lower affinity TCR could result in
the loss of T cell activation [148]. This was exemplified in the MAGE-A3/Titin story. The
affinity enhanced MAGE-A3 TCR recognized MAGE-A3 and Titin very similarly despite
differences in the peptide core sequences [298]. This was also exemplified in our
hands, with the αD26Y/βL98W DMF5 TCR. The αD26Y/βL98W TCR modeled with the
MART-1 9mer peptide, HSV-1 glycoprotein III peptide, and M. tuberculosis protein I
peptide indicated no substantial changes to the TCR CDR loops and side chains in the
three different models [350]. The HSV-1 glycoprotein III peptide differs from the MART-1
9mer peptide in three residues and the M. tuberculosis protein I peptide differs from the
MART-1 9mer peptide in seven residues, even in the peptide core. This demonstrated
how the high affinity TCR accommodates structural differences in the peptide. In
summary, 3D affinity can generally predict overarching patterns of antigen specificity

and cross-reactivity in

CD4+
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T cells, however, this is not always the case, and is TCR

and ligand-dependent.
Contribution of CD4 and CD8
Another factor that affects antigen specificity and cross-reactivity is the CD4 and
CD8 co-receptors. Our data indicated the presence of the CD8 co-receptor increased
the percentage of cross-reactive T cells compared to CD4+ T cells (Figures 19-20). This
is not surprising due to the functional role of CD8 [92], and previous studies describing
CD8’s role in cross-reactivity [148, 368]. CD8 stabilizes the TCR/pMHC interaction and
furthermore, has the ability to influence Kon and Koff rates [421, 422, 492-494].
Specifically, CD8 has been shown to strengthen binding of TCR/pMHC by 3- to 4-fold
[422, 494, 495]. Therefore, stabilization of low affinity interactions via CD8, with the aid
in Lck recruitment, could induce T cell activation and T cell responses. This was
apparent in the enhanced percentages of MART-1 homolog reactive WT TCR
expressing CD8+ T cells compared to the CD4+ T cells. However, the specific role of
CD8 becomes more complex within different TCR and ligand interactions. For example,
CD8’s role in both TCR/pMHC stabilization and Lck localization have been implicated
important for T cell function in lower affinity interactions, whereas only the role in Lck
localization was important for T cell function in higher affinity interactions [439, 496].
Furthermore, we did not observe notable differences in the percentages of MART-1 and
MART-1 homolog reactive CD4+ and CD8+ T cells expressing the high affinity
αD26Y/βL98W TCR. There are two plausible explanations for this result. First, CD8
stabilization of a high affinity interaction could prolong the dissociation rate and reduce
serial triggering, resulting in reduced T cell function or partial activation. Secondly, a
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high affinity TCR, 17 μM, previously demonstrated comparable T cell function with and
without the CD8 co-receptor [439]. Thus, implicating in a high affinity interaction, CD8
does not affect T cell function. However, the 3D affinity measurement of the βL98W
TCR with the MART-1 9mer was 12 μM and exhibited notable differences between the
percentages of MART-1 9mer CD4+ (25.9%) and CD8+ (41.9%) reactive T cells. This
suggests the specific role of CD8 is TCR and ligand dependent.
The effect of the MART-1 targeting TCR mutations, αD26Y and βL98W, on
MART-1 recognition was also different in CD4+ and CD8+ T cells. Although not
significant, T cells expressing the αD26Y TCR and βL98W TCR did enhance the
percentages of MART-1 reactive T cells in CD4+ T cells compared to T cells expressing
the WT TCR but not in CD8+ T cells. These results indicated that the effect of the
binding enhancement on MART-1 due to these TCR mutations was potentially
overshadowed in the presence of the CD8 co-receptor. These results indicated that this
structure-guided mutation strategy could have different implications in CD4 + and CD8+ T
cells. For example, the positive and negative design worked in CD8+ T cells for reducing
cross-reactivity, as T cells expressing the αD26Y/αY50A/βL98W exhibited a reduction in
the percentage of MART-1 homolog reactive T cells compared to T cells expressing the
WT TCR. However, WT TCR expressing T cells were barely reactive against the MART1 homologs in the CD4+ T cells. Furthermore, MART-1 potency was significantly
reduced in αD26Y/αY50A/βL98W TCR expressing CD4+ T cells compared to with the
WT TCR. Therefore, the positive and negative design could be more important for
reducing cross-reactivity in CD8+ T cells. Alternatively, although not significant, CD4+ T
cells expressing the βL98W TCR enhanced the percentage of MART-1 reactive T cells
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compared to the WT TCR, with some minor increases in the percentages MART-1
homolog reactive T cells. This enhanced percentage of MART-1 reactive T cells was not
observed in the CD8+ T cells between the two TCRs. These results suggest that in
CD4+ T cells, positive design could be more important in enhancing on-target potency,
but most importantly, if the introduced TCR mutations do not, or very minimally, affect
off-target recognition. In summary, CD8 augments cross-reactivity and masks the
potential effect of peptide targeting mutations in the enhancement of antigen specific T
cell potency. Therefore, the positive and negative design approach could have different
therapeutic implications in CD4+ and CD8+ T cells.
Cytotoxicity vs. Cytokine Expression
It was notable that cytotoxicity against the HLA-A2+ melanoma tumor, MEL 624,
did not correlate with 3D TCR affinity or polyfunctionality. Using 3D TCR affinity as a
predictor, we would have expected T cells expressing the αD26Y/αY50A/βL98W or
αD26Y/αY50V/βL98W TCRs to elicit reduced targeted melanoma killing compared to T
cells expressing the WT TCR. However, T cells expressing the αD26Y/αY50A/βL98W
TCR or the αD26Y/αY50V/βL98W TCR exhibited comparable or a trend towards better
killing, respectively, compared to T cells expressing the WT TCR. If cytotoxicity directly
correlated with CD107A and cytokine expression, we also would not have expected this
based upon the total percentages of functional (CD107A and or/cytokine expression) T
cells elicited against the MART-1 9mer.
There is evidence in the literature that explains how TCR affinity and T cell
cytokine production do not always correlate with cytotoxicity. Initially, it had been shown
that it is possible for just one TCR/pMHC interaction to induce a cytolytic T cell
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response [151, 497] . Subsequent studies indicated three TCR/pMHC interactions
elicited targeted cell death [498]. This is thought to be important for efficient immunity
because a small number of antigenic pMHC complexes can be expressed on a target
cell. Thus, cytotoxicity was determined to be the most antigen sensitive effector T cell
response [499]. It was also demonstrated that using TCRs that varied in affinity, by up
to 9-fold, resulted in similar killing. Furthermore, the induced cytotoxicity was elicited in
transient immune synapse formation and reduced calcium flux [498]. This is suggests
that T cell targeted killing is less dependent upon affinity and can occur in the absence
of full T cell activation [500]. These findings coincide with our findings. Even though T
cells expressing the two highest 3D affinity TCRs (αD26Y and αD26Y/βL98W) did
significantly elicit a higher percentage of tumor killing compared to T cells expressing
the WT TCR, cytotoxicity was comparable with the other higher and the lower affinity
TCRs. Overall, these results indicate that 3D affinity does not always correlate to
cytotoxicity.
Our cytotoxicity results also did not directly correlate with the observed
polyfunctional T cell responses. It has been shown that cytokine production is more
dependent upon kinetic factors. Cytokine production requires sustained signaling and
maintenance at the immunological synapse for maximum effect [501, 502]. Alteredpeptide ligands can also act as agonists, partial agonists, or antagonists to elicit
different T cell responses. For example, lower affinity interactions have been shown to
elicit cytokine production, but not T cell proliferation [150, 503]. Partial agonistic
peptides have been demonstrated to elicit cytotoxicity and/or release of IFN-γ and TNFα, but not IL-2 [328]. Partial agonists and antagonists tend to have shorter half-lives and
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thus, potentially dissociate from the TCR before full T cell activation is achieved [79,
487, 489, 504]. It has been demonstrated that half-lives between 8 and 12 seconds
allow all six tyrosines on the ITAMS to be phosphorylated, whereas half-lives between 3
and 8 seconds only allow enough time for a subset of the ITAMS to be phosphorylated,
resulting in partial T cell activation [505]. In summary, the release of lytic granules and
the expression of cytokines are governed by different mechanisms in T cells [506].
Based on the percentage of MART-1 reactive T cells, our results suggest that T cells
expressing the αD26Y/αY50A/βL98W TCR could result in partial activation. Coinciding
with our results, cytokine production is more correlated to 3D affinity and kinetic
TCR/pMHC parameters, where cytotoxicity is less dependent upon TCR affinity.
Lastly, our results indicated that the percentages of CD107A+ T cells in response
to the MART-1 9mer (Figures 35-36) generally correlated with cytotoxicity. The one
exception to this correlation was observed with T cells expressing the αD26Y/βL98W
TCR. Specifically, compared to T cells expressing the WT TCR, αD26Y/βL98W TCR
expressing T cells exhibited a statistically significant increase in MEL 624 killing (Figure
17), but a statistically significant decrease in the percentage of CD107A+ CD8+ MART-1
9mer reactive T cells and a comparable percentage of CD107A+ CD4+ MART-1 9mer
reactive T cells (Figure 36). It was notable that the drastic lack in correlation was
observed with the TCR with the supraphysiological affinity. These results suggested at
this level of affinity, CD107A expression is not correlative to lysis and/or CD107A
expression is antigen density dependent. Following the results obtained from the offtarget tumor panel, it is plausible to hypothesize that T cells expressing the modified
DMF5 TCRs were exhibiting lysis in response antigens other than MART-1 on MEL 624
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cells. However, the patterns in recognition of MEL 624 in terms of IFN-γ production,
generally correlated with patterns observed in the percentages of MART-1 9mer
reactive CD8+ T cells in Figure 20. It is possible the DMF5 TCRs recognized other
antigens on MEL 624, however, these results implicated that was not the likely or sole
justification. We would have to knockout MART-1 in MEL 624 tumor cells to determine
the level of recognition due to other antigens. Overall, lysis broadly correlated to
expression of CD107A except in T cells harboring a TCR with supraphysiological
affinity.
Polyfunction and Donor Variability
Another factor that affects T cell responses is the donor in which T cells were
derived. Our results indicated that T cells expressing the same TCR elicited different
polyfunctional T cells responses in different donors even when seeing the same ligand.
This was not surprising, as there are several factors that contribute to the T cell
response. The structure of the TCR/pMHC interaction affects numerous biophysical
parameters (i.e. affinity, on-rate, off-rate, t1/2, serial triggering, force) and then the
combination with numerous cellular parameters (CD4/CD8, co-stimulatory molecules,
ligand density, receptor density, activation status, exhaustion status, signaling
molecules, TCR mispairing) subsequently dictates a polyfunctional response by a T cell.
The T cell response is initiated by the TCR/pMHC interaction. Thus, the first variable
here is the structure of the TCR/pMHC tri-molecular complex. This interaction affects
numerous biophysical/kinetic parameters such as affinity, on-rate, off-rate, t1/2, serial
triggering, and force. How these parameters can affect T cell function has been
described in previous sections. The ability of a mutated TCR to alter T cell responses
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compared to the WT TCR has also been previously demonstrated [507]. However, the
kinetic factors are not the sole contributor to T cell function. There are numerous cellular
factors that affect T cell function as well (CD4/CD8, co-stimulatory molecules, ligand
density, receptor density, activation status, exhaustion status, signaling molecules, TCR
mispairing).
First, a heterogeneous T cell population was used for generating TCR
transduced T cells. This included T cells of various functional subsets and numerous
specificities [508]. This can affect the T cell response for a number of reasons. For
example, T cells exhibiting a stem cell memory or central memory phenotype
demonstrated a more potent antigen response than effector memory T cells and longterm immune responses [509, 510]. Efficacy of CAR T cell therapy has also been
associated with the proportion of naïve vs. effector T cells in the final product [511].
Furthermore, memory T cells have been shown to be stimulated by significantly lower
peptide concentrations than naïve T cells, and have demonstrated faster and more
efficient T cell function than naïve T cells [130, 512]. Therefore, the proportions of these
T cell subtypes in different donors could affect their polyfunctional T cell response. An
analysis of PBL from healthy patients demonstrated the percentage of naïve and
memory CD8+ T cells varied widely among patients [513]. Different subsets of T cells
express varying levels of activation and co-stimulatory molecules [514]. Additionally,
one study demonstrated the donor variation in immune cell subpopulations as well as
signaling responses in 60 healthy donors. Specifically, this study showed that IL-2
responses in naïve CD4+ T cells varied widely among the healthy donors [515]. Lastly,
one study of 123 healthy donors indicated donors over the age of 40 exhibited lower
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T cells

compared to donors under the age of 40 [516]. These results illustrate the wide potential
for donor variability associated with a heterogeneous PBL population.
Donor variability has been exemplified in numerous clinical trials both in terms of
clinical responses and adverse events. When the WT DMF5 TCR was used clinically,
objective cancer regressions were seen in 30% of the patients. Furthermore, on-target,
off-tumor adverse events of varying degrees were seen in 16/20 patients [288]. If the T
cells all were transduced the same way the same TCR, why didn’t every patient exhibit
a clinical response or toxicities? Or why were they exhibited at different levels? In the
MAGE-A3 clinical trial that resulted in lethal neurological toxicities, two out of nine
patients died. However, five patients did not exhibit any neurological toxicities. Two
patients exhibited neurological toxicities that were not lethal. Additionally, one patient
exhibited a complete response and four patients exhibited a partial response [5]. In a
clinical trial using NY-ESO-1 specific TCR engineered T cells, 16 out of 20 treated
patients exhibited clinical responses [302]. These are a few examples of results that
demonstrated the variety of T cell responses that can occur in different donors despite
expressing the same introduced TCR. In summary, the structure of the TCR/pMHC
impacts numerous kinetic factors that influences T cell function. However, numerous
cellular factors further dictate the T cell response. Overall, donor variability and
experimental variability occur for numerous reasons, therefore, it is not feasible to
predict or associate a polyfunctional phenotype with a specific structural TCR/pMHC
interaction.
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Importance of MHC Weakening Site
One of the unique aspects of this project is combining TCR mutations that target
the peptide, with TCR mutations that weaken binding with the MHC. Although peptide
targeting TCR mutations would be ligand-dependent and thus TCR specific, the MHC
targeting TCR mutations could be translatable to other TCRs. Our results indicated the
translatability of the CDR2 region mutation in the TCR alpha chain that weaken binding
with the MHC. More specifically, TCR mutation weakened or eliminated binding with
positions 154, 155, and 158 in the HLA-A2 α2 helix with a valine or alanine mutation,
respectively [350]. Residues at position 50 the CDR2 TCR alpha chain make one of the
most frequent contacts between TCRs and MHC class I [37, 398]. These single TCR
mutations in the DMF5 TCR eliminated all detectable reactivity against MART-1 loaded
targets, further supporting the importance of this residue in pMHC binding and their
evolutionarily selection. In the HCV 1406 TCR, alanine mutation at the same TCR
contact site eliminated all detectable reactivity against the WT NS3 peptide loaded
targets. However, the valine mutation eliminated all detectable reactivity against some
of the mutant NS3 epitope loaded targets and reduced reactivity against other mutant
NS3 epitopes and the WT NS3 peptide loaded targets compared to the WT TCR. These
results indicated that these mutations impact HLA-A2 restricted TCRs differently, but
yield a similar trend in eliminating or reducing off-target peptide recognition. Therefore,
this conserved TCR alpha chain residue could be mutated in high affinity and/or
potentially cross-reactive TCRs to reduce HLA-A2 restricted cross-reactivity. More
importantly, this strategy could again be implemented in the positive/negative design
strategy with other TCRs. This contact site has been broadly implicated in MHC class I
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interactions, and not just limited to specifically HLA-A2. Furthermore, the alanine
substitution had more of an impact than the valine substitution. Therefore, it is feasible
to hypothesize that a smaller amino acid substitution, such as a glycine, would have
even more of an impact than the alanine substitution. It would be interesting to
determine how mutation in the TCR at this contact site in the MAGE-A3 affinity
enhanced TCR would affect cross-reactivity with Titin, even though this TCR is HLA-A1
restricted. Furthermore, similar residues have been identified for MHC class II binding,
indicating this strategy could be implemented in TCRs in CD4+ T cells as well [37]. Even
though peptide targeting mutations would be TCR and ligand specific, this TCR alpha
chain residue is seemingly broadly applicable to MHC class I restricted TCRs. In
summary, this CDR2 TCR alpha chain residue could be translatable to other TCRs as a
strategy to reduce potential cross-reactivity. Importantly, the unique role of the negative
design in this novel positive and negative design strategy can be implemented in other
TCRs.
How DMF5 Mutations Affect Recognition of Processed Antigens
Correlation to MART-1 Homologs
It is important to also observe recognition of processed antigens because
exogenous peptide loaded T2 cells are not entirely biologically relevant. Furthermore,
many peptide reactive T cells do not recognize processed antigen. The patterns of T
cell reactivity against the MART-1 homologs by T cells expressing each of the different
DMF5 TCRs did not directly correlate with their cross-reactivity against off-target
tumors. These results exemplify the differences in conclusions that can be obtained
when observing cross-reactivity via two distinct methods.
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It is evident that utilizing peptides derived from a sequence homology search with
the target ligand are not always adequate in assessing inclusive cross-reactivity. T cell
cross-reactivity has been described based upon peptides with sequence homology,
peptides with very minimal sequence homology but also, with unrelated peptides [517].
It is known that TCRs can recognize divergent peptides that would not be found in
homology searches [350, 518]. Estimations suggest that one TCR can recognize one
million different peptides [519]. This is possible due to their inherent plasticity in the
CDR loops. TCR protein adaptability has been described and is critical for recognition of
diverse peptides [474, 520]. Therefore, it is thought that cross-reactivity is not due to
recognizing numerous unrelated peptides, but rather the tolerance of peptide
alterations, and conservative alterations at residues that contact the TCR CDR loops
[521]. These principles highlight the pitfalls associated with focusing solely on sequence
homology as a predictor for cross-reactivity. An example of this was exemplified in our
data. T cells expressing the αD26Y/αY50A/βL98W TCR did reduce cross-reactivity
against the MART-1 homologs compared to T cells expressing the WT TCR. However,
recognition of the off-target tumors was either comparable or enhanced with T cells
expressing the αD26Y/αY50A/βL98W TCR compared to T cells expressing the WT
TCR. In conclusion, we observed two very different results dependent upon the method
in which we examined cross-reactivity. These results highlight the importance of
addressing cross-reactivity in an inclusive manner.
Multiple studies indicated molecular mimicry could occur with structural and
chemical similarities and not sequence similarities, thus implicating the importance of
the antigenic peptide surface [517, 522-525]. Moreover, TCR recognition can rely on
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sequence similarities in few regions of the peptide while tolerating vast diversity
elsewhere in the peptide [369, 521, 526]. Specifically, it has been shown that just one
conserved residue in the peptide can still result in partial T cell activation [527]. If T cells
are estimated to recognize up to one million peptides, focusing on epitopes that have
homology with only one of those potential million recognized peptides, is actually a very
incomplete pool of potentially recognized targets. Based on what is known about TCR
cross-reactivity and recognition of sequence dissimilar epitopes, it is understandable
how focusing on MART-1 homologs, selected upon sequence homology, did not
correlate to cross-reactivity against an abundant number of antigens on the off-target
tumor cell lines. Furthermore, the TCRs harboring the structure-guided mutations did
not always directly correlate to recognition of MART-1 homologs according to their
sequence and the proposed structural effect of the specific TCR mutation. In summary,
this inconsistency can be explained by the idea of TCRs recognizing structural mimicry
as well as sequence mimicry.
The DMF5 TCR was identified based upon its recognition of MART-1.
Accordingly, peptides in the MART-1 homolog peptide panel were selected based upon
sequence homology with MART-1. However, the DMF5 TCR actually commonly
recognizes two distinct classes of epitopes. One class is the hydrophobic motif, GIG, in
the peptide core, and the second class is a central core consisting of charged amino
acids [404, 423]. The DMF5 TCR tolerates such different antigenic surfaces by rotating
its side chains to optimize electrostatic interactions [404]. Other TCR adaptability
mechanism can involve CDR loop conformational changes or TCR repositioning [528530]. The lack of conformational changes or repositioning indicates the DMF5 TCR
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requires minimal alterations to accommodate divergent changes in the peptide core.
MART-1 and the MART-1 homologs used in these studies fall into the peptide class with
a hydrophobic motif in the peptide core. It would have been of interest to also
investigate how each of the DMF5 TCRs recognize peptides in the second peptide
class, consisting of central cores dominated by charged amino acids. The structureguided mutations were designed based on the hydrophobic MART-1 peptide with the
GIG peptide core, and thus, we are unsure of how these mutations in the DMF5 TCR
would affect recognition of this other class of peptides. Therefore, antigens in this class
of peptides, with a central charged core, could be expressed on the off-target tumors
and were potentially recognized targets, however, we are unaware of how the different
DMF5 TCRs recognize them.
Notably, our data generated by the combinatorial peptide libraries indicated
enhanced recognition of peptides containing an aspartic acid at position 5 by cells
expressing the αD26Y/αY50A/βL98W TCR compared to the WT TCR. Furthermore, this
pool is recognized starkly more than all the other pools by cells expressing the
αD26Y/αY50A/βL98W TCR. These results indicated that the αD26Y/αY50A/βL98W
TCR might easily conform to or even prefer peptides with this antigenic surface. It is
possible that the αD26Y mutation in this TCR removes an unfavorable interaction
between the two negative charges that is present with the WT TCR. Furthermore, the
removal of this repulsion is strong enough to not be offset by the αY50A mutation. T cell
potency against this pool is enhanced with cells expressing the αD26Y/βL98W TCR
compared to cells expressing the WT TCR. However, the addition of the αY50A
mutation to the αD26Y/βL98W TCR was not enough to restore T cell reactivity to the
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level observed with the WT TCR. Consequently, it is possible that peptides that conform
to structures like the peptides in this specific pool, with an aspartic acid at the core of
the peptide, could be presented on the off-target tumor lines. This would explain why T
cells expressing the αD26Y/αY50A/βL98W TCR were more cross-reactive against some
of the off-target tumors than T cells expressing the WT TCR.
It was demonstrated that the WT DMF5 TCR does exhibit a conserved
interaction upon binding a peptide with the hydrophobic GIG core and a peptide with the
charged core. This conserved interaction consisted of the CDR1 loop in the TCR alpha
chain and the peptide backbone near the N-terminus [404]. This is interesting because
the αD26Y mutation was made in the CDR1 loop targeting the N-terminal region of the
peptide. Furthermore, TCRs containing this mutation were the most cross-reactive
against the off-target tumors amongst the mutated DMF5 TCRs, with the βL98W TCR,
the only mutated TCR lacking the αD26Y mutation, being the least cross-reactive.
These results suggest an important role of this mutation. If the interaction between the
CDR1 TCR alpha chain loop and the N-terminal region of the peptide is conserved
despite divergent peptides in the HLA-A2 complex, then the αD26Y mutation would be
in the same conformation in every interface, and thus, could non-specifically enhance
binding to any peptide. Our results suggested the structural role of the αD26Y mutation,
in a conserved interaction, could be contributing the unpredicted off-target recognition of
the off-target tumor lines.
It is possible for mutated TCRs to exhibit one pattern of cross-reactivity against
certain classes of peptides while displaying a different pattern of cross-reactivity against
a different class of peptides. This is most likely the reason why our results using the
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MART-1 homologs did not directly align with reactivity against processed antigens on
off-target tumor lines. Our results and other studies demonstrated valuable information
that can be revealed using combinatorial peptide libraries. This will be discussed in a
later section. In summary, when assessing TCR cross-reactivity, the sole use of
peptides with sequence homology is not always a completely sufficient method.
3D Affinity vs. 2D Affinity
Our results indicated that 3D measurements better correlated with crossreactivity against the MART-1 homologs, or with sequence homology, whereas 2D
measurements better correlated with cross-reactivity against off-target tumor cells.
There are numerous reasons why the 2D affinity measurements might better correlate
to the more biologically relevant system. 2D measurements take into account the
geometric and physical constraints involved in membrane-bound interactions, where 3D
measurements do not [156, 166]. Thus, there are many intrinsic T cell factors such as
membrane organization and orientation, membrane anchor, cytoskeleton regulation,
and TCR structure in the CD3 complex that are involved in 2D measurements [380,
531-534]. Additionally, proteins in 3D SPR are in solution, whereas in the 2D
micropipette frequency assay, the pMHC and TCR are directly, and head on, brought
into contact. This affects how the TCR and pMHC come in contact with each other and
thus how they bind together. Our results begin to illuminate the caveat with predicting T
cell function and cross-reactivity based on 3D affinity measurements [168].
3D affinity measures the in vitro molecular binding properties, while 2D affinity
measures physiological in situ kinetics [534]. Thus, our data highlight the differences
between binding specificity and functional specificity in regards to 3D affinity and 2D
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affinity. Specifically, 3D affinity measurements better correlated with recognition of
MART-1 and the MART-1 homologs. For example, compared to the WT TCR, T cells
expressing the αD26Y/αY50A/βL98W TCR reduced T cell potency against MART-1 and
the MART-1 homologs, aligning with a reduction in this TCR’s 3D affinity. However,
when observing recognition of off-target tumors, the overall functional specificity of T
cells expressing the αD26Y/αY50A/βL98W TCR better correlated to its 2D affinity, in
relation to the WT TCR. Figure 45 depicts the rankings of cross-reactivity with the
different DMF5 TCRs in regards to the MART-1 homologs and the off-target tumor
panel and their correlation with 3D and 2D affinity. The ranking of MART-1 homolog
cross-reactivity in Figure 45A is based up the results calculated in Table 7. It is evident
that reactivity against the MART-1 homologs followed the pattern of enhanced 3D
affinity, enhanced cross-reactivity. Exceptions are the αD26Y/βL98W TCR, due to
supraphysiological high affinity, and the αD26Y/αY50V/βL98W TCR being comparable
to the WT TCR in terms of cross-reactivity but not 3D affinity. The ranking of off-target
tumor cross-reactivity in Figure 45B is based up the results calculated in Figure 41.
DMF5 TCR ranking in regards to the cross-reactivity against the off-target tumors lines
is different than with the MART-1 homologs, but directly aligns with the measured 2D
affinity. As mentioned previously, 2D affinity measurements have been better correlated
with T cell function. An example of this has also been demonstrated in the clinic, where
the 2D affinity of TCR transduced T cells correlated to clinical outcomes in a small
sample set of patients [290]. Specifically in three patients, patient one exhibited no
clinical response to treatment and their TCR transduced T cells exhibited the lowest 2D
affinity measurement against the targeted ligand [290].
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Figure 45. Cross-Reactivity Rankings of TCRs in Relation to 3D and 2D Affinity.
(a) Ranking of TCRs in regards to cross-reactivity against the MART-1 homologs
(based on Table 7). 3D affinity measurements are shown above the TCRs, respectively.
(b) Ranking of TCRs in regards to cross-reactivity against the tumor panel (based on
Figure 41). 2D affinity measurements are shown above the TCRs, respectively

Moreover, the other two patients exhibited clinical and biological responses and their
TCR transduced T cells exhibited a statistically significant increase in their 2D affinity
measurements [290]. These results indicated that donor variability is a factor in 2D
affinity and can have implications in clinical outcomes. Overall, observing general
reactivity against only one peptide, specifically with sequence homology to the targeted
peptide, better correlated to 3D affinity. Conversely, observing reactivity in the presence
of numerous peptides better correlated to 2D affinity and can be associated with
functional specificity.
Potential Tumor Targets
Based on our data, and what we know about T cell cross-reactivity, we believe
the mutated DMF5 TCRs were capable of recognizing multiple different peptides that fit
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an antigenic structure that is tolerated by the TCRs. First, we can eliminate TCR chain
mispairing as the sole cause because Jurkat 76 cells expressing the WT and modified
TCRs still recognized some of the tumors (data not shown – experiments completed by
our collaborators in the Baker lab, results obtained through personal communication).
Jurkat 76 cells lack an endogenous TCR and thus, any expressed TCR is the properly
paired introduced TCR. Although TCR chain mispairing is always a potential cause of
autoimmunity, these results demonstrated that cross-reactivity was not exclusively due
to mispairing.
In the combinatorial peptide library data, the abundant recognition of nearly all
the pools by the αD26Y/βL98W TCR supports the theory of plausible recognition of
multiple peptides. Additionally, our results from the alanine scan also provided insight
into the potential number of targets the mutated DMF5 TCRs could recognize (Figure
16). As mentioned previously, Titin was identified as the cross-reactive peptide with the
affinity enhanced MAGE-A3 TCR. This was identified by fixing residues important for
recognition based on an alanine scan, and searching for homologous epitopes in
proteins [299]. When we performed a similar search based upon our alanine scan data,
the results are far more extensive. For instance, with the αD26Y TCR, positions 4 and 6
in the MART-1 9mer peptide appeared important for recognition of the MART-1 9mer
(Figure 16). When we fixed position 4 and position 6 and used the ScanProsite tool to
search the UniProtKB/Swiss database for XXXIXIXXX motifs in proteins in Homo
sapiens (including splice variants), 6,391 matches are found. When we performed the
same search for the MAGE-A3 motif based upon the authors alanine scan results
(EXDPIXXXY), only 17 matches were found in Homo sapiens (including splice variants)

246
[299]. Albiet, this does not mean all 6,391 epitopes are presented on HLA-A2. Recent
advancements in modeling, bioinformatics, and epitope-mapping have been made in
order to better predict epitope presentation by MHC class I and MHC class II [535-542].
Nonetheless, this drastic difference illuminates the vast potential of targets that these
modified DMF5 TCRs are recognizing. Furthermore, this does not even begin to
address the potential recognized epitopes that do not follow MART-1 sequence
homology. In summary, our results indicated mutations in the DMF5 TCR allowed the
TCRs to be more permissive in their recognition and allowed for non-specific recognition
of multiple different peptides.
There are a few methods that could be utilized to determine the recognized
targets on the off-target tumor cells lines. One potential approach to determine the
recognized targets would be acid eluting off the peptides from the HLA-A2 complexes
[543-546]. Following elution, peptide extracts would be fractionated by reverse phased
high-performance liquid chromatography (HPLC). Cytotoxicity assays would be
performed with T2 cells loaded with peptide fractions and effector T cells. Further
fractionation of reactive peaks would narrow down the number of potential peptides.
Lastly, mass spectrometry would determine the sequence of peptides, and all potential
peptides would be made and put in final functional assays. This approach has been
utilized to identify an antigenic peptide (YXEPGPVTA) for melanoma specific T cell
clones [546]. A second approach is using combinatorial peptide libraries in a positional
scanning format [547-550]. A scoring matrix is generated based upon lysis of the
specific amino acids at each residue. This matrix is then implemented with protein
databases to predict stimulatory scores for epitopes present in proteins. This approach
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was utilized to predict off-target reactivity of the 7B5 TCR (HLA-A2 restricted,
recognizes the HA-2 peptide), and even identified a cross-reactive peptide. Notably, this
study demonstrated that results from their alanine scan assay were insufficient for
identifying this cross-reactive peptide [442]. However, these approaches might be
impractical for identifying the recognized peptides on the off-target tumor cells in this
study. We have already partially completed the combinatorial peptide library approach,
and results indicated recognition of nearly all the pools by the WT and αD26Y/βL98W
TCR, suggesting the extensive number of potential targets with a wide variety of
potential sequences (Figure 44). Nonetheless, when used clinically, the DMF5 WT TCR
did not cause adverse events due to off-target autoimmunity [332]. These results
indicated that despite observation of off-target cross-reactivity in vitro, it was not
observed in a human. Therefore, there could be a “cut off” point or range in which
autoimmunity might occur in vivo. Based on what we know about donor variability, this
cut off is not likely to be highly definitive. Furthermore, it is plausible that the threshold
for causing off-target autoimmunity in vivo is TCR and ligand dependent. Albeit, the
peptide elution or combinatorial peptide library approaches could be more practical for
identifying the off-target peptides for the αD26Y/αY50A/βL98W TCR. Results from the
combinatorial peptide library with this TCR, indicated far fewer peptide pools that
elicited discernable reactivity, and thus, could be parsed apart more easily. Taken
together, our results suggested the number of peptides recognized on the off-target
tumor cells was potentially very extensive for the highly cross-reactive DMF5 TCRs
(αD26Y TCR, αD26Y/βL98W TCR, and αD26Y/αY50V/βL98W TCR) but limited for the
αD26Y/αY50A/βL98W TCR.
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Implications for Future Use of Structure-Guided Design Strategy
The results from our studies have critical implications for future utilization of this
structure-guided design strategy for manipulating TCR specificity. Some of our findings
were expected. However, our results do not undervalue the structure-guided design
strategy and its implications for future use. Importantly, our results provided critical
insight for the field in terms of modifying TCRs and addressing cross-reactivity.
We initially thought the DMF5 TCR/MART-1 peptide model would be useful to
study the cross-reactive properties of TCRs. This was based upon the reports of high
frequencies of MART-1 reactive T cells in the blood of cancer patients and healthy
donors [323, 327, 551], and the evidence that MART-1 “like” epitopes recurrently
appear among self and non-self-proteins [327]. However, the inherent nature of this
TCR and its ligand, could have exacerbated some of the findings compared to if a
different TCR and ligand were used. For example, MART-1 9mer is extremely
hydrophobic, being all hydrophobic except for the neutral threonine at position 8. Since
immunogenicity and hydrophobicity have been directly correlated [68], it makes sense
the DMF5 TCR is cross-reactive. However, recognition of hydrophobic peptides is
already preferred by TCRs, compared to more polar peptides, because there is less
defined geometry for the CDR loops to match [72]. Herein, we made peptide enhancing
mutations to a TCR that was already very permissive in terms of cross-reactivity of
sequence homologous and non-sequence homologous epitopes. One of the main
challenges associated with the MART-1 peptide for our approach was that there are no
unique residues to target that could be considered relatively MART-1 “specific”.
Therefore, the combination with negative, MHC weakening, TCR mutation did not offset
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the positive, MART-1 targeting, TCR mutation enough to prevent cross-reactivity
against all potential targets. That being said, this positive and negative design strategy
could be implemented in other TCRs and perceivably yield different results. This
concept of the MART-1 9mer being very hydrophobic and “featureless” relates to the
commonly described features of a “vanilla” peptide or a “spicy” peptide [552]. Spicy
peptides are described as having a prominent feature exposed to the TCR, whereas
vanilla peptides are described as being featureless. Thus, others have hypothesized
that TCRs that recognize a spicy peptide should be less cross-reactive because most
other peptides would lack the defining peptide feature. Conversely, TCRs that target a
vanilla peptide should be more cross-reactive because peptide features are more
shared amongst other peptides [552]. Our studies with the DMF5 TCR and other studies
with MART-1 reactive T cells exemplify this hypothesis [327, 350]. Consequently, in
TCRs that recognize less hydrophobic peptides, there could be more distinct peptide
residues to target for positive TCR mutation. Thus, introduction of a TCR mutation that
enhances binding to that distinct peptide feature, could further enhance antigen
specificity. Subsequent addition of a negative, MHC weakening, TCR mutation, could
then reduce any remaining potential off-target cross-reactivity. Every TCR/pMHC ligand
will be different, but these results outlined preliminary stipulations to bear in mind when
mutating TCRs and altering their functional specificities. In summary, it is plausible that
this structure-guided strategy would yield different results with another TCR and ligand.
Our results also highlight the importance, but difficulty, in the introduction of a
peptide targeting TCR mutation that only impacts on binding with the peptide and not
the MHC. Specifically, our results indicated that the αD26Y mutation was most likely
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driving off-target cross-reactivity and the structural effect of this mutation was too
impactful to be completely countered balanced by the negative mutation. This was
demonstrated in the both the first and the second round of DMF5 TCR mutations, where
every mutant DMF5 TCR containing the αD26Y TCR mutation enhanced recognition of
the off-target tumors, compared to mutant DMF5 TCRs that did not contain the αD26Y
TCR mutation. As mentioned previously, we cannot discern the impact of the MART-1
enhancement of this mutation versus the MHC enhancement, but it could be imperative
for future mutations to avoid also enhancing binding with the MHC molecule.
Unfortunately, this is easier said than done, as TCR contact with the MHC accounts for
75-80% of the TCR/pMHC interaction, and the peptide and MHC are closely packed
together [71, 349]. Furthermore, the impact of binding enhancement with the MHC could
be TCR and ligand dependent. Specifically, it is possible that the removal of the charge
repulsion between the HLA-A2 and the DMF5 TCR with the αD26Y TCR mutation was
important for the observed enhancement in cross-reactivity. Conversely, it is possible
that the introduction of a favorable interaction between the TCR and MHC in a different
model would have a minor effect on cross-reactivity. A future strategy for this DMF5
TCR would be remove the αD26Y mutation from the αD26Y/αY50A/βL98W TCR and
replace it with possibly another CDR3 region mutation that targets the core of the
peptide. Overall, the goal of the positive design strategy was to introduce mutations that
only impact peptide binding. Furthermore, this can be a difficult task, and implications
are likely to be TCR and ligand dependent.
It was very interesting that just one or two mutations in the DMF5 TCR (αD26Y or
αD26Y/βL98W) frequently elicited recognition of the off-target HLA-A2+ tumors in our
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panel. We believe that in the proper system, these TCRs could potentially be
therapeutic. This system would be an off the shelf reagent of TCR transduced
allogeneic T cells for intra-tumoral injection in an HLA-A2+ tumor (E. Fleming-Trujillo, et.
al. unpublished). First, the TCR transduced T cells have to be allogeneic because,
activated TCR transduced HLA-A2+ T cells commit fratricide. Secondly, it would have to
be an intra-tumoral injection because it could be detrimental to systemically inject
allogenic T cells expressing a highly cross-reactive TCR. The TCR transduced
allogeneic T cells could also be irradiated to limit any potential damage. Furthermore,
intra-tumoral injection of irradiated TCR transduced allogeneic T cells has already been
demonstrated as feasible and safe, with the potential to elicit regression of untreated
tumors [331]. In summary, we believe the off-target cross-reactive properties of the
αD26Y and αD26Y/βL98W TCRs could be widely therapeutic as an off the shelf reagent
for treatment of HLA-A2+ tumors, if implemented in the proper and safe system.
The results of this dissertation highlight the need for the advancement in
modeling and prediction tools for protein interactions, specifically in the area of crossreactivity. We demonstrated that when examining potential cross-reactivity, sequence
homology searches are not always adequate, and furthermore, our panel of tumors did
not encompass every tissue. Addressing cross-reactivity in murine models is also not
completely sufficient, due to lack of complete homology between the mouse and
human. At this point, there is no better model than a human to fully examine potential
cross-reactivity, and even then, results are not identical. Immunogenicity predictions
tools such as the Immune Epitope Database, are a step in the right direction to better
predict and characterize B cell and T cell epitopes involved in disease, autoimmunity,
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allergy, and transplant [541]. In summary, the advancements in modifying TCRs and
their antigen specificities should coexist with the advancements in modeling and
prediction tools.
In vivo Future Directions
Our data demonstrated some of the challenges associated with using xenograft
in vivo models for our studies. Our results suggested that human TCR transduced T
cells had difficulty trafficking to the site of the tumor, most likely due to the
immunodeficient nature of the NSG mouse model and the lack of human environment.
Aside from what was examined in these studies, there are other methods of trying to
enhance T cell persistence and trafficking to the tumor that could be explored in the
future. For example, IL-7 is important for T cell survival and differentiation. IL-7 has
been shown to enhance adoptive T cell therapy, and more specifically, the combination
of IL-7 and IL-15 [460, 553-556]. Thus, it would be of interest to determine how IL-7 or
how the combination of IL-7, IL-15, and IL-2 affect the persistence and anti-tumor
activity of the introduced TCR transduced T cells. In our engraftment model, engrafted T
cells did persist, but did not enhance the anti-tumor activity of the introduced TCR
transduced T cells. It is plausible that engraftment of whole hematopoietic stem cells
would better recapitulate a human immune system than engrafted PBMCs due to the
multiple hematopoietic lineages. Therefore, they might better support to persistence of
the introduced T cells [385, 557-561]. Lastly, another option would be to murinize the
TCR constant regions of DMF5 TCRs and transduce murine T cells. These TCR
transduced murine T cells could be used in immunocompetent mice for analysis of antitumor activity. In conclusion, different cytokine support, humanized NSG mice, or
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switching mouse models to immunocompetent mice are a few examples of alternative
strategies to enhance the in vivo anti-tumor efficacy and analysis of TCR transduced T
cells in these studies.
Concluding Remarks
In these studies we developed and implemented a novel structure-guided
approach to enhance antigen specificity and reduce off-target cross-reactivity. We
sought to determine how structure-guided mutations in the DMF5 TCR altered tumor
lysis, polyfunctional T cell responses, on-target specificity, and recognition of processed
antigens. When measuring polyfunctional T cell responses against a panel of MART-1
homologs, the structure guided approach appeared to be promising, with T cells
expressing the αD26Y/αY50A/βL98W TCR exhibiting reduced percentages of MART-1
homolog reactive T cells compared to T cells expressing the WT TCR. However, when
T cell responses were measured against processed antigens on a variety of different
tissues, large off-target cross-reactivity was observed. Our results demonstrate that
sequence homology is not the sole factor in cross-reactivity, and that 3D affinity against
the “cognate” antigen is not always correlative to broad cross-reactivity. Furthermore, T
cell responses vary due to biophysical properties/kinetics of the TCR/pMHC interaction
and how structural changes in the interface affect these properties and consequent
downstream T cell function is not feasibly predictable. Despite this, our structure-based
designed strategy could be utilized in the future, as it is more meticulous and specific
than random mutation through yeast or phage display. It important to understand how
alterations in the TCR/pMHC interface can affect functional T cell phenotypes to
maximize the efficacy and safety of TCRs to be used in gene modified T cells in
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adoptive cell transfer. In conclusion, when altering TCRs for therapeutic use, safety
should be of the utmost importance and herein, we emphasize the importance of
rigorous preclinical testing of modified TCRs and the need for advancement in
modeling/prediction tools for protein interactions.

APPENDIX A:
ADDITIONAL FIGURES
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Figure 46. Impact of DMF5 Mutations in TCR Transduced CD4+ T cells on
Polyfunctional Responses against MART-1 (Donor One). The data indicate reactivity
against T2 cells loaded with the MART-1 9mer peptide in donor one, experiment two.
“Cool plots” were generated to include any functional phenotype present over 0.1%. In
the functional phenotypes listed, “+” indicates positive for the marker and “-“ indicates
negative for the marker. As described in Chapter Two, reactivity is defined after
background subtraction and specifically, any phenotype expressed by over 0.1% of
TCR transduced T cells (subtraction of the background immunofluorescence observed
with T2 cells loaded with an irrelevant, HCV, peptide). The color depicted in the “cool
plot” correlates to the scale on the right. An “X” indicates no T cells were positive
(<0.1% after background subtraction) for given functional phenotype. The color white for
a given functional phenotype indicates a percentage less than 0.2%.
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Figure 47. Impact of DMF5 Mutations in TCR Transduced CD4+ T cells on
Polyfunctional Responses against MART-1 (Donor Two). The data indicate reactivity
against T2 cells loaded with the MART-1 9mer peptide in donor two, experiment two.
“Cool plots” were generated to include any functional phenotype present over 0.1%. In
the functional phenotypes listed, “+” indicates positive for the marker and “-“ indicates
negative for the marker. As described in Chapter Two, reactivity is defined after
background subtraction and specifically, any phenotype expressed by over 0.1% of
TCR transduced T cells (subtraction of the background immunofluorescence observed
with T2 cells loaded with an irrelevant, HCV, peptide). The color depicted in the “cool
plot” correlates to the scale on the right. An “X” indicates no T cells were positive
(<0.1% after background subtraction) for given functional phenotype. The color white for
a given functional phenotype indicates a percentage less than 0.2%.
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Figure 48. Impact of DMF5 Mutations in TCR Transduced CD4+ T cells on
Polyfunctional Responses against MART-1 (Donor Three). The data indicate
reactivity against T2 cells loaded with the MART-1 9mer peptide in donor three,
experiment two. “Cool plots” were generated to include any functional phenotype
present over 0.1%. In the functional phenotypes listed, “+” indicates positive for the
marker and “-“ indicates negative for the marker. As described in Chapter Two,
reactivity is defined after background subtraction and specifically, any phenotype
expressed by over 0.1% of TCR transduced T cells (subtraction of the background
immunofluorescence observed with T2 cells loaded with an irrelevant, HCV, peptide).
The color depicted in the “cool plot” correlates to the scale on the right. An “X” indicates
no T cells were positive (<0.1% after background subtraction) for given functional
phenotype. The color white for a given functional phenotype indicates a percentage less
than 0.5%.
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Figure 49. Impact of DMF5 Mutations in TCR Transduced CD8+ T cells on
Polyfunctional Responses against MART-1 (Donor One). The data indicate reactivity
against T2 cells loaded with the MART-1 9mer peptide in donor one, experiment two.
“Cool plots” were generated to include any functional phenotype present over 0.1%. In
the functional phenotypes listed, “+” indicates positive for the marker and “-“ indicates
negative for the marker. As described in Chapter Two, reactivity is defined after
background subtraction and specifically, any phenotype expressed by over 0.1% of
TCR transduced T cells (subtraction of the background immunofluorescence observed
with T2 cells loaded with an irrelevant, HCV, peptide). The color depicted in the “cool
plot” correlates to the scale on the right. An “X” indicates no T cells were positive
(<0.1% after background subtraction) for given functional phenotype. The color white for
a given functional phenotype indicates a percentage less than 0.5%. Five prominent
phenotypes are highlighted with red boxes.
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Figure 50. Impact of DMF5 Mutations in TCR Transduced CD8+ T cells on
Polyfunctional Responses against MART-1 (Donor Two). The data indicate reactivity
against T2 cells loaded with the MART-1 9mer peptide in donor two, experiment two.
“Cool plots” were generated to include any functional phenotype present over 0.1%. In
the functional phenotypes listed, “+” indicates the positive for marker and “-“ indicates
negative for the marker. As described in Chapter Two, reactivity is defined after
background subtraction and specifically, any phenotype expressed by over 0.1% of
TCR transduced T cells (subtraction of the background immunofluorescence observed
with T2 cells loaded with an irrelevant, HCV, peptide). The color depicted in the “cool
plot” correlates to the scale on the right. An “X” indicates no T cells were positive
(<0.1% after background subtraction) for given functional phenotype. The color white for
a given functional phenotype indicates a percentage less than 0.5%. Five prominent
phenotypes are highlighted with red boxes.
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Figure 51. Impact of DMF5 Mutations in TCR Transduced CD8+ T cells on
Polyfunctional Responses against MART-1 (Donor Three). The data indicate
reactivity against T2 cells loaded with the MART-1 9mer peptide in donor three,
experiment two. “Cool plots” were generated to include any functional phenotype
present over 0.1%. In the functional phenotypes listed, “+” indicates positive for the
marker and “-“ indicates negative for the marker. As described in Chapter Two,
reactivity is defined after background subtraction and specifically, any phenotype
expressed by over 0.1% of TCR transduced T cells (subtraction of the background
immunofluorescence observed with T2 cells loaded with an irrelevant, HCV, peptide).
The color depicted in the “cool plot” correlates to the scale on the right. An “X” indicates
no T cells were positive (<0.1% after background subtraction) for given functional
phenotype. The color white for a given functional phenotype indicates a percentage less
than 0.5%. Five prominent phenotypes are highlighted with red boxes.
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Figure 52. Impact of DMF5 Mutations on Cross-Reactivity Using Multi-Tissue
Tumor Panel. Human T cells expressing either WT or a mutant DMF5 TCR were
stimulated with tumor cell lines (see Table 2 – Chapter Two, Methods). IFN-γ release
was measured by ELISA in triplicate wells. SAUJ and MEL 624-28 are HLA-A2-, all
other tumors are HLA-A2+. Two patterns of off-target tumor recognition were observed.
(a) Highly cross-reactive TCRs compared to the WT TCR. (b) Modestly cross-reactive
TCRs compared to the WT TCR. One representative experiment and donor is shown.
Reactivity is defined as a T cell culture that secretes twice background, or twice the
amount of IFN-γ produced as against MEL 624-28, and greater than 200 pg/mL. Donor
1, experiment 2.
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Figure 53. Impact of DMF5 Mutations on Cross-Reactivity Using Multi-Tissue
Tumor Panel. Human T cells expressing either WT or a mutant DMF5 TCR were
stimulated with tumor cell lines (see Table 2 – Chapter Two, Methods). IFN-γ release
was measured by ELISA in triplicate wells. SAUJ and MEL 624-28 are HLA-A2-, all
other tumors are HLA-A2+. Two patterns of off-target tumor recognition were observed.
(a) Highly cross-reactive TCRs compared to the WT TCR. (b) Modestly cross-reactive
TCRs compared to the WT TCR. One representative experiment and donor is shown.
Reactivity is defined as a T cell culture that secretes twice background, or twice the
amount of IFN-γ produced as against MEL 624-28, and greater than 200 pg/mL. Donor
2, experiment 1.
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Figure 54. Impact of DMF5 Mutations on Cross-Reactivity Using Multi-Tissue
Tumor Panel. Human T cells expressing either WT or a mutant DMF5 TCR were
stimulated with tumor cell lines (see Table 2 – Chapter Two, Methods). IFN-γ release
was measured by ELISA in triplicate wells. SAUJ and MEL 624-28 are HLA-A2-, all
other tumors are HLA-A2+. Two patterns of off-target tumor recognition were observed.
(a) Highly cross-reactive TCRs compared to the WT TCR. (b) Modestly cross-reactive
TCRs compared to the WT TCR. One representative experiment and donor is shown.
Reactivity is defined as a T cell culture that secretes twice background, or twice the
amount of IFN-γ produced as against MEL 624-28, and greater than 200 pg/mL. Donor
2, experiment 2.
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Figure 55. Impact of DMF5 Mutations on Cross-Reactivity Using Multi-Tissue
Tumor Panel. Human T cells expressing either WT or a mutant DMF5 TCR were
stimulated with tumor cell lines (see Table 2 – Chapter Two, Methods). IFN-γ release
was measured by ELISA in triplicate wells. SAUJ and MEL 624-28 are HLA-A2-, all
other tumors are HLA-A2+. Two patterns of off-target tumor recognition were observed.
(a) Highly cross-reactive TCRs compared to the WT TCR. (b) Modestly cross-reactive
TCRs compared to the WT TCR. One representative experiment and donor is shown.
Reactivity is defined as a T cell culture that secretes twice background, or twice the
amount of IFN-γ produced as against MEL 624-28, and greater than 200 pg/mL. Donor
3, experiment 1.
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Figure 56. Impact of DMF5 Mutations on Cross-Reactivity Using Multi-Tissue
Tumor Panel. Human T cells expressing either WT or a mutant DMF5 TCR were
stimulated with tumor cell lines (see Table 2 – Chapter Two, Methods). IFN-γ release
was measured by ELISA in triplicate wells. SAUJ and MEL 624-28 are HLA-A2-, all
other tumors are HLA-A2+. Two patterns of off-target tumor recognition were observed.
(a) Highly cross-reactive TCRs compared to the WT TCR. (b) Modestly cross-reactive
TCRs compared to the WT TCR. One representative experiment and donor is shown.
Reactivity is defined as a T cell culture that secretes twice background, or twice the
amount of IFN-γ produced as against MEL 624-28, and greater than 200 pg/mL. Donor
3, experiment 2.
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Figure 57. Impact of DMF5 Mutations on Cross-Reactivity Using Multi-Tissue
Tumor Panel. Human T cells expressing either WT or a mutant DMF5 TCR were
stimulated with tumor cell lines (see Table 2 – Chapter Two, Methods). IFN-γ release
was measured by ELISA in triplicate wells. SAUJ and MEL 624-28 are HLA-A2-, all
other tumors are HLA-A2+. Two patterns of off-target tumor recognition were observed.
(a) Highly cross-reactive TCRs compared to the WT TCR. (b) Modestly cross-reactive
TCRs compared to the WT TCR. One representative experiment and donor is shown.
Reactivity is defined as a T cell culture that secretes twice background, or twice the
amount of IFN-γ produced as against MEL 624-28, and greater than 200 pg/mL. Donor
4, experiment 1.
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Figure 58. Impact of DMF5 Mutations on Cross-Reactivity Using Multi-Tissue
Tumor Panel. Human T cells expressing either WT or a mutant DMF5 TCR were
stimulated with tumor cell lines (see Table 2 – Chapter Two, Methods). IFN-γ release
was measured by ELISA in triplicate wells. SAUJ and MEL 624-28 are HLA-A2-, all
other tumors are HLA-A2+. Two patterns of off-target tumor recognition were observed.
(a) Highly cross-reactive TCRs compared to the WT TCR. (b) Modestly cross-reactive
TCRs compared to the WT TCR. One representative experiment and donor is shown.
Reactivity is defined as a T cell culture that secretes twice background, or twice the
amount of IFN-γ produced as against MEL 624-28, and greater than 200 pg/mL. Donor
4, experiment 2.
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Figure 59. Impact of Second Round of DMF5 Mutations on Cross-Reactivity Using
Multi-Tissue Tumor Panel. Human T cells expressing either WT or mutant DMF5 TCR
were stimulated with tumor cell lines for 18 hours (see Table 2 – Chapter Two,
Methods). IFN-γ release was measured by ELISA in triplicate wells Reactivity is defined
as a T cell culture that secretes twice background, or twice the amount of IFN-γ
produced as against MEL 624-28, and greater than 200 pg/mL.
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Figure 60. Engraftment of PBMCs in NSG A2+ Mice. (a) Schematic of experimental
design is depicted. (b) Persistence of human CD3+ T cells in the blood of non-engrafted
and engrafted mice on day 72 post engraftment of human PBMCs. Cells were
immunofluorescently labeled with a human anti-CD3 mAb. Each group consisted of 3
mice. One representative mouse per group is shown.
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Figure 61. Effect of Engraftment on Therapeutic Efficacy of TCR Transduced T
cell Treatment. (a) Schematic of experimental design is depicted. Mice were engrafted
with PBMC on day -7 via retro-orbital injection. Mice were tumor challenged on day 0
with MEL 624 tumor cells. Mice were treated on day 17 with untransduced, WT DMF5
TCR transduced, αD26Y TCR, or αD26Y/αY50A/βL98W TCR T cells via retro-orbital
injection. (b) Tumor growth of MEL 624. N = 3 mice/group. Data represent the mean +
standard deviation.
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Figure 62. CD34 Expression Prior and Post in Vivo Injection. (a) Human
untransduced, WT TCR expressing, αD26Y TCR, and αD26Y/αY50A/βL98W TCR
expressing T cells were labeled with an anti-CD34 mAb 12 days after REP and 1 day
prior to in vivo injection. (b) Persistence of human CD3+CD34+ TCR transduced T cells
in the blood of treated and untreated mice on day 13 post therapeutic TCR transduced
T cell injection. Cells were immunofluorescently labeled with human anti-CD3 and antiCD34 mAbs. Each group consisted of 3 mice. One representative mouse per group is
shown.
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Figure 63. Effect of Cytokine Support on Therapeutic Efficacy of TCR Transduced
T cell Treatment. (a) Schematic of experimental design is depicted. Mice were tumor
challenged on day 0 with MEL 624 tumor cells. On day 17, mice were treated with
untransduced or WT DMF5 TCR transduced T cells via retro-orbital injection. Beginning
on day 17, cytokine treatment groups of mice were treated with 2.5 μg rhIL-15 every 3
days or 60,000 IU rhIL-2 twice a day for four days, then every 3 days via intraperitoneal
injection. (b) Tumor growth of MEL 624. N = 3 mice/group. Data represent the mean +
standard deviation.
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Figure 64. CD34 Expression Of Injected T Cells 10 Days Post In Vivo Injection.
Persistence of human CD3+CD34+ TCR transduced T cells in the blood of mice treated
with untransduced or WT TCR transduced T cells, with or without IL-2 or IL-15 cytokine
support on day 10 post therapy. Cells were immunofluorescently labeled with human
anti-CD3 and anti-CD34 mAbs. Each group consisted of 3 mice. One representative
mouse per group is shown.
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Figure 65. TCR Transduced T cells in the Tumor on Day 16 Post Treatment. On
day 16 post treatment, tumors were harvested and processed from one mouse per
group. Cells were immunofluorescently labeled with human anti-CD3 and anti-CD34
mAbs.
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Figure 66. TCR Transduced T cells In the Spleen on Day 16 Post Treatment. On
day 16 post treatment, spleens were harvested and processed from one mouse per
group. Cells were immunofluorescently labeled with human anti-CD3 and anti-CD34
mAbs.
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Figure 67. Effect of Anti-PD-1 on Therapeutic Efficacy of TCR Transduced T cell
Treatment. (a) Schematic of experimental design is depicted. Mice were tumor
challenged on day 0 with MEL 624 tumor cells. On day 17, mice were treated with
untransduced or WT DMF5 TCR transduced T cells via retro-orbital injection. Beginning
on day 17, anti-PD-1 groups of mice were treated with 0.25 mg of anti-PD-1 every 3
days via intraperitoneal injection. (b) Tumor growth of MEL 624. N = 3 mice/group. Data
represent the mean + standard deviation.
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Figure 68. Schematic Of In Vivo CTL Assay. On day 0, PBS or effector T cells were
injected via retro-orbital route. On day 1, 6x106 MART-1 9mer HLA-A2+ PBMCs labeled
with a high concentration of CFSE and 6x106 HLA-A2+ PBMCs labeled with a low
concentration of CFSE were injected via retro-orbital route. On day 3, spleens were
harvested and processed and analyzed via flow cytometry for CFSE cells.
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Figure 69. Example of CFSE Cells in the Spleen of PBS and WT DMF5 TCR
Transduced T cell Treated Mice. Splenocytes from each group were analyzed via flow
cytometry. Splenocytes were first gated on HLA-A2+ cells to differentiate the target cells
from any murine splenocytes. Cells were then gates on SSC and CFSE. Depicted
above is an example of CFSE low and high cells in a PBS treated mouse and CFSE low
and high cells in a WT DMF5 TCR transduced T cell treated mouse.
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Figure 70. MART-1 Specific Lysis by WT DMF5 TCR Transduced T Cells. One day
post PBS or WT DMF5 TCR transduced T cell treatment, mice were treated with 6x10 6
MART-1 pulsed [0.5 μM] and 6x106 [5 μM] CFSE labeled HLA-A2+ PBMCs. Two days
after injection of CFSE labeled target cells, spleens were harvested and processed.
Proportions of CFSE labeled cells in the spleen were analyzed via flow cytometry. Data
represent the mean + the standard error of the mean. N = 5 mice/group.
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